0000719135-23-000056.txt : 20231109 0000719135-23-000056.hdr.sgml : 20231109 20231109154934 ACCESSION NUMBER: 0000719135-23-000056 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apyx Medical Corp CENTRAL INDEX KEY: 0000719135 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 112644611 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31885 FILM NUMBER: 231392059 BUSINESS ADDRESS: STREET 1: 5115 ULMERTON ROAD CITY: CLEARWATER STATE: FL ZIP: 33760 BUSINESS PHONE: 7273842323 MAIL ADDRESS: STREET 1: 5115 ULMERTON ROAD CITY: CLEARWATER STATE: FL ZIP: 33760 FORMER COMPANY: FORMER CONFORMED NAME: BOVIE MEDICAL Corp DATE OF NAME CHANGE: 20150319 FORMER COMPANY: FORMER CONFORMED NAME: BOVIE MEDICAL CORP DATE OF NAME CHANGE: 19990216 FORMER COMPANY: FORMER CONFORMED NAME: AN CON GENETICS INC DATE OF NAME CHANGE: 19920703 10-Q 1 apyx-20230930.htm 10-Q apyx-20230930
0000719135FALSEDecember 31Q3202300007191352023-01-012023-09-3000007191352023-11-08xbrli:shares00007191352023-09-30iso4217:USD00007191352022-12-31iso4217:USDxbrli:shares00007191352023-07-012023-09-3000007191352022-07-012022-09-3000007191352022-01-012022-09-300000719135us-gaap:CommonStockMember2022-06-300000719135us-gaap:AdditionalPaidInCapitalMember2022-06-300000719135us-gaap:RetainedEarningsMember2022-06-300000719135us-gaap:NoncontrollingInterestMember2022-06-3000007191352022-06-300000719135us-gaap:CommonStockMember2022-07-012022-09-300000719135us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000719135us-gaap:RetainedEarningsMember2022-07-012022-09-300000719135us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000719135us-gaap:CommonStockMember2022-09-300000719135us-gaap:AdditionalPaidInCapitalMember2022-09-300000719135us-gaap:RetainedEarningsMember2022-09-300000719135us-gaap:NoncontrollingInterestMember2022-09-3000007191352022-09-300000719135us-gaap:CommonStockMember2023-06-300000719135us-gaap:AdditionalPaidInCapitalMember2023-06-300000719135us-gaap:RetainedEarningsMember2023-06-300000719135us-gaap:NoncontrollingInterestMember2023-06-3000007191352023-06-300000719135us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000719135us-gaap:CommonStockMember2023-07-012023-09-300000719135us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000719135us-gaap:RetainedEarningsMember2023-07-012023-09-300000719135us-gaap:CommonStockMember2023-09-300000719135us-gaap:AdditionalPaidInCapitalMember2023-09-300000719135us-gaap:RetainedEarningsMember2023-09-300000719135us-gaap:NoncontrollingInterestMember2023-09-300000719135us-gaap:CommonStockMember2021-12-310000719135us-gaap:AdditionalPaidInCapitalMember2021-12-310000719135us-gaap:RetainedEarningsMember2021-12-310000719135us-gaap:NoncontrollingInterestMember2021-12-3100007191352021-12-310000719135us-gaap:CommonStockMember2022-01-012022-09-300000719135us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000719135us-gaap:RetainedEarningsMember2022-01-012022-09-300000719135us-gaap:NoncontrollingInterestMember2022-01-012022-09-300000719135us-gaap:CommonStockMember2022-12-310000719135us-gaap:AdditionalPaidInCapitalMember2022-12-310000719135us-gaap:RetainedEarningsMember2022-12-310000719135us-gaap:NoncontrollingInterestMember2022-12-310000719135us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000719135us-gaap:CommonStockMember2023-01-012023-09-300000719135us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000719135us-gaap:RetainedEarningsMember2023-01-012023-09-3000007191352018-01-012018-12-3100007191352022-01-012022-12-310000719135apyx:ShelfRegistrationMember2022-11-222022-11-220000719135apyx:AtTheMarketMember2022-11-222022-11-220000719135apyx:MidCapCreditAgreementMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:SecuredDebtMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentCovenantTrancheOneMemberus-gaap:SecuredDebtMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentCovenantTrancheTwoMemberus-gaap:SecuredDebtMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:DebtInstrumentCovenantTrancheThreeMemberapyx:MidCapCreditAgreementMemberus-gaap:SecuredDebtMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:PerceptiveCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-080000719135us-gaap:LineOfCreditMemberapyx:PerceptiveCreditAgreementInitialLoanMemberus-gaap:SubsequentEventMember2023-11-080000719135us-gaap:LineOfCreditMemberapyx:PerceptiveCreditAgreementDelayedDrawLoanMemberus-gaap:SubsequentEventMember2023-11-0800007191352023-03-142023-03-1400007191352023-05-082023-05-0800007191352023-01-012023-01-3100007191352023-08-102023-08-1000007191352023-01-092023-01-09xbrli:pure0000719135us-gaap:LandMember2023-09-300000719135us-gaap:LandMember2022-12-310000719135us-gaap:BuildingAndBuildingImprovementsMember2023-09-300000719135us-gaap:BuildingAndBuildingImprovementsMember2022-12-310000719135us-gaap:MachineryAndEquipmentMember2023-09-300000719135us-gaap:MachineryAndEquipmentMember2022-12-310000719135us-gaap:FurnitureAndFixturesMember2023-09-300000719135us-gaap:FurnitureAndFixturesMember2022-12-310000719135apyx:ComputerEquipmentAndSoftwareMember2023-09-300000719135apyx:ComputerEquipmentAndSoftwareMember2022-12-310000719135us-gaap:LeaseholdImprovementsMember2023-09-300000719135us-gaap:LeaseholdImprovementsMember2022-12-310000719135apyx:MoldsMember2023-09-300000719135apyx:MoldsMember2022-12-3100007191352023-05-0800007191352023-05-012023-05-310000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:SecuredDebtMember2023-07-012023-09-300000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:SecuredDebtMember2023-01-012023-09-300000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-07-012023-09-300000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-09-300000719135us-gaap:SecuredDebtMemberapyx:TermLoanMember2023-09-300000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMember2023-01-012023-09-300000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMember2023-02-170000719135apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:SecuredDebtMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:SecuredDebtMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentCovenantTrancheOneMemberus-gaap:SecuredDebtMember2023-09-30apyx:monthlyPayment0000719135apyx:DebtInstrumentPrepaymentPeriodOneMemberus-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:SecuredDebtMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentPrepaymentPeriodTwoMemberus-gaap:SecuredDebtMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentPrepaymentPeriodThreeMemberus-gaap:SecuredDebtMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentTerminationPeriodOneMemberus-gaap:RevolvingCreditFacilityMember2023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentTerminationPeriodOneMemberus-gaap:RevolvingCreditFacilityMember2023-02-172023-02-170000719135apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMemberus-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentTerminationPeriodOneMemberus-gaap:RevolvingCreditFacilityMember2023-09-300000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberapyx:DebtInstrumentTerminationPeriodTwoMemberus-gaap:RevolvingCreditFacilityMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:DebtInstrumentTerminationPeriodThreeMemberapyx:MidCapCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-09-3000007191352023-02-172023-02-1700007191352023-02-170000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMember2023-02-172023-02-170000719135us-gaap:LineOfCreditMemberapyx:PerceptiveCreditAgreementInitialLoanMemberus-gaap:SubsequentEventMember2023-11-082023-11-080000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-082023-11-080000719135us-gaap:LineOfCreditMemberapyx:MidCapCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-080000719135us-gaap:LineOfCreditMemberapyx:PerceptiveCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-082023-11-080000719135apyx:DebtInstrumentPrepaymentPeriodOneMemberus-gaap:LineOfCreditMemberapyx:PerceptiveCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-082023-11-080000719135us-gaap:LineOfCreditMemberapyx:DebtInstrumentPrepaymentPeriodTwoMemberapyx:PerceptiveCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-082023-11-080000719135us-gaap:LineOfCreditMemberapyx:DebtInstrumentPrepaymentPeriodThreeMemberapyx:PerceptiveCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-082023-11-080000719135us-gaap:LineOfCreditMemberapyx:DebtInstrumentPrepaymentPeriodFourMemberapyx:PerceptiveCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-082023-11-080000719135us-gaap:LineOfCreditMemberapyx:DebtInstrumentPrepaymentPeriodAfterYearFourMemberapyx:PerceptiveCreditAgreementMemberus-gaap:SubsequentEventMember2023-11-082023-11-080000719135us-gaap:SubsequentEventMember2023-11-082023-11-080000719135us-gaap:SubsequentEventMember2023-11-080000719135apyx:ChineseSupplierMember2019-12-310000719135us-gaap:CorporateJointVentureMember2019-12-310000719135us-gaap:CorporateJointVentureMember2021-01-012021-12-310000719135us-gaap:CorporateJointVentureMember2020-01-012020-12-310000719135us-gaap:CorporateJointVentureMember2023-06-300000719135us-gaap:CorporateJointVentureMember2023-06-012023-09-300000719135us-gaap:CorporateJointVentureMember2022-06-300000719135us-gaap:CorporateJointVentureMember2022-12-310000719135us-gaap:CorporateJointVentureMember2021-12-310000719135us-gaap:CorporateJointVentureMember2023-07-012023-09-300000719135us-gaap:CorporateJointVentureMember2022-07-012022-09-300000719135us-gaap:CorporateJointVentureMember2023-01-012023-09-300000719135us-gaap:CorporateJointVentureMember2022-01-012022-09-300000719135us-gaap:CorporateJointVentureMember2023-09-300000719135us-gaap:CorporateJointVentureMember2022-09-300000719135us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000719135us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000719135us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000719135us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000719135us-gaap:WarrantMember2023-07-012023-09-300000719135us-gaap:WarrantMember2022-07-012022-09-300000719135us-gaap:WarrantMember2023-01-012023-09-300000719135us-gaap:WarrantMember2022-01-012022-09-300000719135srt:MinimumMember2023-01-012023-09-300000719135srt:MaximumMember2023-01-012023-09-300000719135srt:MinimumMemberapyx:SuitAgainstGoodwinAndSimbMember2023-09-300000719135srt:MaximumMemberapyx:SuitAgainstGoodwinAndSimbMember2023-09-300000719135apyx:SuitAgainstGoodwinAndSimbMember2023-09-300000719135apyx:SuitsFiledIn2022Membersrt:MinimumMember2023-09-300000719135srt:MaximumMemberapyx:SuitsFiledIn2022Member2023-09-300000719135apyx:SuitsFiledIn2022Member2023-09-300000719135us-gaap:CoVenturerMember2023-07-012023-09-300000719135us-gaap:CoVenturerMember2022-07-012022-09-300000719135us-gaap:CoVenturerMember2023-01-012023-09-300000719135us-gaap:CoVenturerMember2022-01-012022-09-300000719135us-gaap:CoVenturerMember2023-09-300000719135us-gaap:CoVenturerMember2022-12-31apyx:segment0000719135apyx:AdvancedEnergyMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300000719135us-gaap:OperatingSegmentsMemberapyx:OEMMember2023-07-012023-09-300000719135us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000719135apyx:AdvancedEnergyMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000719135us-gaap:OperatingSegmentsMemberapyx:OEMMember2022-07-012022-09-300000719135us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000719135apyx:AdvancedEnergyMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300000719135us-gaap:OperatingSegmentsMemberapyx:OEMMember2023-01-012023-09-300000719135us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000719135apyx:AdvancedEnergyMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000719135us-gaap:OperatingSegmentsMemberapyx:OEMMember2022-01-012022-09-300000719135us-gaap:CorporateNonSegmentMember2022-01-012022-09-300000719135country:US2023-07-012023-09-300000719135country:US2022-07-012022-09-300000719135country:US2023-01-012023-09-300000719135country:US2022-01-012022-09-300000719135us-gaap:NonUsMember2023-07-012023-09-300000719135us-gaap:NonUsMember2022-07-012022-09-300000719135us-gaap:NonUsMember2023-01-012023-09-300000719135us-gaap:NonUsMember2022-01-012022-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
September 30, 2023
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission File Number: 001-31885
apyxmedicallogotagline.jpg
APYX MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
Delaware11-2644611
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
5115 Ulmerton Road, Clearwater, FL 33760
(Address of principal executive offices, zip code)
(727) 384-2323
(Registrant’s telephone number)
Securities Registered Pursuant to Section 12 (b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common StockAPYXNasdaq Stock Market, LLC

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes: ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes: ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer☒Smaller reporting company☒
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: ☐ No ☒

As of November 8, 2023, 34,643,855 shares of the registrant’s $0.001 par value common stock were outstanding.

APYX MEDICAL CORPORATION
INDEX TO QUARTERLY REPORT ON FORM 10-Q
For the quarterly period ended September 30, 2023

Page
Part I.
Item 1.
Condensed Consolidated Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets at September 30, 2023 and December 31, 2022
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022
Condensed Consolidated Statements of Changes in Equity for the three and nine months ended September 30, 2023 and 2022
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022
Item 2.
Item 3.
Item 4.
Part II.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
1
PART I.     Financial Information

ITEM 1. Condensed Consolidated Financial Statements

APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
September 30, 2023
(Unaudited)
December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents$22,134 $10,192 
   Trade accounts receivable, net of allowance of $652 and $668
12,648 10,602 
Income tax receivables— 7,545 
Other receivables596 99 
Inventories, net of provision for obsolescence of $611 and $457
11,285 11,797 
Prepaid expenses and other current assets3,487 2,737 
Total current assets50,150 42,972 
Property and equipment, net2,093 6,761 
Operating lease right-of-use assets5,274 710 
Finance lease right-of-use assets74 115 
Other assets1,855 1,217 
Total assets$59,446 $51,775 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$2,050 $2,669 
Accrued expenses and other current liabilities7,914 8,928 
Current portion of operating lease liabilities310 216 
Current portion of finance lease liabilities20 37 
Total current liabilities10,294 11,850 
Term loan, net9,009 — 
Long-term operating lease liabilities4,992 470 
Long-term finance lease liabilities58 73 
Long-term contract liabilities1,326 1,408 
Other liabilities181 181 
Total liabilities25,860 13,982 
EQUITY
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2023 and December 31, 2022
— — 
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,855 issued and outstanding as of September 30, 2023, and 34,597,822 issued and outstanding as of December 31, 2022
35 35 
Additional paid-in capital78,154 73,282 
Accumulated deficit(44,841)(35,735)
Total stockholders’ equity
33,34837,582
Non-controlling interest 238 211 
Total equity33,586 37,793 
Total liabilities and equity$59,446 $51,775 
The accompanying notes are an integral part of the condensed consolidated financial statements.
2
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)

Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Sales$11,976 $9,114 $37,687 $31,899 
Cost of sales3,998 3,357 12,857 11,009 
Gross profit7,978 5,757 24,830 20,890 
Other costs and expenses:
Research and development1,276 1,061 3,596 3,289 
Professional services1,831 1,936 5,165 6,611 
Salaries and related costs4,667 3,871 14,770 13,944 
Selling, general and administrative4,841 4,671 15,474 14,675 
Total other costs and expenses12,615 11,539 39,005 38,519 
   Gain on sale-leaseback— — 2,692 — 
Loss from operations(4,637)(5,782)(11,483)(17,629)
Interest income248 73 478 93 
Interest expense(585)(1)(1,362)(12)
Other (expense) income, net(19)(35)622 551 
Total other (expense) income, net(356)37 (262)632 
Loss before income taxes(4,993)(5,745)(11,745)(16,997)
Income tax (benefit) expense(318)50 (2,519)216 
Net loss(4,675)(5,795)(9,226)(17,213)
   Net loss attributable to non-controlling interest(46)(31)(120)(78)
Net loss attributable to stockholders$(4,629)$(5,764)$(9,106)$(17,135)
Loss per share:
Basic and diluted$(0.13)$(0.17)$(0.26)$(0.50)

The accompanying notes are an integral part of the condensed consolidated financial statements.
3
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
(In thousands)
Three Months Ended September 30, 2023 and 2022
Common StockAdditional Paid-In CapitalAccumulated DeficitNon-controlling InterestTotal Equity
SharesPar Value
Balance at June 30, 202234,493 $34 $69,793 $(23,922)$258 $46,163 
Shares issued on stock options exercises for cash62 1 156 — —157 
Stock based compensation— — 1,692 — —1,692 
Shares issued on net settlement of stock options33 — — — —— 
Net loss— — — (5,764)(31)(5,795)
Balance at September 30, 202234,588 $35 $71,641 $(29,686)$227 $42,217 
Balance at June 30, 202334,629 $35 $76,773 $(40,212)$137 $36,733 
Contributions from non-controlling interest— — — — 147147 
Shares issued on stock options exercises for cash10 — 30 — —30 
Stock based compensation— — 1,351 — —1,351 
Shares issued on net settlement of stock options5 — — — —— 
Net loss— — — (4,629)(46)(4,675)
Balance at September 30, 202334,644 $35 $78,154 $(44,841)$238 $33,586 
Nine Months Ended September 30, 2023 and 2022
Common StockAdditional Paid-In CapitalAccumulated DeficitNon-controlling InterestTotal
SharesPar Value
Balance at December 31, 202134,410 $34 $66,221 $(12,551)$305 $54,009 
Shares issued on stock options exercises for cash106 1 364 — —365 
Stock based compensation— — 5,056 — —5,056 
Shares issued on net settlement of stock options72 — — — —— 
Net loss— — — (17,135)(78)(17,213)
Balance at September 30, 202234,588 $35 $71,641 $(29,686)$227 $42,217 
Balance at December 31, 202234,598 $35 $73,282 $(35,735)$211 $37,793 
Contributions from non-controlling interest— — — — 147147 
Shares issued on stock options exercises for cash35 — 86 — —86 
Stock based compensation— — 4,200 — —4,200 
Shares issued on net settlement of stock options11 — — — —— 
Proceeds received from issuance of warrants— — 586 — —586 
Net loss— — — (9,106)(120)(9,226)
Balance at September 30, 202334,644 $35 $78,154 $(44,841)$238 $33,586 
 
The accompanying notes are an integral part of the condensed consolidated financial statements.
4
APYX MEDICAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Nine Months Ended September 30,
20232022
Cash flows from operating activities
Net loss$(9,226)$(17,213)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization540 688 
Provision for inventory obsolescence229 158 
(Gain) loss on disposal of property and equipment(2,656)76 
Stock based compensation4,200 5,056 
Provision for allowance for doubtful accounts176 283 
Non-cash interest expense354 — 
Non-cash lease expense56 — 
Changes in operating assets and liabilities:
Trade receivables(2,192)3,273 
Prepaid expenses and other assets(698)(521)
Income tax receivables7,545 97 
Inventories401 (5,672)
Accounts payable(613)(439)
Accrued and other liabilities(1,153)(1,536)
Net cash used in operating activities(3,037)(15,750)
Cash flows from investing activities
Purchases of property and equipment(440)(868)
Proceeds from sale of property and equipment7,267 — 
Net cash provided by (used in) investing activities6,827 (868)
Cash flows from financing activities
Proceeds from stock option exercises86 365 
Proceeds from term loan9,289 — 
Payment of debt issuance costs(1,754)— 
Proceeds from issuance of warrants586 — 
Repayment of finance lease liabilities(32)(138)
Contributions from non-controlling interest147 — 
Net cash provided by financing activities8,322 227 
Effect of exchange rates on cash(170)354 
Net change in cash and cash equivalents11,942 (16,037)
Cash and cash equivalents, beginning of period10,192 30,870 
Cash and cash equivalents, end of period$22,134 $14,833 
Cash paid for:
Interest$834 $12 
Income taxes$261 $128 
Non cash activities:
Right-of-use assets capitalized and operating lease liabilities recognized upon execution of lease$4,917 $— 
Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification$— $769 
Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease$— $103 
Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification$— $28 
The accompanying notes are an integral part of the condensed consolidated financial statements.
5
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1.     BASIS OF PRESENTATION

Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.

The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.

As part of its plan to accelerate and fully fund the development of its advanced energy business, with a focus in the cosmetic surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances.

On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures, but had not yet been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.

On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.

On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures.

On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region.

On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.

On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.

On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

6
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



The May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. Management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should assist in mitigating the financial effects of the Safety Communication in future periods.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.

While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the nine months ended September 30, 2023, the Company incurred an operating loss of $11.5 million and used $11.1 million of cash in operations exclusive of the receipt of the Company's tax refund, including interest, of approximately $8.1 million. As of September 30, 2023, the Company had cash and cash equivalents of $22.1 million, of which the Company must maintain $10.0 million under its Credit Agreement. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.

In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity.

On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, the Company has not utilized this facility.

On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.

The MidCap Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the MidCap Credit Agreement.

On November 8, 2023, the Company entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto.

7
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million.

For a more in depth description of the terms of the MidCap Credit Agreement and the Perceptive Credit Agreement, see Note 7.

On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company’s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.

For a more in depth description of the terms of the Purchase Agreement, see Notes 4 and 5.

During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company’s tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. On August 10, 2023, the Company received $8.1 million from the IRS, which included approximately $0.4 million of interest on the $7.7 million income tax refunds.

The Company also re-assessed its operating expenditures and cost structure and made adjustments in light of expected levels of revenue. This included reducing some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company’s U.S. headcount by 14%.

Management believes that the actions already taken, including replacing the MidCap Credit Agreement with the Perceptive Credit Agreement, alleviate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of its unaudited condensed consolidated financial statements.


NOTE 2.     RECENT ACCOUNTING PRONOUNCEMENTS

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.

No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
8
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



NOTE 3.     INVENTORIES

Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.

Inventories consisted of the following:
(In thousands)September 30,
2023		December 31,
2022
Raw materials$4,578 $4,979 
Work in process2,522 2,160 
Finished goods 4,796 5,115 
Gross inventories11,896 12,254 
Less: provision for obsolescence(611)(457)
Inventories, net$11,285 $11,797 
9
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)





NOTE 4.     PROPERTY AND EQUIPMENT
(In thousands)September 30, 2023
(Unaudited)		December 31,
2022
Land$— $1,600 
Building and improvements— 4,426 
Machinery and equipment2,635 2,613 
Furniture and fixtures216 211 
Computer equipment and software1,079 1,420 
Leasehold improvements178 178 
Molds1,017 847 
Total property, plant and equipment5,125 11,295 
Less: accumulated depreciation and amortization(3,489)(5,041)
Property and equipment in service1,636 6,254 
Construction in progress457 507 
Property and equipment, net$2,093 $6,761 

In an effort to improve liquidity and the balance sheet condition of the Company, management explored options to leverage the Company’s unencumbered real property. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL.

On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000.

On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser (see Note 5). The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit of approximately $0.6 million, equal to one year's rent, taxes, first months rent, expenses, and fees. The $2,700,000 gain on this transaction is presented in gain on sale-leaseback in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2023.

10
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



NOTE 5.     LEASES

Operating Leases

The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. These operating leases have terms expiring through December 2027.

In connection with the terms of the Purchase Agreement (see Note 4), during May 2023, the Company entered into a Single Tenant Industrial Building Lease (the “Lease”), pursuant to which the Property was leased back to the Company. The Lease has an initial term of ten (10) years commencing from the closing (the “Initial Term”), and a renewal term of five (5) years, exercisable at the Company’s option. The annual fixed rent is $619,500 for the first year of the Initial Term, and is subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term.

The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.

Information about the Company’s weighted average remaining operating lease terms and discount rate assumptions are as follows:
September 30, 2023December 31,
2022
Weighted average remaining lease term (in years)9.24.4
Weighted average discount rate8.42%2.54%

Maturities of operating lease liabilities as of September 30, 2023 are as follows:
(In thousands)
2023$190 
2024773 
2025799 
2026826 
2027855 
Thereafter4,516 
Total lease payments7,959 
Less imputed interest(2,657)
Present value of lease liabilities5,302 
Less current portion of lease liabilities(310)
Long-term portion of lease liabilities$4,992 


11
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



NOTE 6.     ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following:
(in thousands)September 30,
2023		December 31,
2022
Accrued payroll$879 $563 
Accrued bonuses1,188 — 
Accrued commissions1,183 847 
Accrued product warranties386 391 
Accrued product liability claim insurance deductibles2,060 1,825 
Accrued professional fees and legal related contingent liabilities607 901 
Joint and several payroll liability— 345 
Short-term contract liabilities712 853 
Uncertain tax positions— 2,079 
Sales tax payable245 245 
Other accrued expenses and current liabilities654 879 
Total accrued expenses and other current liabilities$7,914 $8,928 

During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations. This adjustment is included in other (expense) income, net for the nine months ended September 30, 2023.
12
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



NOTE 7.     DEBT

Included in interest expense for the three and nine months ended September 30, 2023 are $36,000 and $87,000, respectively, of amortization of the debt issuance costs and $81,000 and $198,000, respectively, of amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three and nine months ended September 30, 2023 are $25,000 and $62,000, respectively, of amortization of the debt issuance costs and $3,000 and $7,000, respectively, of amortization of the debt discount on the revolving facility.

The Company’s term loan, net consists of the following at September 30, 2023:

(In thousands)
Term loan$10,000 
Unamortized debt issuance costs(414)
Unamortized debt discount, including accretion of exit fee(577)
Term loan, net$9,009 

The term loan, net was paid in full on November 8, 2023 in connection with the execution of the Perceptive Credit Agreement. The Company is still determining the appropriate accounting treatment for the MidCap Credit Agreement and Perceptive Credit Agreement. While the Perceptive Credit Agreement contains a subjective acceleration clause, management has determined that there is remote probability that Perceptive would accelerate of the obligations under the subjective acceleration clause. Accordingly, term loan, net has been presented as a long term liability in the accompanying condensed consolidated balance sheet as of September 30, 2023. The Company expects to record a loss on extinguishment of the MidCap Credit Agreement of approximately $2.5 million in connection with the write-off of unamortized debt issuance costs, debt discounts and unamortized debt premiums.

MIDCAP CREDIT AGREEMENT

On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively “MidCap”).

The MidCap Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The MidCap Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the MidCap Credit Agreement. The MidCap Credit Agreement was to mature on February 1, 2028. The outstanding borrowings under the MidCap Credit Agreement were repaid in full using proceeds from the execution of the Perceptive Credit Agreement.

Term Loans

The initial tranche of $10 million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the MidCap Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company’s ability to access these additional tranches was conditioned upon, among other things, the achievement of certain minimum revenue targets.

Each term loan bore interest at a floating rate reset monthly based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.8% at September 30, 2023). Interest was payable monthly in arrears on the first day of each month.

The first twenty-four (24) months of the term loans constituted an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans was to be repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, was to be due at maturity on February 1, 2028. The term loans could be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the MidCap Credit Agreement. Additionally, the term loans were subject to mandatory prepayment fees, pursuant to the terms of the MidCap Credit Agreement. Prepayments of the
13
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company was also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee was being accreted over the life of the MidCap Credit Agreement utilizing the effective interest method. In connection with the satisfaction of the MidCap Credit Agreement, the Company paid MidCap a prepayment fee of 3% and the full 4% exit fee with proceeds from the Perceptive Credit Agreement discussed below.

As the MidCap Credit Agreement contained a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet as of September 30, 2023.

Revolving Facility

The Company could borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility would terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must have been repaid. Borrowings were limited to the lesser of the Company’s borrowing base and the revolving commitment of $10,000,000.

In connection with the revolving facility, the Company was required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account were swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings were promptly returned to the Company.

Loans made under the revolving facility bore interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (9.4% at September 30, 2023). The Company was obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility was terminated or reduced before maturity, the Company was subject to a deferred origination fee. Terminations and reductions of the commitments were subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company was also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10 million under the revolving facility. If the average outstanding balance for a month was less than the minimum balance, the Company paid a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees were payable monthly on the first day of each month. In connection with the satisfaction of the MidCap Credit Agreement, the Company paid MidCap a deferred origination fee of 3% of the revolving commitment with proceeds from the Perceptive Credit Agreement discussed below.

As of September 30, 2023, the Company had drawn no amounts on the revolving facility. As of September 30, 2023, the Company had approximately $7,800,000 available to be drawn on the revolving facility. As the MidCap Credit Agreement contained a subjective acceleration clause and the Company was required to maintain a lockbox, any amounts drawn on the revolving facility would be presented as a current liability in the consolidated balance sheet.

Collateral

The obligations of the Company under the MidCap Credit Agreement were secured by first priority liens on substantially all of its assets.

Covenants

The MidCap Credit Agreement contained customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions.

The MidCap Credit Agreement also required the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49 million, $60 million and $70 million for 2023, 2024, and 2025, respectively. Additionally, the Company had to maintain a balance of $10 million in cash and cash equivalents during the duration of the MidCap Credit Agreement’s term.

As of September 30, 2023, the Company was not in compliance with the minimum trailing twelve month net revenue financial covenant. As a result of the repayment of amounts outstanding under the MidCap Credit Agreement with proceeds from the Perceptive Credit Agreement discussed below, there were no implications to the Company from this event of noncompliance.
14
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)




Events of Default

The MidCap Credit Agreement also contained customary Events of Default that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.

Upon the occurrence and during the continuance of an Event of Default under the MidCap Credit Agreement, the respective administrative agent, if requested by the respective lenders, could, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The MidCap Credit Agreement provided that, under certain circumstances, a default interest rate would apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.

The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the MidCap Credit Agreement. The bifurcated derivative is de minimis to the Company’s unaudited condensed consolidated financial statements.

Issuance of Warrants

In connection with the Company’s obligations under the MidCap Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.

The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.

The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements.

Debt Issuance Costs

In connection with entering into the MidCap Credit Agreement, the Company incurred debt issuance costs of approximately $1.8 million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan were being amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and were being amortized over the life of the term loans starting at the issuance date. The Company recognized the deferred costs at the point that the Company’s rights to borrow on the term loans expired. The costs allocated to the revolving facility were to be recognized on a straight-line basis over the term of the MidCap Credit Agreement. The Company expects to recognize all unamortized costs in loss on extinguishment of the MidCap Credit Agreement.

The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet.

PERCEPTIVE CREDIT AGREEMENT

On November 8, 2023, the Company entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto.

The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million. The Credit Agreement matures on November 8, 2028.
15
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)




Loans

The initial loan of $37.5 million was fully funded on November 8, 2023, with approximately $11.0 million of the proceeds used to payoff the obligations under the MidCap Credit Agreement, including approximately $1.0 million of related prepayment penalties and exit fees, and $2.5 million for transaction fees and other expenses incurred in connection with the Perceptive Credit Agreement, which includes a 2% fee of the total facility payable to Perceptive at closing. The delayed draw loan is available until December 31, 2024, conditioned upon, among other things, the achievement of a minimum revenue target. After repayment of the MidCap Credit Agreement and payment of transaction fees and other expenses in connection with the Perceptive Credit Agreement, the net proceeds of these loans will be used for working capital and general corporate purposes.

The initial loan and delayed draw loan bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The first forty-eight (48) months of the loans constitute an interest-only period, with interest payable monthly on the last day of each month. Subsequent to the interest-only period, the outstanding principal amount of the loans is repayable in monthly payments of 3% of the outstanding balance on the payment date. All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity. The loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Perceptive Credit Agreement. Additionally, the loans are subject to mandatory prepayment obligations, pursuant to the terms of the Perceptive Credit Agreement. Prepayments of the loans are subject to fees of 10%, 9%, 6%, 4% and 2% of the prepayment amounts made during the first year, second year, third year, fourth year, and thereafter, respectively.

Collateral

The obligations of the Company under the Perceptive Credit Agreement are secured by first priority liens on substantially all of its assets.

Covenants

The Perceptive Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions set forth in the Perceptive Credit Agreement. The Perceptive Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $41.6 million, $57.0 million, $70.2 million, and $87.8 million for 2024, 2025, 2026, and 2027, respectively. Additionally, the Company must maintain a balance of $3 million in cash and cash equivalents during the duration of the Perceptive Credit Agreement’s term.

Events of Default

The Perceptive Credit Agreement also contains customary Events of Default (as defined in the Perceptive Credit Agreement) that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.

Upon the occurrence and during the continuance of an Event of Default under the Perceptive Credit Agreement, the administrative agent, if requested by the respective lenders, may, among other things, (i) terminate commitments, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Perceptive Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations upon the occurrence and during the existence of an Event of Default, at a per annum rate equal to 3% in excess of the applicable interest rate.

Issuance of Warrants

In connection with the Company’s initial loan under the Perceptive Credit Agreement, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock, par value $0.001, with an exercise price of $2.43 per share. Upon the
16
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



issuance of the delayed draw loan, if applicable, the Company will issue Perceptive warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of equal to the 10-day volume weighted average sale price from the preceding business day.
17
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



NOTE 8.     CHINA JOINT VENTURE

In 2019, the Company executed a joint venture agreement with its Chinese supplier (the “China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. In June 2023, the Company executed an amendment to the joint venture agreement to increase the amount of it’s registered capital. The amendment requires the Company to make additional capital contributions to the China JV of $255,000, of which $153,000 has been made as of September 30, 2023. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.

Changes in the Company’s ownership investment in the China JV were as follows:

Three Months Ended September 30,Nine Months Ended
September 30,
(In thousands)2023202220232022
Beginning interest in China JV$142$269$219$317
Contributions $153$—$153$—
Net loss attributable to Apyx$(48)$(33)$(125)$(81)
Ending interest in China JV$247$236$247$236

NOTE 9.     EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2023202220232022
Numerator:
Net loss attributable to stockholders$(4,629)$(5,764)$(9,106)$(17,135)
Denominator:
Weighted average shares outstanding - basic and diluted
34,642 34,569 34,614 34,488 
Loss per share:
Basic and diluted$(0.13)$(0.17)$(0.26)$(0.50)
Anti-dilutive instruments excluded from diluted loss per common share:
Options7,713 6,635 7,713 6,635 
Warrants250 — 250 — 

18
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



NOTE 10.     STOCK-BASED COMPENSATION

Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.

The Company recognized approximately $1,351,000 and $4,200,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2023, as compared with $1,692,000 and $5,056,000, respectively, for the three and nine months ended September 30, 2022.

Stock option activity is summarized as follows:
Number of optionsWeighted average exercise price
Outstanding at December 31, 2022
6,520,444 $7.12 
Granted1,527,865 2.63 
Exercised(57,000)2.65 
Canceled and forfeited(278,546)7.03 
Outstanding at September 30, 2023
7,712,763 $6.27 

The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2023 and 2022, respectively, we received 6,662 and 55,853 options as payment in the exercise of 5,338 and 33,313 options. For the nine months ended September 30, 2023 and 2022, respectively, we received 10,967 and 92,520 options as payment in the exercise of 11,033 and 72,313 options.

Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black-Scholes model.
2023 Grants
Strike price$2.50-$4.21
Risk-free rate3.6%-4.3%
Expected dividend yield—
Expected volatility85.8%-88.4%
Expected term (in years)6

NOTE 11.     INCOME TAXES

Income tax (benefit) expense was approximately $(318,000) and $50,000 with effective tax rates of 6.4% and (0.9)% for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to interest income on the Company's income tax refund that it received during the quarter, partially offset by the full valuation allowance recorded on the net operating loss (“NOL”) generated during the period. For the three months ended September 30, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period.

Income tax (benefit) expense was approximately $(2,519,000) and $216,000 with effective tax rates of 21.4% and (1.3)% for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company’s liability for uncertain tax positions, including accrued interest and penalties, of approximately $2.1 million, which were sustained upon the completion in January 2023 of the IRS examination of the Company's 2018 through 2020 income tax returns and interest income on the Company's
19
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



income tax refund, partially offset by the full valuation allowance on the NOL and net deferred tax assets generated during the period. For the nine months ended September, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.

NOTE 12.     COMMITMENTS AND CONTINGENCIES

Litigation

The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.

The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.

During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. During 2022, the Company recorded an estimated loss of $250,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. The Company has not experienced any movement on the matter since our response to the distributor in the fourth quarter of 2022. Accordingly, we have revised our estimated loss on the matter to $0 as it is no longer probable that a loss has been incurred. The reduction in estimated loss of $250,000 is included in professional services in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2023.

As previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Hattaway Complaint”) was filed in the United States District Court for the Middle District of Florida (the “U.S. District Court”) by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Hattaway Complaint sought an unspecified amount of damages.

While the matter was in the early stages, management had determined that a loss was probable in the estimated range of $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. On June 15, 2023, the U.S. District Court issued an Order dismissing the Hattaway Complaint and granting plaintiff until July 3, 2023 to file a second amended complaint, failing which the U.S. District Court would close the case. On June 27, 2023, the Plaintiff formally notified the Court that a Second Amended Complaint will not be filed and on July 17, 2023, the case was marked closed based on the Court’s June 15 dismissal order. This closed the matter for the estimated loss recorded by the Company.

During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff’s allegations could be subject to separate deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is
20
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.

On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the “Stein Suit”) against individual members of the Company’s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the “Pritchard Case”). The Stein Suit sought unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing. On April 3, 2023, the Company formally moved to dismiss the case as time-barred and on other legal grounds, which triggered the plaintiff’s right to file an amended complaint. On July 12, 2023, plaintiff’s counsel informed the Company’s counsel that plaintiff Stein did not intend to file an amended complaint, and on July 17, 2023 plaintiff’s counsel filed a notice of voluntary dismissal. An order of the Court dismissing the Stein Suit, with prejudice, was entered on July 20, 2023.

The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.

Purchase Commitments

At September 30, 2023, the Company had purchase commitments totaling approximately $3.5 million, substantially all of which is expected to be purchased within the next twelve months.

21
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



NOTE 13.     RELATED PARTY TRANSACTIONS

Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department.

The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September 30, 2023 and 2022, the Company made purchases from this supplier of approximately $50,000 and $85,000, respectively. For the nine months ended September 30, 2023 and 2022, the Company made purchases from this supplier of approximately $501,000 and $455,000, respectively. At September 30, 2023 and December 31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $12,000 and $8,000, respectively.

NOTE 14.     GEOGRAPHIC AND SEGMENT INFORMATION

Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.

The Company’s reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. “Corporate & Other” includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.

Summarized financial information with respect to reportable segments is as follows:

Three Months Ended September 30, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$9,836 $2,140 $— $11,976 
Income (loss) from operations70 591 (5,298)(4,637)
Interest income— — 248 248 
Interest expense— — (585)(585)
Other loss, net— — (19)(19)
Income tax benefit— — (318)(318)

22
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



Three Months Ended September 30, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$7,080 $2,034 $— $9,114 
(Loss) income from operations(1,174)356 (4,964)(5,782)
Interest income— — 73 73 
Interest expense— — (1)(1)
Other loss, net— — (35)(35)
Income tax expense— — 50 50 

Nine Months Ended September 30, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$31,248 $6,439 $— $37,687 
(Loss) income from operations(509)1,795 (12,769)(11,483)
Interest income— — 478 478 
Interest expense— — (1,362)(1,362)
Other income, net— — 622 622 
Income tax benefit— — (2,519)(2,519)

Nine Months Ended September 30, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$26,258 $5,641 $— $31,899 
(Loss) income from operations(3,765)1,142 (15,006)(17,629)
Interest income— — 93 93 
Interest expense— — (12)(12)
Other income, net— — 551 551 
Income tax expense— — 216 216 

International sales represented approximately 27.8% and 26.6% of total revenues for the three and nine months ended September 30, 2023, respectively, as compared with approximately 23.2% and 29.5% of total revenues for the three and nine months ended September 30, 2022, respectively.









23
APYX MEDICAL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued
(Unaudited)



Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)2023202220232022
Sales by Domestic and International
Domestic$8,652 $6,997 $27,660 $22,492 
International3,324 2,117 10,027 9,407 
Total$11,976 $9,114 $37,687 $31,899 

24
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS


ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.

Executive Level Overview

We are an advanced energy technology company with a passion for elevating people’s lives through innovative products, including our Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.

As part of our plan to accelerate and fully fund the development of our advanced energy business, with a focus in the cosmetic surgery market, we sold our Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, we had and still have, some significant non-recurring discretionary expenditures associated with completing our multi-year marketing initiatives related to our dermal resurfacing and skin laxity clearances.

On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Safety Communication that warns consumers and health care providers against the use of our Advanced Energy products outside of their FDA-cleared indications for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures. Following the Safety Communication, we experienced slowed demand for the adoption of our Helium Plasma Technology.

On May 26, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for certain skin contraction procedures.

On June 2, 2022, and July 21, 2022, FDA updated the Medical Device Safety Communication to recognize the new 510(k) clearances for the Renuvion® Dermal handpiece, and the expanded indications for the Renuvion® APR handpieces. The 510(k) clearance for the Renuvion® Dermal handpiece allows surgeons to perform dermal resurfacing procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. The 510(k) clearance for the Renuvion® APR handpieces now addresses improving the appearance of lax (loose) skin in the neck and submental region.

On July 18, 2022, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region.

On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.

On February 27, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.

25
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

On April 28, 2023, we announced that we received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

The May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. We believe that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should assist in mitigating the financial effects of the Safety Communication in future periods.

While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of our sale of the Core business segment to Symmetry Surgical during 2018, we have incurred recurring net losses and cash outflows from operations and we anticipate that losses will continue in the near term. During the year ended December 31, 2022, we incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the nine months ended September 30, 2023, we incurred an operating loss of $11.5 million and used $11.1 million of cash in operations exclusive of the receipt of our tax refund of approximately $8.1 million. As of September 30, 2023, we had cash and cash equivalents of $22.1 million, of which we must maintain $10.0 million under our Credit Agreement. These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.

In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity.

On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, we have not utilized this facility.

On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.

The Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.

On November 8, 2023, we entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”) with Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto.

The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million.

For a more in depth description of the terms of the MidCap Credit Agreement and the Perceptive Credit Agreement,, see Note 7 of Notes to Condensed Consolidated Financial Statements in Item 1 of this Quarterly Report on Form 10-Q.

On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. The Purchase Agreement is subject to the satisfactory completion of due diligence by the Purchaser. On May 8, 2023, we closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.

For a more in depth description of the terms of the Purchase Agreement, see Notes 4 and 5 of Notes to Condensed Consolidated Financial Statements in Item 1 of this Quarterly Report on Form 10-Q.
26
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued


During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the our tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. On August 10, 2023, we received $8.1 million from the IRS, which included approximately $0.4 million of interest on the $7.7 million income tax refunds.

We also reassessed our operating expenditures and cost structure and made adjustments in light of expected levels of revenue. This included reducing some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the our U.S. headcount by 14%.

We believe that the actions already taken, including replacing the MidCap Credit Agreement with the Perceptive Credit Agreement, alleviate the conditions that raised substantial doubt about the our ability to continue as a going concern for a period of at least one year from the date of issuance of our unaudited condensed consolidated financial statements.

We continue to drive sales in our Advanced Energy business by increasing the adoption and utilization of our handpieces by surgeons in the U.S. and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 60 countries. As of September 30, 2023, we had a direct sales force of 36 field-based selling professionals and utilized 3 independent sales agencies. We also had 4 sales managers. This selling organization is focused on the use of Renuvion® in the cosmetic surgery market, supported by our global medical affairs team. This global team of clinical support specialists focuses on supporting our users to ensure optimal outcomes for their patients. In addition, we have invested in training programs and marketing-related activities to support accelerated adoption of Renuvion® into physicians’ practices.

In regards to our operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.

Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate & Other" includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.

In response to the global supply chain instability and inflationary cost increases, we continue to take action to minimize, as much as possible, any potential adverse impacts by working closely with our suppliers to closely monitor the availability of raw material components (i.e. semiconductors and plastics), lead times, and freight carrier availability. We expect global supply chain instability will continue to have an impact on our business, but to date that has not been material to our financial performance. The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty.

We strongly encourage investors to visit our website: www.apyxmedical.com to view the most current news and to review our filings with the Securities and Exchange Commission.











27
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued




Results of Operations

Sales
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)20232022Change20232022Change
Sales by Reportable Segment
Advanced Energy$9,836 $7,080 38.9 %$31,248 $26,258 19.0 %
OEM2,140 2,034 5.2 %6,439 5,641 14.1 %
Total$11,976 $9,114 31.4 %$37,687 $31,899 18.1 %
(632,000)
Sales by Domestic and International
Domestic$8,652 $6,997 23.7 %$27,660 $22,492 23.0 %
International3,324 2,117 57.0 %10,027 9,407 6.6 %
Total$11,976 $9,114 31.4 %$37,687 $31,899 18.1 %

Total revenue increased by 31.4%, or approximately $2.9 million, for the three months ended September 30, 2023 when compared with the three months ended September 30, 2022. Advanced Energy segment sales increased 38.9%, or approximately $2.8 million, for the three months ended September 30, 2023 when compared with the three months ended September 30, 2022. The Advanced Energy sales increase was driven by domestic customers who upgraded their generators to our new Apyx One Console, which we launched in January 2023, and a higher average selling price on sales of new generators due to the introduction of the Apyx One Console. These domestic increases were accompanied by increases in generator and handpiece sales in international markets. OEM segment sales increased 5.2%, or approximately $0.1 million, for the three months ended September 30, 2023 when compared with the three months ended September 30, 2022. The increase in OEM sales was due to increases in sales volume to existing customers.

Total revenue increased by 18.1%, or approximately $5.8 million, for the nine months ended September 30, 2023 when compared with the nine months ended September 30, 2022. Advanced Energy segment sales increased 19.0%, or approximately $5.0 million, for the nine months ended September 30, 2023 when compared with the nine months ended September 30, 2022. The Advanced Energy sales increase was driven by domestic customers who upgraded their generator to our new Apyx One Console, which we launched in January 2023, and a higher average selling price on sales of new generators due to the introduction of the Apyx One Console. OEM segment sales increased 14.1%, or approximately $0.8 million, for the nine months ended September 30, 2023 when compared with the nine months ended September 30, 2022. The increase in OEM sales was due to increases in sales volume to existing customers as well as incremental new sales upon the commencement of the supply arrangement related to the completion of the development portion of some of our OEM development agreements.

International sales represented approximately 27.8% and 26.6% of total revenues for the three and nine months ended September 30, 2023, respectively, as compared with 23.2% and 29.5% of total revenues for the same period in the prior year. Management estimates our products have been sold in more than 60 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.

28
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Gross Profit
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)20232022Change20232022Change
Cost of sales$3,998 $3,357 19.1 %$12,857 $11,009 16.8 %
Percentage of sales33.4 %36.8 %34.1 %34.5 %
Gross profit$7,978 $5,757 38.6 %$24,830 $20,890 18.9 %
Percentage of sales66.6 %63.2 %65.9 %65.5 %
Gross profit for the three months ended September 30, 2023, increased 38.6% to $8.0 million, compared to $5.8 million for the same period in the prior year. Gross margin for the three months ended September 30, 2023, was 66.6%, compared to 63.2% for the same period in 2022. The increase in gross profit margins for the three months ended September 30, 2023 from the prior year period is primarily attributable to changes in the sales mix between our two segments, with our Advanced Energy segment comprising a higher percentage of total sales and product mix within our Advanced Energy segment. These increases were partially offset by geographic mix within our Advanced Energy segment, with international sales comprising a higher percentage of total sales.

Gross profit for the nine months ended September 30, 2023, increased 18.9% to $24.8 million, compared to $20.9 million for the same period in the prior year. Gross margin for the nine months ended September 30, 2023, was 65.9%, compared to 65.5% for the same period in 2022. The increase in gross profit margins for the nine months ended September 30, 2023 from the prior year period is primarily attributable to changes in the product mix within our Advanced Energy and OEM segments and geographic mix within our Advanced Energy segment, with domestic sales comprising a higher percentage of total sales.

Other Costs and Expenses
Research and development
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)20232022Change20232022Change
Research and development expense$1,276 $1,061 20.3 %$3,596 $3,289 9.3 %
Percentage of sales10.7 %11.6 %9.5 %10.3 %
Research and development expenses increased 20.3% for the three months ended September 30, 2023, primarily due to higher spending on our product development initiatives and clinical studies ($0.1 million) and increased labor and benefits costs from the same period in the prior year ($0.1 million).

Research and development expenses increased 9.3% for the nine months ended September 30, 2023, primarily due to higher spending on our product development initiatives and clinical studies ($0.2 million) and increased labor and benefits costs from the same period in the prior year ($0.1 million).
Professional services
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)20232022Change20232022Change
Professional services expense$1,831 $1,936 (5.4)%$5,165 $6,611 (21.9)%
Percentage of sales15.3 %21.2 %13.7 %20.7 %

Professional services expense decreased 5.4% for the three months ended September 30, 2023, primarily attributable to decreases in legal expenses ($0.1 million) and recruiting expenses ($0.1 million). These decreases were partially offset by an increase in board of directors option expense ($0.1 million).

29
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Professional services expense decreased 21.9% for the nine months ended September 30, 2023, primarily attributable to decreases in legal expenses ($1.2 million) associated with the estimated loss recorded in the prior year for the class action lawsuit and current year reversal of a legal loss contingency, accounting and audit fees ($0.1 million), physician consulting fees ($0.1 million) and board of directors option expense ($0.1 million).

Salaries and related costs
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)20232022Change20232022Change
Salaries and related expenses$4,667 $3,871 20.6 %$14,770 $13,944 5.9 %
Percentage of sales39.0 %42.5 %39.2 %43.7 %

During the three months ended September 30, 2023, salaries and related expenses increased 20.6%, primarily driven by increases in bonus expense ($0.7 million) and labor and benefits costs ($0.3 million). These increases were partially offset by lower stock based compensation expense ($0.2 million).

During the nine months ended September 30, 2023, salaries and related expenses increased 5.9%, primarily driven by increases in bonus expense ($1.0 million), temporary labor expenses ($0.3 million) and labor and benefits costs ($0.2 million) as compared to the same period in the prior year. These increases are partially offset by lower stock based compensation expense ($0.7 million).

Selling, general and administrative expenses
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)20232022Change20232022Change
SG&A expense$4,841 $4,671 3.6 %$15,474 $14,675 5.4 %
Percentage of sales40.4 %51.3 %41.1 %46.0 %

During the three months ended September 30, 2023, selling, general and administrative expense increased 3.6%, primarily driven by increases in commissions ($0.3 million), bad debt expense ($0.1 million) and regulatory costs ($0.1 million). These increases were partially offset by lower employee meeting and training costs ($0.2 million) and lower insurance expense, including product liability claims on our policies ($0.1 million).

During the nine months ended September 30, 2023, selling, general and administrative expense increased 5.4%, primarily driven by increases in commissions ($0.7 million), travel expense ($0.4 million), insurance expense, including product liability claims on our policies ($0.3 million), and regulatory costs ($0.2 million). These increases were partially offset by decreases in advertising expense, including trade show fees and related costs ($0.4 million), employee meeting and training costs ($0.3 million) and bad debt expense ($0.1 million).

Gain on sale-leaseback

Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)2023202220232022
Other income, net— $— 2,692 $— 
Percentage of sales— %— %7.1 %— %

During the nine months ended September 30, 2023, gain on sale-leaseback was approximately $2.7 million as a result of the gain on the sale and leaseback of our Clearwater, FL facility in May 2023.



30
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Interest Income (Expense)

Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)2023202220232022
Interest income$248 $73 $478 $93 
Percentage of sales2.1 %0.8 %1.3 %0.3 %
Interest expense(585)$(1)(1,362)$(12)
Percentage of sales(4.9)%— %(3.6)%— %

Interest income increased approximately $0.2 million and $0.4 million, respectively, for the three and nine months ended September 30, 2023, when compared with the same periods the prior year. This increase is due to higher yields on our investments in money market funds and U.S. Treasury securities included in cash and cash equivalents, partially offset by a lower average balance.

Interest expense increased approximately $0.6 million and $1.4 million, respectively, for the three and nine months ended September 30, 2023, when compared with the same periods in the prior year. These increases are due to cash and noncash interest expense on the Credit Agreement executed on February 17, 2023.

Income Taxes
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)2023202220232022
Income tax expense (benefit)$(318)$50 $(2,519)$216 
Effective tax rate6.4 %(0.9)%21.4 %(1.3)%

Our income tax expense was approximately $(318,000) and $50,000 with effective tax rates of 6.4% and (0.9)% for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023 and 2022, the effective rate differs from the statutory rate primarily due to interest income on our income tax refund that we received during the quarter, partially offset by the full valuation allowance recorded on the net operating loss (“NOL”) generated during the period. For the three months ended September 30, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period.

Our income tax expense was approximately $(2,519,000) and $216,000 with effective tax rates of 21.4% and (1.3)% for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the our liability for uncertain tax positions, including accrued interest and penalties, of approximately $2.1 million, which were sustained upon the completion in January 2023 of the IRS examination of our 2018 through 2020 income tax returns and interest income on our income tax refund, partially offset by the full valuation allowance on the NOL and net deferred tax assets generated during the period. For the nine months ended September, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.

Liquidity and Capital Resources

At September 30, 2023, we had approximately $22.1 million in cash and cash equivalents as compared to approximately $10.2 million in cash and cash equivalents at December 31, 2022. Our working capital at September 30, 2023 was approximately $39.9 million compared with $31.1 million at December 31, 2022. The increase in working capital at September 30, 2023 was primarily due to proceeds received from the execution of the MidCap Credit agreement, the proceeds received upon the sale of our Clearwater, FL facility in May 2023 and the reversal of our liability for uncertain tax positions upon the completion in January 2023 of the IRS examination of our 2018, 2019 and 2020 income tax returns. This increase was partially offset by the the net loss we experienced through the first three quarters of 2023, excluding non-cash activity, comprised primarily of stock-based compensation.

31
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

For the nine months ended September 30, 2023, net cash used in operating activities exclusive of the receipt of our income tax refund was approximately $11.1 million, which principally funded our loss from operations of $11.5 million, compared with net cash used in operating activities of approximately $15.8 million in the same period for 2022. As discussed in the Executive Level Overview, our operating loss, cash used in operations and current cash and cash equivalents balance of $22.1 million, of which we must maintain $10.0 million under our Credit Agreement, raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date of issuance of our unaudited condensed consolidated financial statements.

In an effort to alleviate these conditions, we pursued various funding solutions in order to improve liquidity.

On November 22, 2022, the we filed a shelf registration statement providing us the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, we have not utilized this facility.

On February 17, 2023, we entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.

The Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the Credit Agreement.

On November 8, 2023, the we entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”) with Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto.

The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million.

For a more in depth description of the terms of the MidCap Credit Agreement and the Perceptive Credit Agreement, see Note 7 of Notes to Condensed Consolidated Financial Statements in Item 1 of this Quarterly Report on Form 10-Q.

On February 27, 2023, our Board of Directors approved a plan to sell and leaseback the our real property located in Clearwater, FL. On March 14, 2023, we entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of our facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. On May 8, 2023, we closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.

For a more in depth description of the terms of the Purchase Agreement, see Notes 4 and 5 of Notes to Condensed Consolidated Financial Statements in Item 1 of this Quarterly Report on Form 10-Q.

During January 2023, we were notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company's tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company's Consolidated Balance Sheet at December 31, 2022. On August 10, 2023, we received $8.1 million from the IRS, which included approximately $0.4 million of interest on the $7.7 million income tax refunds.

We also continue to re-assess our operating expenditures and cost structure to be commensurate with our expected levels of revenue and we have the ability to reduce or delay expenditures to enhance and preserve liquidity. We have already reduced some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced our U.S. headcount by 14%.

We believe that the actions already taken, including replacing the MidCap Credit Agreement with the Perceptive Credit Agreement, alleviate the conditions that raised substantial doubt about the our ability to continue as a going concern for a period of at least one year from the date of issuance of our unaudited condensed consolidated financial statements.
32
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued


Net cash provided by investing activities for the nine months ended September 30, 2023 was $6.8 million related to the sale of our Clearwater, FL facility ($7.3 million), partially offset by investments in property and equipment ($0.4 million). Net cash used in investing activities for the nine months ended September 30, 2022 was $0.9 million related to investments in property and equipment.

Net cash provided by financing activities for the nine months ended September 30, 2023 was $8.3 million, which primarily related to proceeds received upon the execution of the Credit Agreement ($9.9 million) less debt issuance costs incurred in the transaction ($1.8 million).

At September 30, 2023, our borrowing availability under the revolving facility was approximately $7.8 million.

At September 30, 2023, we had purchase commitments totaling approximately $3.5 million, substantially all of which is expected to be purchased within the next twelve months.




33
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Critical Accounting Estimates

In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our 2022 Form 10-K, filed with the SEC on March 16, 2023.

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

Stock-Based Compensation

Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, Compensation-Stock Compensation, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model, which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the estimates of expected life and volatility used in the calculations.

Expected life

For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.

Volatility

We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. The SEC allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.

Accounts Receivable Allowance

We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze historical bad debt experience, the composition of outstanding receivables by customer class, and the age of outstanding balances, and we make estimates in connection with establishing the allowance for doubtful accounts, including the expected impacts of changes in the operating environment and other trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required.
34
APYX MEDICAL CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued

Inventory Obsolescence Allowance

We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.

Litigation Contingencies

In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.

Income Taxes

The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.

As a result of historical losses and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on our net deferred tax assets. Exclusive of the carryback provisions of the CARES Act and the associated income tax benefit recognized in 2020, we do not anticipate recording an income tax benefit related to our deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent our results of operations improve, and it becomes more likely than not that the deferred tax assets will be realized. As Management has not fully determined the timing of when it will generate taxable income in the U.S., we continued to record a valuation allowance on the net deferred tax assets balance as of September 30, 2023.

We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.

Inflation

The consequences of the pandemic, global supply chain instability and inflationary cost increases and their adverse impact to the global economy, continue to evolve. Accordingly, the significance of the future impact to our business and financial statements remains subject to significant uncertainty. Inflation has not, to date, materially impacted our operations or financial performance. However, as these trends continue for raw materials, freight, and labor costs, our future financial performance could be adversely impacted.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements at this time.

Recent Accounting Pronouncements


35
APYX MEDICAL CORPORATION
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

36
APYX MEDICAL CORPORATION
ITEM 4. Controls and Procedures

Disclosure Controls and Procedures

Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2023, the Company’s disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

In February 2023, we entered into a Credit, Security and Guaranty Agreement (“Credit Agreement”). We have developed new control activities around the accounting for the Credit Agreement, including the review and compliance with debt covenants. We are in the process of testing the effectiveness of the new controls. There were no other changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by the Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

37
APYX MEDICAL CORPORATION
PART II.     Other Information

ITEM 1. Legal Proceedings



38
APYX MEDICAL CORPORATION
ITEM 1A. Risk Factors

There have been no material changes to the risk factors described under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.


39
APYX MEDICAL CORPORATION
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

ITEM 3. Defaults Upon Senior Securities

None.

ITEM 4. Mine Safety Disclosures

Not Applicable.

ITEM 5. Other Information

None.
40
APYX MEDICAL CORPORATION
ITEM 6. Exhibits
3.1
Articles of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s report on Form 10-K/A filed on March 31, 2011)
3.2
By laws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant’s report on Form 10-K/A filed on March 31, 2011)
3.3
Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.5 to the Registrant’s Quarterly Report on Form 10-Q filed on November 3, 2017)
3.4
Certificate of Elimination (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 3, 2018)
3.5Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on December 28, 2018)
10.1
First Amendment to Purchase and Sale Agreement, dated April 12, 2023 (Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8 filed on April 18, 2023).
31.1*
31.2*
32.1*
32.2*
101.INS**XBRL Instance Document
101.SCH**XBRL Taxonomy Extension Schema Document
101.CAL**XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**XBRL Taxonomy Extension Label Linkbase Document
101.PRE**XBRL Taxonomy Extension Label Presentation Document

* Filed herewith.

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.

41
APYX MEDICAL CORPORATION
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Apyx Medical Corporation
Date: November 9, 2023By:/s/ Charles D. Goodwin II
Charles D. Goodwin II
President, Chief Executive Officer and Director
(Principal Executive Officer)
Date: November 9, 2023By:/s/ Tara Semb
Tara Semb
Chief Financial Officer,
Treasurer and Secretary
(Principal Financial Officer)

42
 EX-31.1 2 a2023q310-kexhibit311.htm EX-31.1 Document
EXHIBIT 31.1

Certificate Pursuant to Section 302
of Sarbanes – Oxley Act of 2002
CERTIFICATION OF CEO

I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: November 9, 2023By:/s/ Charles D. Goodwin II
Charles D. Goodwin II
President and Chief Executive Officer

 EX-31.2 3 a2023q310-kexhibit312.htm EX-31.2 Document
EXHIBIT 31.2

Certificate Pursuant to Section 302
of Sarbanes – Oxley Act of 2002
CERTIFICATION OF CFO

I, Tara Semb, the Registrant's Chief Financial Officer, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.
Date: November 9, 2023By:/s/ Tara Semb
Tara Semb
Chief Financial Officer, Treasurer and Secretary


 EX-32.1 4 a2023q310-kexhibit322.htm EX-32.1 Document
EXHIBIT 32.2
Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to
Section 906 of Sarbanes – Oxley Act of 2002
CERTIFICATION OF CFO

In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the "Company") for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2023By:/s/ Tara Semb
Tara Semb
Chief Financial Officer, Treasurer and Secretary


 EX-32.2 5 a2023q310-qexhibit321.htm EX-32.2 Document
EXHIBIT 32.1
Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to
Section 906 of Sarbanes – Oxley Act of 2002
CERTIFICATION OF CEO

In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the "Company") for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2023By:/s/ Charles D. Goodwin II
Charles D. Goodwin II
President and Chief Executive Officer




 EX-101.SCH 6 apyx-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - CHINA JOINT VENTURE link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - EARNINGS (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - CHINA JOINT VENTURE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - LEASES - Lease Terms and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - DEBT - Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - CHINA JOINT VENTURE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - EARNINGS (LOSS) PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 apyx-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 apyx-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 apyx-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Variable Rate [Domain] Variable Rate [Domain] Net loss attributable to non-controlling interest Net loss attributable to Apyx Net Income (Loss) Attributable to Noncontrolling Interest Statistical Measurement [Domain] Statistical Measurement [Domain] Less: provision for obsolescence Inventory Valuation Reserves Credit facility Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] DEBT Debt Disclosure [Text Block] Debt Instrument, Prepayment Period One Debt Instrument, Prepayment Period One [Member] Debt Instrument, Prepayment Period One Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Debt Instrument, Covenant, Tranche One Debt Instrument, Covenant, Tranche One [Member] Debt Instrument, Covenant, Tranche One Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Stock swaps (in shares) Stock Issued During Period, Shares, Stock Swaps Stock Issued During Period, Shares, Stock Swaps Construction in progress Construction in Progress, Gross Proceeds from income tax refund, principal Proceeds From Income Tax Refunds, Principal Proceeds From Income Tax Refunds, Principal Co-venturer Co-venturer [Member] Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification Capitalization Of Lease, Execution Capitalization Of Lease, Execution Geographical [Axis] Geographical [Axis] Sale leaseback, management fee on rent payment Sale Leaseback, Management Fee On Rent Payment Sale Leaseback, Management Fee On Rent Payment INCOME TAXES Income Tax Disclosure [Text Block] Ownership [Axis] Ownership [Axis] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate OEM OEM [Member] Lockbox account, funds to be applied to borrowings Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings Noncontrolling Interest [Abstract] Current liabilities: Liabilities, Current [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2023 and December 31, 2022 Preferred Stock, Value, Issued Proceeds from the disposition of Core business Proceeds from Divestiture of Businesses Subsequent Event Type [Domain] Subsequent Event Type [Domain] Proceeds from stock option exercises Proceeds From Stock Options Exercised And Warrants Exercised Proceeds From Stock Options Exercised And Warrants Exercised Canceled and forfeited (in dollars per shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Diluted (in dollars per share) Earnings Per Share, Diluted At-The-Market At-The-Market [Member] At-The-Market Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Trade accounts receivable, net of allowance of $652 and $668 Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Line of Credit Line of Credit [Member] Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Building and improvements Building and Building Improvements [Member] Litigation Case [Axis] Litigation Case [Axis] Shares issued on stock options exercises for cash Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Gain on sale-leaseback Sale and Leaseback Transaction, Gain (Loss), Net Granted (in dollars per share) Strike price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Net loss attributable to stockholders Net Income (Loss) Income tax receivables Income tax receivables Increase (Decrease) in Income Taxes Receivable Total current liabilities Liabilities, Current Debt Instrument, Covenants [Axis] Debt Instrument, Covenants [Axis] Debt Instrument, Covenants Machinery and equipment Machinery and Equipment [Member] LEASES Lessee, Operating Leases [Text Block] Debt Instrument, Prepayment Period, After Year Four Debt Instrument, Prepayment Period, After Year Four [Member] Debt Instrument, Prepayment Period, After Year Four Beginning balance (in shares) Ending balance (in shares) Shares, Issued LIABILITIES AND EQUITY Liabilities and Equity [Abstract] EQUITY Equity, Attributable to Parent [Abstract] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Borrowing base, minimum balance Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount Gross inventories Inventory, Gross Basic and diluted earnings (loss) per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Goods and Services Sold Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Proceeds received from issuance of warrants Adjustments to Additional Paid in Capital, Warrant Issued Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Warrants, exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Schedule of revenue by geographic area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business Local Phone Number Local Phone Number Trade receivables Increase (Decrease) in Accounts Receivable Sale leaseback, term of lease Sale Leaseback, Term Of Lease Sale Leaseback, Term Of Lease Warrants Warrant [Member] Long-term operating lease liabilities Long-term portion of lease liabilities Operating Lease, Liability, Noncurrent Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Payment of debt issuance costs Payments of Debt Issuance Costs Proceeds from income tax refund, interest Proceeds From Income Tax Refunds, Interest Proceeds From Income Tax Refunds, Interest Term Loan Schedule of Long-Term Debt Instruments [Table Text Block] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Annual fee Debt Instrument, Annual Fee, Percent Debt Instrument, Annual Fee, Percent Debt Instrument, Prepayment Period Three Debt Instrument, Prepayment Period Three [Member] Debt Instrument, Prepayment Period Three Payables and Accruals [Abstract] Payables and Accruals [Abstract] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Lease Costs Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Sale leaseback, security deposit withheld Sale Leaseback, Security Deposit Withheld Sale Leaseback, Security Deposit Withheld Anti-dilutive instruments (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document Quarterly Report Document Quarterly Report Prepayment penalties and exit fees Payment for Debt Extinguishment or Debt Prepayment Cost Property and equipment in service Property, Plant And Equipment, In Service Property, Plant And Equipment, In Service Income tax receivables Income Taxes Receivable, Current Interest expense Interest Expense Default, applicable interest rate Debt Instrument, Default, Applicable Interest Rate Debt Instrument, Default, Applicable Interest Rate Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Principal payments, percentage Line of Credit Facility, Periodic Payment, Principal, Percentage Line of Credit Facility, Periodic Payment, Principal, Percentage Total property, plant and equipment Property, Plant and Equipment, Gross RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Debt Instrument, Prepayment Period [Domain] Debt Instrument, Prepayment Period [Domain] Debt Instrument, Prepayment Period [Domain] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Unamortized debt discount, including accretion of exit fee Debt Instrument, Unamortized Discount Current portion of operating lease liabilities Less current portion of lease liabilities Operating Lease, Liability, Current Accrued product warranties Product Warranty Accrual, Current Accounts payable Accounts Payable Debt Instrument, Covenant, Tranche Three Debt Instrument, Covenant, Tranche Three [Member] Debt Instrument, Covenant, Tranche Three Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Risk-free rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Securities registered, new issues Securities Registered, New Issues Securities Registered, New Issues Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Uncertain tax positions Uncertain Tax Positions Liability Uncertain Tax Positions Liability 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Equity, Attributable to Noncontrolling Interest [Roll Forward] Borrowing base, minimum balance Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent Sale leaseback, annual rent payment Sale Leaseback. Annual Rent Payment Sale Leaseback. Annual Rent Payment Common stock, shares issued (in shares) Common Stock, Shares, Issued Gross profit Gross Profit Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Schedule of option fair value assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Shares issued on net settlement of stock options (in shares) Stock swap to acquire options, Shares Stock swap to acquire options shares. Term loan, net Long-Term Debt Share based compensation Share-Based Payment Arrangement [Policy Text Block] Selling, general and administrative Selling, General and Administrative Expense Perceptive Credit Agreement Perceptive Credit Agreement [Member] Perceptive Credit Agreement Options Employee Stock Option [Member] Other accrued expenses and current liabilities Other Accrued Expenses And Liabilities, Current Other Accrued Expenses And Liabilities, Current Sale leaseback, net cash proceeds Sale Leaseback, Net Cash Proceeds Sale Leaseback, Net Cash Proceeds CHINA JOINT VENTURE Noncontrolling Interest Disclosure [Text Block] Maximum Maximum [Member] Document Type Document Type Entity Address, Address Line One Entity Address, Address Line One Right-of-use assets capitalized and operating lease liabilities recognized upon execution of lease Capitalization Of Lease, Non Cash Capitalization Of Lease, Non Cash Inventories Inventory, Policy [Policy Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification Capitalization Of Lease Derecognized Execution Capitalization Of Lease Derecognized Execution Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Subsequent Event Subsequent Event [Member] Accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Other costs and expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Interest income Interest income Interest Income, Operating Debt Instrument, Termination Period [Axis] Debt Instrument, Termination Period [Axis] Debt Instrument, Termination Period Related Party [Domain] Related Party, Type [Domain] Ownership interest Subsidiary, Ownership Percentage, Noncontrolling Owner Operating Segments Operating Segments [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Advanced Energy Advanced Energy [Member] Advanced Energy [Member] Anti-dilutive instruments excluded from diluted loss per common share: Earnings Per Share, Diluted [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventories, net of provision for obsolescence of $611 and $457 Inventories, net Inventory, Net Security deposit equal to annual rent Sale Leaseback, Security Deposit Equal To Annual Rent Sale Leaseback, Security Deposit Equal To Annual Rent Purchase agreement Sale Leaseback, Purchase Agreement Sale Leaseback, Purchase Agreement Statistical Measurement [Axis] Statistical Measurement [Axis] Land Land [Member] Twelve month net revenue target, year one Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Segments [Domain] Segments [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash used in operations Net Cash Provided by (Used In) Operating Activities, Excluding Operating Income (Loss) Net Cash Provided by (Used In) Operating Activities, Excluding Operating Income (Loss) Consolidation Items [Domain] Consolidation Items [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Twelve month net revenue target, year two Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two Mortgage loan, principal amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Non-cash interest expense Increase (Decrease) in Interest Payable, Net Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Loss per share: Earnings Per Share, Basic [Abstract] Chinese Supplier Chinese Supplier [Member] Chinese Supplier Estimate of possible loss Loss Contingency, Estimate of Possible Loss Molds Molds [Member] Molds Non cash activities: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Perceptive Credit Agreement, Initial Loan Perceptive Credit Agreement, Initial Loan [Member] Perceptive Credit Agreement, Initial Loan Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Net loss attributable to stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Schedule of inventory Schedule of Inventory, Current [Table Text Block] Number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Professional services Professional Fees Debt Instrument [Axis] Debt Instrument [Axis] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Present value of lease liabilities Operating Lease, Liability Contributions from non-controlling interest Contributions Noncontrolling Interest, Increase from Subsidiary Equity Issuance Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Reversal of loss accrual Loss Contingency Accrual, Period Increase (Decrease) PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Long-term contract liabilities Contract with Customer, Liability, Noncurrent Accrued bonuses Accrued Bonuses, Current Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments Debt Instrument, Termination Period One Debt Instrument, Termination Period One [Member] Debt Instrument, Termination Period One Loss per share: Earnings Per Share [Abstract] Debt Instrument, Covenant, Tranche Two Debt Instrument, Covenant, Tranche Two [Member] Debt Instrument, Covenant, Tranche Two Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,855 issued and outstanding as of September 30, 2023, and 34,597,822 issued and outstanding as of December 31, 2022 Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Accrued professional fees and legal related contingent liabilities Accrued Professional Fees, Current Number of monthly payments Debt Instrument, Number Of Monthly Payments Debt Instrument, Number Of Monthly Payments Debt Instrument, Covenants [Domain] Debt Instrument, Covenants [Domain] Debt Instrument, Covenants [Domain] Total current assets Assets, Current Cash paid for: Supplemental Cash Flow Information [Abstract] Twelve month net revenue target, year three Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three Litigation Case [Domain] Litigation Case [Domain] Total other (expense) income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Purchase obligation Purchase Obligation Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date International sales, percent of total revenue Total Revenue, Percent Total Revenue, Percent Debt Instrument, Termination Period Two Debt Instrument, Termination Period Two [Member] Debt Instrument, Termination Period Two Sales tax payable Sales and Excise Tax Payable, Current RECENT ACCOUNTING PRONOUNCEMENTS Accounting Standards Update and Change in Accounting Principle [Text Block] Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents balance Debt Instrument, Covenant, Cash And Cash Equivalents Balance Debt Instrument, Covenant, Cash And Cash Equivalents Balance Warrants to be issued Class of Warrant or Right, Number of Securities to be Called by Warrants or Rights Class of Warrant or Right, Number of Securities to be Called by Warrants or Rights Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Net cash used in operating activities Net cash used in cash operations Net Cash Provided by (Used in) Operating Activities Corporate & Other Corporate, Non-Segment [Member] Accrued payroll Accrued Salaries, Current Depreciation and amortization Depreciation, Depletion and Amortization Other (expense) income, net Other income (loss), net Other Operating Income (Expense), Net Furniture and fixtures Furniture and Fixtures [Member] Perceptive Credit Agreement, Delayed Draw Loan Perceptive Credit Agreement, Delayed Draw Loan [Member] Perceptive Credit Agreement, Delayed Draw Loan Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Adjusted Term Secured Overnight Financing Rate (SOFR) Adjusted Term Secured Overnight Financing Rate (SOFR) [Member] Adjusted Term Secured Overnight Financing Rate (SOFR) Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Debt Instrument, Prepayment Period [Axis] Debt Instrument, Prepayment Period [Axis] Debt Instrument, Prepayment Period Interest rate floor Debt Instrument, Interest Rate Floor, Percent Debt Instrument, Interest Rate Floor, Percent Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Salaries and related costs Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Accrued commissions Accrued Sales Commission, Current Leaseback term Sale Leaseback Transaction, Lease Term Earnings Per Share Reconciliation [Abstract] Earnings Per Share Reconciliation [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Accounting Standards Update and Change in Accounting Principle [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Computer equipment and software Computer Equipment And Software [Member] Computer Equipment And Software Unamortized debt issuance costs Debt Issuance Costs, Net Finished goods Inventory, Finished Goods, Gross Repayment of finance lease liabilities Repayment of Finance Lease Liabilities Repayment of Finance Lease Liabilities Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Proceeds from income tax refunds Proceeds from Income Tax Refunds City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code EARNINGS (LOSS) PER SHARE Earnings Per Share [Text Block] Corporate Joint Venture Corporate Joint Venture [Member] Interest rate floor spread Debt Instrument, Interest Rate Floor Spread Adjustment, Percent Debt Instrument, Interest Rate Floor Spread Adjustment, Percent Inventories, provision for obsolescence Provision For Obsolescence, Inventory Provision For Obsolescence, Inventory Thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Summary of stock options and stock awards Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exit fee Debt Instrument, Exit Fee Debt Instrument, Exit Fee Debt Instrument, Prepayment Period Four Debt Instrument, Prepayment Period Four [Member] Debt Instrument, Prepayment Period Four Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Debt Instrument, Termination Period [Domain] Debt Instrument, Termination Period [Domain] Debt Instrument, Termination Period [Domain] Proceeds from term loan Proceeds from Issuance of Long-Term Debt Accrued product liability claim insurance deductibles Accrued Insurance, Current MidCap Credit Agreement Mid Cap Credit Agreement [Member] Mid Cap Credit Agreement Debt issuance costs Debt Issuance Costs, Gross Net loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Prepayment fee Debt Instrument, Prepayment Fee, Percent Debt Instrument, Prepayment Fee, Percent Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Total liabilities and equity Liabilities and Equity Other assets Other Assets, Noncurrent Ownership [Domain] Ownership [Domain] Basic (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Number of positions eliminated Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Sale of Stock [Domain] Sale of Stock [Domain] Risk-free rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Warrants term Warrants and Rights Outstanding, Term 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Net loss attributable to stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Entity Address, City or Town Entity Address, City or Town Schedule of reporting information by segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Termination fees Debt Instrument, Termination Fees Debt Instrument, Termination Fees Income taxes Income Taxes Paid Document Transition Report Document Transition Report Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Repayments of lines of credit Repayments of Lines of Credit Raw materials Inventory, Raw Materials, Gross Contributions from non-controlling interest Proceeds from Noncontrolling Interests Property, Plant and Equipment [Abstract] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Term loan Long-Term Debt, Gross Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Period of interest only Debt Instrument, Period Of Interest Only Debt Instrument, Period Of Interest Only Provision for allowance for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Additional paid-in capital Additional Paid in Capital Subsequent Event Type [Axis] Subsequent Event Type [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Work in process Inventory, Work in Process, Gross Allowance for doubtful accounts receivable Accounts Receivable, Allowance for Credit Loss Related Party [Axis] Related Party, Type [Axis] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Shares issued on stock options exercises for cash (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Joint and several payroll liability Joint And Several Payroll Liability Joint And Several Payroll Liability Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Suits Filed In 2022 Suits Filed In 2022 [Member] Suits Filed In 2022 Non-controlling interest Beginning interest in China JV Ending interest in China JV Equity, Attributable to Noncontrolling Interest Document Period End Date Document Period End Date Proceeds from line of credit Proceeds from Lines of Credit Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Amortization of debt discounts Amortization of Debt Issuance Costs and Discounts Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Costs accrued Loss Contingency Accrual (Gain) loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Stock based compensation Share-Based Payment Arrangement, Expense Denominator: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Income tax (benefit) expense Income Tax Expense (Benefit) International Non-US [Member] Finance lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Number of operating segments Number of Operating Segments Schedule of China Joint Venture Noncontrolling Interest [Table Text Block] Noncontrolling Interest INVENTORIES Inventory Disclosure [Text Block] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Sales Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other Receivables, Net, Current Term Loan Term Loan [Member] Term Loan Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Suit Against Goodwin and Simb Suit against Goodwin and Simb [Member] Suit against Goodwin and Simb Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Required capital contribution Noncontrolling Interest, Required Capital Contribution Noncontrolling Interest, Required Capital Contribution Credit Facility [Domain] Credit Facility [Domain] Sale leaseback, annual rent increase Sale Leaseback, Annual Rent Increase Sale Leaseback, Annual Rent Increase Variable rate Debt Instrument, Basis Spread on Variable Rate Term loan, net Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Weighted average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Debt Instrument, Termination Period Three Debt Instrument, Termination Period Three [Member] Debt Instrument, Termination Period Three Sale leaseback, renewal term Sale Leaseback, Renewal Term Sale Leaseback, Renewal Term Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Additional Paid-In Capital Additional Paid-in Capital [Member] Stock swaps equity instruments received (in shares) Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received Total assets Assets Loss Contingencies [Line Items] Loss Contingencies [Line Items] Twelve month net revenue target, year four Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Four Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Four Shelf Registration Shelf Registration [Member] Shelf Registration Cover [Abstract] Cover [Abstract] Proceeds from issuance of warrants Proceeds from Issuance of Warrants Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities, Current Accrued Liabilities and Other Liabilities, Current Stock based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs Domestic UNITED STATES Short-term contract liabilities Short-Term Contract Liabilities Short-Term Contract Liabilities Other liabilities Other Liabilities, Noncurrent Canceled and forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Total lease payments Lessee, Operating Lease, Liability, to be Paid Purchases from related party Related Party Transaction, Purchases from Related Party Transaction cost and other expenses Debt Instrument, Transaction Cost and Other Expenses Debt Instrument, Transaction Cost and Other Expenses Total other costs and expenses Operating Expenses GEOGRAPHIC AND SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Secured Debt Secured Debt [Member] Equity Component [Domain] Equity Component [Domain] Current portion of finance lease liabilities Finance Lease, Liability, Current Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Debt Instrument [Line Items] Debt Instrument [Line Items] Entity Current Reporting Status Entity Current Reporting Status Loss from operations Loss from operations (Loss) income from operations Operating Income (Loss) Number of monthly payments, extension Debt Instrument, Number Of Monthly Payments, Extension Debt Instrument, Number Of Monthly Payments, Extension Provision for inventory obsolescence Provision For Inventory Obsolescence Provision For Inventory Obsolescence Related Party Transaction [Axis] Related Party Transaction [Axis] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Extension period Debt Instrument, Extension Period Debt Instrument, Extension Period Debt Instrument, Prepayment Period Two Debt Instrument, Prepayment Period Two [Member] Debt Instrument, Prepayment Period Two Non-cash lease expense Non-Cash Lease Expense Non-Cash Lease Expense Non-controlling Interest Noncontrolling Interest [Member] EX-101.PRE 10 apyx-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 apyx-20230930_g1.jpg begin 644 apyx-20230930_g1.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 08, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-31885  
Entity Registrant Name APYX MEDICAL CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 11-2644611  
Entity Address, Address Line One 5115 Ulmerton Road,  
Entity Address, City or Town Clearwater  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33760  
City Area Code 727  
Local Phone Number 384-2323  
Title of 12(b) Security Common Stock  
Trading Symbol APYX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   34,643,855
Entity Central Index Key 0000719135  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 22,134 $ 10,192
Trade accounts receivable, net of allowance of $652 and $668 12,648 10,602
Income tax receivables 0 7,545
Other receivables 596 99
Inventories, net of provision for obsolescence of $611 and $457 11,285 11,797
Prepaid expenses and other current assets 3,487 2,737
Total current assets 50,150 42,972
Property and equipment, net 2,093 6,761
Operating lease right-of-use assets 5,274 710
Finance lease right-of-use assets 74 115
Other assets 1,855 1,217
Total assets 59,446 51,775
Current liabilities:    
Accounts payable 2,050 2,669
Accrued expenses and other current liabilities 7,914 8,928
Current portion of operating lease liabilities 310 216
Current portion of finance lease liabilities 20 37
Total current liabilities 10,294 11,850
Term loan, net 9,009 0
Long-term operating lease liabilities 4,992 470
Long-term finance lease liabilities 58 73
Long-term contract liabilities 1,326 1,408
Other liabilities 181 181
Total liabilities 25,860 13,982
EQUITY    
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2023 and December 31, 2022 0 0
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,855 issued and outstanding as of September 30, 2023, and 34,597,822 issued and outstanding as of December 31, 2022 35 35
Additional paid-in capital 78,154 73,282
Accumulated deficit (44,841) (35,735)
Total stockholders’ equity 33,348 37,582
Non-controlling interest 238 211
Total equity 33,586 37,793
Total liabilities and equity $ 59,446 $ 51,775
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts receivable $ 652 $ 668
Inventories, provision for obsolescence $ 611 $ 457
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 75,000,000 75,000,000
Common stock, shares issued (in shares) 34,643,855 34,597,822
Common stock, shares outstanding (in shares) 34,643,855 34,597,822
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Sales $ 11,976 $ 9,114 $ 37,687 $ 31,899
Cost of sales 3,998 3,357 12,857 11,009
Gross profit 7,978 5,757 24,830 20,890
Other costs and expenses:        
Research and development 1,276 1,061 3,596 3,289
Professional services 1,831 1,936 5,165 6,611
Salaries and related costs 4,667 3,871 14,770 13,944
Selling, general and administrative 4,841 4,671 15,474 14,675
Total other costs and expenses 12,615 11,539 39,005 38,519
Gain on sale-leaseback 0 0 2,692 0
Loss from operations (4,637) (5,782) (11,483) (17,629)
Interest income 248 73 478 93
Interest expense (585) (1) (1,362) (12)
Other (expense) income, net (19) (35) 622 551
Total other (expense) income, net (356) 37 (262) 632
Loss before income taxes (4,993) (5,745) (11,745) (16,997)
Income tax (benefit) expense (318) 50 (2,519) 216
Net loss (4,675) (5,795) (9,226) (17,213)
Net loss attributable to non-controlling interest (46) (31) (120) (78)
Net loss attributable to stockholders $ (4,629) $ (5,764) $ (9,106) $ (17,135)
Loss per share:        
Basic (in dollars per share) $ (0.13) $ (0.17) $ (0.26) $ (0.50)
Diluted (in dollars per share) $ (0.13) $ (0.17) $ (0.26) $ (0.50)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2021   34,410      
Beginning balance at Dec. 31, 2021 $ 54,009 $ 34 $ 66,221 $ (12,551) $ 305
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued on stock options exercises for cash (in shares)   106      
Shares issued on stock options exercises for cash 365 $ 1 364    
Stock based compensation 5,056   5,056    
Shares issued on net settlement of stock options (in shares)   72      
Net loss (17,213)     (17,135) (78)
Ending balance (in shares) at Sep. 30, 2022   34,588      
Ending balance at Sep. 30, 2022 42,217 $ 35 71,641 (29,686) 227
Beginning balance (in shares) at Jun. 30, 2022   34,493      
Beginning balance at Jun. 30, 2022 46,163 $ 34 69,793 (23,922) 258
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Shares issued on stock options exercises for cash (in shares)   62      
Shares issued on stock options exercises for cash 157 $ 1 156    
Stock based compensation 1,692   1,692    
Shares issued on net settlement of stock options (in shares)   33      
Net loss (5,795)     (5,764) (31)
Ending balance (in shares) at Sep. 30, 2022   34,588      
Ending balance at Sep. 30, 2022 42,217 $ 35 71,641 (29,686) 227
Beginning balance (in shares) at Dec. 31, 2022   34,598      
Beginning balance at Dec. 31, 2022 37,793 $ 35 73,282 (35,735) 211
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Contributions from non-controlling interest 147       147
Shares issued on stock options exercises for cash (in shares)   35      
Shares issued on stock options exercises for cash 86   86    
Stock based compensation 4,200   4,200    
Shares issued on net settlement of stock options (in shares)   11      
Proceeds received from issuance of warrants 586   586    
Net loss (9,226)     (9,106) (120)
Ending balance (in shares) at Sep. 30, 2023   34,644      
Ending balance at Sep. 30, 2023 33,586 $ 35 78,154 (44,841) 238
Beginning balance (in shares) at Jun. 30, 2023   34,629      
Beginning balance at Jun. 30, 2023 36,733 $ 35 76,773 (40,212) 137
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Contributions from non-controlling interest 147       147
Shares issued on stock options exercises for cash (in shares)   10      
Shares issued on stock options exercises for cash 30   30    
Stock based compensation 1,351   1,351    
Shares issued on net settlement of stock options (in shares)   5      
Net loss (4,675)     (4,629) (46)
Ending balance (in shares) at Sep. 30, 2023   34,644      
Ending balance at Sep. 30, 2023 $ 33,586 $ 35 $ 78,154 $ (44,841) $ 238
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities    
Net loss $ (9,226) $ (17,213)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 540 688
Provision for inventory obsolescence 229 158
(Gain) loss on disposal of property and equipment (2,656) 76
Stock based compensation 4,200 5,056
Provision for allowance for doubtful accounts 176 283
Non-cash interest expense 354 0
Non-cash lease expense 56 0
Changes in operating assets and liabilities:    
Trade receivables (2,192) 3,273
Prepaid expenses and other assets (698) (521)
Income tax receivables 7,545 97
Inventories 401 (5,672)
Accounts payable (613) (439)
Accrued and other liabilities (1,153) (1,536)
Net cash used in operating activities (3,037) (15,750)
Cash flows from investing activities    
Purchases of property and equipment (440) (868)
Proceeds from sale of property and equipment 7,267 0
Net cash provided by (used in) investing activities 6,827 (868)
Cash flows from financing activities    
Proceeds from stock option exercises 86 365
Proceeds from term loan 9,289 0
Payment of debt issuance costs (1,754) 0
Proceeds from issuance of warrants 586 0
Repayment of finance lease liabilities (32) (138)
Contributions from non-controlling interest 147 0
Net cash provided by financing activities 8,322 227
Effect of exchange rates on cash (170) 354
Net change in cash and cash equivalents 11,942 (16,037)
Cash and cash equivalents, beginning of period 10,192 30,870
Cash and cash equivalents, end of period 22,134 14,833
Cash paid for:    
Interest 834 12
Income taxes 261 128
Non cash activities:    
Right-of-use assets capitalized and operating lease liabilities recognized upon execution of lease 4,917 0
Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification 0 769
Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease 0 103
Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification $ 0 $ 28
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.3
BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION BASIS OF PRESENTATION
Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.

The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.

As part of its plan to accelerate and fully fund the development of its advanced energy business, with a focus in the cosmetic surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances.

On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures, but had not yet been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.

On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III.

On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures.

On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region.

On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin.

On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.

On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.

On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.
The May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. Management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should assist in mitigating the financial effects of the Safety Communication in future periods.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.

While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the nine months ended September 30, 2023, the Company incurred an operating loss of $11.5 million and used $11.1 million of cash in operations exclusive of the receipt of the Company's tax refund, including interest, of approximately $8.1 million. As of September 30, 2023, the Company had cash and cash equivalents of $22.1 million, of which the Company must maintain $10.0 million under its Credit Agreement. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.

In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity.

On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, the Company has not utilized this facility.

On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.

The MidCap Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the MidCap Credit Agreement.

On November 8, 2023, the Company entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto.
The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million.

For a more in depth description of the terms of the MidCap Credit Agreement and the Perceptive Credit Agreement, see Note 7.

On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company’s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser.

For a more in depth description of the terms of the Purchase Agreement, see Notes 4 and 5.

During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company’s tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. On August 10, 2023, the Company received $8.1 million from the IRS, which included approximately $0.4 million of interest on the $7.7 million income tax refunds.

The Company also re-assessed its operating expenditures and cost structure and made adjustments in light of expected levels of revenue. This included reducing some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company’s U.S. headcount by 14%.

Management believes that the actions already taken, including replacing the MidCap Credit Agreement with the Perceptive Credit Agreement, alleviate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of its unaudited condensed consolidated financial statements.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.3
RECENT ACCOUNTING PRONOUNCEMENTS
 9 Months Ended
Sep. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.

No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
INVENTORIES
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.

Inventories consisted of the following:
(In thousands)September 30,
2023		December 31,
2022
Raw materials$4,578 $4,979 
Work in process2,522 2,160 
Finished goods 4,796 5,115 
Gross inventories11,896 12,254 
Less: provision for obsolescence(611)(457)
Inventories, net$11,285 $11,797 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT
 9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
(In thousands)September 30, 2023
(Unaudited)		December 31,
2022
Land$— $1,600 
Building and improvements— 4,426 
Machinery and equipment2,635 2,613 
Furniture and fixtures216 211 
Computer equipment and software1,079 1,420 
Leasehold improvements178 178 
Molds1,017 847 
Total property, plant and equipment5,125 11,295 
Less: accumulated depreciation and amortization(3,489)(5,041)
Property and equipment in service1,636 6,254 
Construction in progress457 507 
Property and equipment, net$2,093 $6,761 

In an effort to improve liquidity and the balance sheet condition of the Company, management explored options to leverage the Company’s unencumbered real property. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL.

On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000.

On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser (see Note 5). The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit of approximately $0.6 million, equal to one year's rent, taxes, first months rent, expenses, and fees. The $2,700,000 gain on this transaction is presented in gain on sale-leaseback in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2023.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.3
LEASES
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
LEASES LEASES
Operating Leases

The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. These operating leases have terms expiring through December 2027.

In connection with the terms of the Purchase Agreement (see Note 4), during May 2023, the Company entered into a Single Tenant Industrial Building Lease (the “Lease”), pursuant to which the Property was leased back to the Company. The Lease has an initial term of ten (10) years commencing from the closing (the “Initial Term”), and a renewal term of five (5) years, exercisable at the Company’s option. The annual fixed rent is $619,500 for the first year of the Initial Term, and is subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term.

The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.

Information about the Company’s weighted average remaining operating lease terms and discount rate assumptions are as follows:
September 30, 2023December 31,
2022
Weighted average remaining lease term (in years)9.24.4
Weighted average discount rate8.42%2.54%

Maturities of operating lease liabilities as of September 30, 2023 are as follows:
(In thousands)
2023$190 
2024773 
2025799 
2026826 
2027855 
Thereafter4,516 
Total lease payments7,959 
Less imputed interest(2,657)
Present value of lease liabilities5,302 
Less current portion of lease liabilities(310)
Long-term portion of lease liabilities$4,992 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.3
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
 9 Months Ended
Sep. 30, 2023
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following:
(in thousands)September 30,
2023		December 31,
2022
Accrued payroll$879 $563 
Accrued bonuses1,188 — 
Accrued commissions1,183 847 
Accrued product warranties386 391 
Accrued product liability claim insurance deductibles2,060 1,825 
Accrued professional fees and legal related contingent liabilities607 901 
Joint and several payroll liability— 345 
Short-term contract liabilities712 853 
Uncertain tax positions— 2,079 
Sales tax payable245 245 
Other accrued expenses and current liabilities654 879 
Total accrued expenses and other current liabilities$7,914 $8,928 

During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations. This adjustment is included in other (expense) income, net for the nine months ended September 30, 2023.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
DEBT DEBT
Included in interest expense for the three and nine months ended September 30, 2023 are $36,000 and $87,000, respectively, of amortization of the debt issuance costs and $81,000 and $198,000, respectively, of amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three and nine months ended September 30, 2023 are $25,000 and $62,000, respectively, of amortization of the debt issuance costs and $3,000 and $7,000, respectively, of amortization of the debt discount on the revolving facility.

The Company’s term loan, net consists of the following at September 30, 2023:

(In thousands)
Term loan$10,000 
Unamortized debt issuance costs(414)
Unamortized debt discount, including accretion of exit fee(577)
Term loan, net$9,009 

The term loan, net was paid in full on November 8, 2023 in connection with the execution of the Perceptive Credit Agreement. The Company is still determining the appropriate accounting treatment for the MidCap Credit Agreement and Perceptive Credit Agreement. While the Perceptive Credit Agreement contains a subjective acceleration clause, management has determined that there is remote probability that Perceptive would accelerate of the obligations under the subjective acceleration clause. Accordingly, term loan, net has been presented as a long term liability in the accompanying condensed consolidated balance sheet as of September 30, 2023. The Company expects to record a loss on extinguishment of the MidCap Credit Agreement of approximately $2.5 million in connection with the write-off of unamortized debt issuance costs, debt discounts and unamortized debt premiums.

MIDCAP CREDIT AGREEMENT

On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively “MidCap”).

The MidCap Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The MidCap Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the MidCap Credit Agreement. The MidCap Credit Agreement was to mature on February 1, 2028. The outstanding borrowings under the MidCap Credit Agreement were repaid in full using proceeds from the execution of the Perceptive Credit Agreement.

Term Loans

The initial tranche of $10 million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the MidCap Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company’s ability to access these additional tranches was conditioned upon, among other things, the achievement of certain minimum revenue targets.

Each term loan bore interest at a floating rate reset monthly based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.8% at September 30, 2023). Interest was payable monthly in arrears on the first day of each month.

The first twenty-four (24) months of the term loans constituted an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans was to be repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, was to be due at maturity on February 1, 2028. The term loans could be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the MidCap Credit Agreement. Additionally, the term loans were subject to mandatory prepayment fees, pursuant to the terms of the MidCap Credit Agreement. Prepayments of the
term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company was also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee was being accreted over the life of the MidCap Credit Agreement utilizing the effective interest method. In connection with the satisfaction of the MidCap Credit Agreement, the Company paid MidCap a prepayment fee of 3% and the full 4% exit fee with proceeds from the Perceptive Credit Agreement discussed below.

As the MidCap Credit Agreement contained a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet as of September 30, 2023.

Revolving Facility

The Company could borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility would terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must have been repaid. Borrowings were limited to the lesser of the Company’s borrowing base and the revolving commitment of $10,000,000.

In connection with the revolving facility, the Company was required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account were swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings were promptly returned to the Company.

Loans made under the revolving facility bore interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (9.4% at September 30, 2023). The Company was obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility was terminated or reduced before maturity, the Company was subject to a deferred origination fee. Terminations and reductions of the commitments were subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company was also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10 million under the revolving facility. If the average outstanding balance for a month was less than the minimum balance, the Company paid a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees were payable monthly on the first day of each month. In connection with the satisfaction of the MidCap Credit Agreement, the Company paid MidCap a deferred origination fee of 3% of the revolving commitment with proceeds from the Perceptive Credit Agreement discussed below.

As of September 30, 2023, the Company had drawn no amounts on the revolving facility. As of September 30, 2023, the Company had approximately $7,800,000 available to be drawn on the revolving facility. As the MidCap Credit Agreement contained a subjective acceleration clause and the Company was required to maintain a lockbox, any amounts drawn on the revolving facility would be presented as a current liability in the consolidated balance sheet.

Collateral

The obligations of the Company under the MidCap Credit Agreement were secured by first priority liens on substantially all of its assets.

Covenants

The MidCap Credit Agreement contained customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions.

The MidCap Credit Agreement also required the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49 million, $60 million and $70 million for 2023, 2024, and 2025, respectively. Additionally, the Company had to maintain a balance of $10 million in cash and cash equivalents during the duration of the MidCap Credit Agreement’s term.

As of September 30, 2023, the Company was not in compliance with the minimum trailing twelve month net revenue financial covenant. As a result of the repayment of amounts outstanding under the MidCap Credit Agreement with proceeds from the Perceptive Credit Agreement discussed below, there were no implications to the Company from this event of noncompliance.
Events of Default

The MidCap Credit Agreement also contained customary Events of Default that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.

Upon the occurrence and during the continuance of an Event of Default under the MidCap Credit Agreement, the respective administrative agent, if requested by the respective lenders, could, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The MidCap Credit Agreement provided that, under certain circumstances, a default interest rate would apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.

The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the MidCap Credit Agreement. The bifurcated derivative is de minimis to the Company’s unaudited condensed consolidated financial statements.

Issuance of Warrants

In connection with the Company’s obligations under the MidCap Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.

The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.

The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements.

Debt Issuance Costs

In connection with entering into the MidCap Credit Agreement, the Company incurred debt issuance costs of approximately $1.8 million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan were being amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and were being amortized over the life of the term loans starting at the issuance date. The Company recognized the deferred costs at the point that the Company’s rights to borrow on the term loans expired. The costs allocated to the revolving facility were to be recognized on a straight-line basis over the term of the MidCap Credit Agreement. The Company expects to recognize all unamortized costs in loss on extinguishment of the MidCap Credit Agreement.

The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet.

PERCEPTIVE CREDIT AGREEMENT

On November 8, 2023, the Company entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto.

The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million. The Credit Agreement matures on November 8, 2028.
Loans

The initial loan of $37.5 million was fully funded on November 8, 2023, with approximately $11.0 million of the proceeds used to payoff the obligations under the MidCap Credit Agreement, including approximately $1.0 million of related prepayment penalties and exit fees, and $2.5 million for transaction fees and other expenses incurred in connection with the Perceptive Credit Agreement, which includes a 2% fee of the total facility payable to Perceptive at closing. The delayed draw loan is available until December 31, 2024, conditioned upon, among other things, the achievement of a minimum revenue target. After repayment of the MidCap Credit Agreement and payment of transaction fees and other expenses in connection with the Perceptive Credit Agreement, the net proceeds of these loans will be used for working capital and general corporate purposes.

The initial loan and delayed draw loan bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The first forty-eight (48) months of the loans constitute an interest-only period, with interest payable monthly on the last day of each month. Subsequent to the interest-only period, the outstanding principal amount of the loans is repayable in monthly payments of 3% of the outstanding balance on the payment date. All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity. The loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Perceptive Credit Agreement. Additionally, the loans are subject to mandatory prepayment obligations, pursuant to the terms of the Perceptive Credit Agreement. Prepayments of the loans are subject to fees of 10%, 9%, 6%, 4% and 2% of the prepayment amounts made during the first year, second year, third year, fourth year, and thereafter, respectively.

Collateral

The obligations of the Company under the Perceptive Credit Agreement are secured by first priority liens on substantially all of its assets.

Covenants

The Perceptive Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions set forth in the Perceptive Credit Agreement. The Perceptive Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $41.6 million, $57.0 million, $70.2 million, and $87.8 million for 2024, 2025, 2026, and 2027, respectively. Additionally, the Company must maintain a balance of $3 million in cash and cash equivalents during the duration of the Perceptive Credit Agreement’s term.

Events of Default

The Perceptive Credit Agreement also contains customary Events of Default (as defined in the Perceptive Credit Agreement) that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.

Upon the occurrence and during the continuance of an Event of Default under the Perceptive Credit Agreement, the administrative agent, if requested by the respective lenders, may, among other things, (i) terminate commitments, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Perceptive Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations upon the occurrence and during the existence of an Event of Default, at a per annum rate equal to 3% in excess of the applicable interest rate.

Issuance of Warrants

In connection with the Company’s initial loan under the Perceptive Credit Agreement, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock, par value $0.001, with an exercise price of $2.43 per share. Upon the
issuance of the delayed draw loan, if applicable, the Company will issue Perceptive warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of equal to the 10-day volume weighted average sale price from the preceding business day.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.3
CHINA JOINT VENTURE
 9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
CHINA JOINT VENTURE CHINA JOINT VENTURE
In 2019, the Company executed a joint venture agreement with its Chinese supplier (the “China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. In June 2023, the Company executed an amendment to the joint venture agreement to increase the amount of it’s registered capital. The amendment requires the Company to make additional capital contributions to the China JV of $255,000, of which $153,000 has been made as of September 30, 2023. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.

Changes in the Company’s ownership investment in the China JV were as follows:

Three Months Ended September 30,Nine Months Ended
September 30,
(In thousands)2023202220232022
Beginning interest in China JV$142$269$219$317
Contributions $153$—$153$—
Net loss attributable to Apyx$(48)$(33)$(125)$(81)
Ending interest in China JV$247$236$247$236
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.3
EARNINGS (LOSS) PER SHARE
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE EARNINGS (LOSS) PER SHARE
Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2023202220232022
Numerator:
Net loss attributable to stockholders$(4,629)$(5,764)$(9,106)$(17,135)
Denominator:
Weighted average shares outstanding - basic and diluted
34,642 34,569 34,614 34,488 
Loss per share:
Basic and diluted$(0.13)$(0.17)$(0.26)$(0.50)
Anti-dilutive instruments excluded from diluted loss per common share:
Options7,713 6,635 7,713 6,635 
Warrants250 — 250 — 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.3
STOCK-BASED COMPENSATION
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.

The Company recognized approximately $1,351,000 and $4,200,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2023, as compared with $1,692,000 and $5,056,000, respectively, for the three and nine months ended September 30, 2022.

Stock option activity is summarized as follows:
Number of optionsWeighted average exercise price
Outstanding at December 31, 2022
6,520,444 $7.12 
Granted1,527,865 2.63 
Exercised(57,000)2.65 
Canceled and forfeited(278,546)7.03 
Outstanding at September 30, 2023
7,712,763 $6.27 

The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2023 and 2022, respectively, we received 6,662 and 55,853 options as payment in the exercise of 5,338 and 33,313 options. For the nine months ended September 30, 2023 and 2022, respectively, we received 10,967 and 92,520 options as payment in the exercise of 11,033 and 72,313 options.

Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black-Scholes model.
2023 Grants
Strike price$2.50-$4.21
Risk-free rate3.6%-4.3%
Expected dividend yield—
Expected volatility85.8%-88.4%
Expected term (in years)6
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.3
INCOME TAXES
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
Income tax (benefit) expense was approximately $(318,000) and $50,000 with effective tax rates of 6.4% and (0.9)% for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to interest income on the Company's income tax refund that it received during the quarter, partially offset by the full valuation allowance recorded on the net operating loss (“NOL”) generated during the period. For the three months ended September 30, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period.

Income tax (benefit) expense was approximately $(2,519,000) and $216,000 with effective tax rates of 21.4% and (1.3)% for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company’s liability for uncertain tax positions, including accrued interest and penalties, of approximately $2.1 million, which were sustained upon the completion in January 2023 of the IRS examination of the Company's 2018 through 2020 income tax returns and interest income on the Company's
income tax refund, partially offset by the full valuation allowance on the NOL and net deferred tax assets generated during the period. For the nine months ended September, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Litigation

The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.

The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.

During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. During 2022, the Company recorded an estimated loss of $250,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. The Company has not experienced any movement on the matter since our response to the distributor in the fourth quarter of 2022. Accordingly, we have revised our estimated loss on the matter to $0 as it is no longer probable that a loss has been incurred. The reduction in estimated loss of $250,000 is included in professional services in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2023.

As previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Hattaway Complaint”) was filed in the United States District Court for the Middle District of Florida (the “U.S. District Court”) by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Hattaway Complaint sought an unspecified amount of damages.

While the matter was in the early stages, management had determined that a loss was probable in the estimated range of $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. On June 15, 2023, the U.S. District Court issued an Order dismissing the Hattaway Complaint and granting plaintiff until July 3, 2023 to file a second amended complaint, failing which the U.S. District Court would close the case. On June 27, 2023, the Plaintiff formally notified the Court that a Second Amended Complaint will not be filed and on July 17, 2023, the case was marked closed based on the Court’s June 15 dismissal order. This closed the matter for the estimated loss recorded by the Company.

During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff’s allegations could be subject to separate deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is
probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.

On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the “Stein Suit”) against individual members of the Company’s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the “Pritchard Case”). The Stein Suit sought unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing. On April 3, 2023, the Company formally moved to dismiss the case as time-barred and on other legal grounds, which triggered the plaintiff’s right to file an amended complaint. On July 12, 2023, plaintiff’s counsel informed the Company’s counsel that plaintiff Stein did not intend to file an amended complaint, and on July 17, 2023 plaintiff’s counsel filed a notice of voluntary dismissal. An order of the Court dismissing the Stein Suit, with prejudice, was entered on July 20, 2023.

The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.

Purchase Commitments

At September 30, 2023, the Company had purchase commitments totaling approximately $3.5 million, substantially all of which is expected to be purchased within the next twelve months.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.3
RELATED PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department.

The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September 30, 2023 and 2022, the Company made purchases from this supplier of approximately $50,000 and $85,000, respectively. For the nine months ended September 30, 2023 and 2022, the Company made purchases from this supplier of approximately $501,000 and $455,000, respectively. At September 30, 2023 and December 31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $12,000 and $8,000, respectively.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.3
GEOGRAPHIC AND SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
GEOGRAPHIC AND SEGMENT INFORMATION GEOGRAPHIC AND SEGMENT INFORMATION
Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.

The Company’s reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. “Corporate & Other” includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.

Summarized financial information with respect to reportable segments is as follows:

Three Months Ended September 30, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$9,836 $2,140 $— $11,976 
Income (loss) from operations70 591 (5,298)(4,637)
Interest income— — 248 248 
Interest expense— — (585)(585)
Other loss, net— — (19)(19)
Income tax benefit— — (318)(318)
Three Months Ended September 30, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$7,080 $2,034 $— $9,114 
(Loss) income from operations(1,174)356 (4,964)(5,782)
Interest income— — 73 73 
Interest expense— — (1)(1)
Other loss, net— — (35)(35)
Income tax expense— — 50 50 

Nine Months Ended September 30, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$31,248 $6,439 $— $37,687 
(Loss) income from operations(509)1,795 (12,769)(11,483)
Interest income— — 478 478 
Interest expense— — (1,362)(1,362)
Other income, net— — 622 622 
Income tax benefit— — (2,519)(2,519)

Nine Months Ended September 30, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$26,258 $5,641 $— $31,899 
(Loss) income from operations(3,765)1,142 (15,006)(17,629)
Interest income— — 93 93 
Interest expense— — (12)(12)
Other income, net— — 551 551 
Income tax expense— — 216 216 

International sales represented approximately 27.8% and 26.6% of total revenues for the three and nine months ended September 30, 2023, respectively, as compared with approximately 23.2% and 29.5% of total revenues for the three and nine months ended September 30, 2022, respectively.
Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)2023202220232022
Sales by Domestic and International
Domestic$8,652 $6,997 $27,660 $22,492 
International3,324 2,117 10,027 9,407 
Total$11,976 $9,114 $37,687 $31,899 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.3
BASIS OF PRESENTATION (Policies)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Recent Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.

No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.
Share based compensation Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.3
INVENTORIES (Tables)
 9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of inventory
Inventories consisted of the following:
(In thousands)September 30,
2023		December 31,
2022
Raw materials$4,578 $4,979 
Work in process2,522 2,160 
Finished goods 4,796 5,115 
Gross inventories11,896 12,254 
Less: provision for obsolescence(611)(457)
Inventories, net$11,285 $11,797 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT (Tables)
 9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
(In thousands)September 30, 2023
(Unaudited)		December 31,
2022
Land$— $1,600 
Building and improvements— 4,426 
Machinery and equipment2,635 2,613 
Furniture and fixtures216 211 
Computer equipment and software1,079 1,420 
Leasehold improvements178 178 
Molds1,017 847 
Total property, plant and equipment5,125 11,295 
Less: accumulated depreciation and amortization(3,489)(5,041)
Property and equipment in service1,636 6,254 
Construction in progress457 507 
Property and equipment, net$2,093 $6,761 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.3
LEASES (Tables)
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Lease Costs
Information about the Company’s weighted average remaining operating lease terms and discount rate assumptions are as follows:
September 30, 2023December 31,
2022
Weighted average remaining lease term (in years)9.24.4
Weighted average discount rate8.42%2.54%
Maturities of Operating Lease Liabilities
Maturities of operating lease liabilities as of September 30, 2023 are as follows:
(In thousands)
2023$190 
2024773 
2025799 
2026826 
2027855 
Thereafter4,516 
Total lease payments7,959 
Less imputed interest(2,657)
Present value of lease liabilities5,302 
Less current portion of lease liabilities(310)
Long-term portion of lease liabilities$4,992 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.3
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
 9 Months Ended
Sep. 30, 2023
Payables and Accruals [Abstract]  
Schedule of Accounts Payable and Accrued Liabilities
Accrued expenses and other current liabilities consisted of the following:
(in thousands)September 30,
2023		December 31,
2022
Accrued payroll$879 $563 
Accrued bonuses1,188 — 
Accrued commissions1,183 847 
Accrued product warranties386 391 
Accrued product liability claim insurance deductibles2,060 1,825 
Accrued professional fees and legal related contingent liabilities607 901 
Joint and several payroll liability— 345 
Short-term contract liabilities712 853 
Uncertain tax positions— 2,079 
Sales tax payable245 245 
Other accrued expenses and current liabilities654 879 
Total accrued expenses and other current liabilities$7,914 $8,928 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Term Loan
The Company’s term loan, net consists of the following at September 30, 2023:

(In thousands)
Term loan$10,000 
Unamortized debt issuance costs(414)
Unamortized debt discount, including accretion of exit fee(577)
Term loan, net$9,009 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.3
CHINA JOINT VENTURE (Tables)
 9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
Schedule of China Joint Venture
Changes in the Company’s ownership investment in the China JV were as follows:

Three Months Ended September 30,Nine Months Ended
September 30,
(In thousands)2023202220232022
Beginning interest in China JV$142$269$219$317
Contributions $153$—$153$—
Net loss attributable to Apyx$(48)$(33)$(125)$(81)
Ending interest in China JV$247$236$247$236
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.3
EARNINGS (LOSS) PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Basic and diluted earnings (loss) per share The following table provides the computation of basic and diluted loss per share.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2023202220232022
Numerator:
Net loss attributable to stockholders$(4,629)$(5,764)$(9,106)$(17,135)
Denominator:
Weighted average shares outstanding - basic and diluted
34,642 34,569 34,614 34,488 
Loss per share:
Basic and diluted$(0.13)$(0.17)$(0.26)$(0.50)
Anti-dilutive instruments excluded from diluted loss per common share:
Options7,713 6,635 7,713 6,635 
Warrants250 — 250 — 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.3
STOCK-BASED COMPENSATION (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of stock options and stock awards
Stock option activity is summarized as follows:
Number of optionsWeighted average exercise price
Outstanding at December 31, 2022
6,520,444 $7.12 
Granted1,527,865 2.63 
Exercised(57,000)2.65 
Canceled and forfeited(278,546)7.03 
Outstanding at September 30, 2023
7,712,763 $6.27 
Schedule of option fair value assumptions The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black-Scholes model.
2023 Grants
Strike price$2.50-$4.21
Risk-free rate3.6%-4.3%
Expected dividend yield—
Expected volatility85.8%-88.4%
Expected term (in years)6
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.3
GEOGRAPHIC AND SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Schedule of reporting information by segment
Summarized financial information with respect to reportable segments is as follows:

Three Months Ended September 30, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$9,836 $2,140 $— $11,976 
Income (loss) from operations70 591 (5,298)(4,637)
Interest income— — 248 248 
Interest expense— — (585)(585)
Other loss, net— — (19)(19)
Income tax benefit— — (318)(318)
Three Months Ended September 30, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$7,080 $2,034 $— $9,114 
(Loss) income from operations(1,174)356 (4,964)(5,782)
Interest income— — 73 73 
Interest expense— — (1)(1)
Other loss, net— — (35)(35)
Income tax expense— — 50 50 

Nine Months Ended September 30, 2023
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$31,248 $6,439 $— $37,687 
(Loss) income from operations(509)1,795 (12,769)(11,483)
Interest income— — 478 478 
Interest expense— — (1,362)(1,362)
Other income, net— — 622 622 
Income tax benefit— — (2,519)(2,519)

Nine Months Ended September 30, 2022
(In thousands)Advanced EnergyOEMCorporate & OtherTotal
Sales$26,258 $5,641 $— $31,899 
(Loss) income from operations(3,765)1,142 (15,006)(17,629)
Interest income— — 93 93 
Interest expense— — (12)(12)
Other income, net— — 551 551 
Income tax expense— — 216 216 
Schedule of revenue by geographic area
Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In thousands)2023202220232022
Sales by Domestic and International
Domestic$8,652 $6,997 $27,660 $22,492 
International3,324 2,117 10,027 9,407 
Total$11,976 $9,114 $37,687 $31,899 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.3
BASIS OF PRESENTATION (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 10, 2023
May 08, 2023
Mar. 14, 2023
Jan. 09, 2023
Nov. 22, 2022
Jan. 31, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2018
Nov. 08, 2023
Feb. 17, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Proceeds from the disposition of Core business                       $ 97,000    
Loss from operations             $ 4,637 $ 5,782 $ 11,483 $ 17,629 $ 23,600      
Net cash used in cash operations                 3,037 15,750        
Cash used in operations                 11,100   20,300      
Cash and cash equivalents             22,134   22,134   $ 10,192      
Cash and cash equivalents balance             $ 10,000   10,000         $ 10,000
Purchase agreement     $ 7,650                      
Leaseback term   10 years                        
Income tax receivables           $ 200     (7,545) $ (97)        
Proceeds from income tax refunds $ 8,100               $ 8,100          
Proceeds from income tax refund, interest 400                          
Proceeds from income tax refund, principal $ 7,700                          
Number of positions eliminated       14.00%                    
Subsequent Event                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Cash and cash equivalents balance                         $ 3,000  
MidCap Credit Agreement                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Credit facility                           35,000
MidCap Credit Agreement | Line of Credit                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Credit facility                           35,000
MidCap Credit Agreement | Line of Credit | Secured Debt                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Mortgage loan, principal amount                           25,000
MidCap Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche One                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Mortgage loan, principal amount                           10,000
MidCap Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche Two                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Mortgage loan, principal amount                           5,000
MidCap Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche Three                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Mortgage loan, principal amount                           10,000
MidCap Credit Agreement | Line of Credit | Revolving Credit Facility                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Credit facility                           $ 10,000
Perceptive Credit Agreement | Line of Credit | Subsequent Event                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Credit facility                         45,000  
Perceptive Credit Agreement, Initial Loan | Line of Credit | Subsequent Event                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Credit facility                         37,500  
Perceptive Credit Agreement, Delayed Draw Loan | Line of Credit | Subsequent Event                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Credit facility                         $ 7,500  
Shelf Registration                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Securities registered, new issues         $ 100,000                  
At-The-Market                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Securities registered, new issues         $ 40,000                  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
INVENTORIES (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 4,578 $ 4,979
Work in process 2,522 2,160
Finished goods 4,796 5,115
Gross inventories 11,896 12,254
Less: provision for obsolescence (611) (457)
Inventories, net $ 11,285 $ 11,797
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment $ 5,125 $ 11,295
Less: accumulated depreciation and amortization (3,489) (5,041)
Property and equipment in service 1,636 6,254
Construction in progress 457 507
Property and equipment, net 2,093 6,761
Land    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 0 1,600
Building and improvements    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 0 4,426
Machinery and equipment    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 2,635 2,613
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 216 211
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 1,079 1,420
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment 178 178
Molds    
Property, Plant and Equipment [Line Items]    
Total property, plant and equipment $ 1,017 $ 847
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
May 08, 2023
Mar. 14, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Property, Plant and Equipment [Abstract]            
Purchase agreement   $ 7,650        
Leaseback term 10 years          
Sale leaseback, net cash proceeds $ 6,600          
Sale leaseback, security deposit withheld $ 600          
Security deposit equal to annual rent 1 year          
Gain on sale-leaseback     $ 0 $ 0 $ 2,692 $ 0
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.3
LEASES - Narrative (Details)
 1 Months Ended
May 31, 2023
USD ($)
Leases [Abstract]  
Sale leaseback, term of lease 10 years
Sale leaseback, renewal term 5 years
Sale leaseback, annual rent payment $ 619,500
Sale leaseback, annual rent increase 4.00%
Sale leaseback, management fee on rent payment 3.00%
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.3
LEASES - Lease Terms and Discount Rates (Details)
Sep. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Weighted average remaining lease term 9 years 2 months 12 days 4 years 4 months 24 days
Weighted average discount rate 8.42% 2.54%
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.3
LEASES - Maturities of Lease Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
2023 $ 190  
2024 773  
2025 799  
2026 826  
2027 855  
Thereafter 4,516  
Total lease payments 7,959  
Less imputed interest (2,657)  
Present value of lease liabilities 5,302  
Less current portion of lease liabilities (310) $ (216)
Long-term portion of lease liabilities $ 4,992 $ 470
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.3
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued payroll $ 879 $ 563
Accrued bonuses 1,188 0
Accrued commissions 1,183 847
Accrued product warranties 386 391
Accrued product liability claim insurance deductibles 2,060 1,825
Accrued professional fees and legal related contingent liabilities 607 901
Joint and several payroll liability 0 345
Short-term contract liabilities 712 853
Uncertain tax positions 0 2,079
Sales tax payable 245 245
Other accrued expenses and current liabilities 654 879
Total accrued expenses and other current liabilities $ 7,914 $ 8,928
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT - Term Loan (Details) - Secured Debt - Term Loan
$ in Thousands
Sep. 30, 2023
USD ($)
Debt Instrument [Line Items]  
Term loan $ 10,000
Unamortized debt issuance costs (414)
Unamortized debt discount, including accretion of exit fee (577)
Term loan, net $ 9,009
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT - Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Nov. 08, 2023
USD ($)
$ / shares
shares
Feb. 17, 2023
USD ($)
monthlyPayment
$ / shares
shares
Sep. 30, 2023
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
$ / shares
Dec. 31, 2022
$ / shares
Debt Instrument [Line Items]          
Twelve month net revenue target, year one   $ 49,000      
Twelve month net revenue target, year two   60,000      
Twelve month net revenue target, year three   70,000      
Cash and cash equivalents balance   $ 10,000 $ 10,000 $ 10,000  
Warrants (in shares) | shares   250,000      
Common stock, par value (in dollars per share) | $ / shares   $ 0.001 $ 0.001 $ 0.001 $ 0.001
Warrants, exercise price (in dollars per share) | $ / shares   $ 3.40      
Warrants term   10 years      
Debt issuance costs   $ 1,800      
Subsequent Event          
Debt Instrument [Line Items]          
Twelve month net revenue target, year one $ 41,600        
Twelve month net revenue target, year two 57,000        
Twelve month net revenue target, year three 70,200        
Cash and cash equivalents balance $ 3,000        
Warrants (in shares) | shares 1,250,000        
Common stock, par value (in dollars per share) | $ / shares $ 0.001        
Warrants, exercise price (in dollars per share) | $ / shares $ 2.43        
Twelve month net revenue target, year four $ 87,800        
Warrants to be issued | shares 250,000        
MidCap Credit Agreement          
Debt Instrument [Line Items]          
Credit facility   35,000      
Line of Credit | MidCap Credit Agreement          
Debt Instrument [Line Items]          
Loss on extinguishment of debt       $ 2,500  
Credit facility   $ 35,000      
Default, applicable interest rate   2.00%      
Line of Credit | MidCap Credit Agreement | Subsequent Event          
Debt Instrument [Line Items]          
Repayments of lines of credit $ 11,000        
Prepayment penalties and exit fees 1,000        
Transaction cost and other expenses 2,500        
Line of Credit | MidCap Credit Agreement | Secured Debt          
Debt Instrument [Line Items]          
Amortization of debt issuance costs     $ 36 87  
Amortization of debt discounts     $ 81 $ 198  
Mortgage loan, principal amount   $ 25,000      
Interest rate floor   2.50%      
Interest rate floor spread   7.35%      
Period of interest only   24 months      
Extension period   12 months      
Number of monthly payments | monthlyPayment   36      
Number of monthly payments, extension | monthlyPayment   24      
Exit fee   4.00%      
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period One          
Debt Instrument [Line Items]          
Prepayment fee   3.00%      
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period Two          
Debt Instrument [Line Items]          
Prepayment fee   2.00%      
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period Three          
Debt Instrument [Line Items]          
Prepayment fee   1.00%      
Line of Credit | MidCap Credit Agreement | Secured Debt | Adjusted Term Secured Overnight Financing Rate (SOFR)          
Debt Instrument [Line Items]          
Variable rate   0.10%      
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche One          
Debt Instrument [Line Items]          
Mortgage loan, principal amount   $ 10,000      
Effective interest rate     12.80% 12.80%  
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche Two          
Debt Instrument [Line Items]          
Mortgage loan, principal amount   5,000      
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche Three          
Debt Instrument [Line Items]          
Mortgage loan, principal amount   10,000      
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility          
Debt Instrument [Line Items]          
Amortization of debt issuance costs     $ 25 $ 62  
Amortization of debt discounts     3 7  
Credit facility   $ 10,000      
Interest rate floor   2.50%      
Interest rate floor spread   4.00%      
Annual fee   0.50%      
Remaining borrowing capacity     $ 7,800 $ 7,800  
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period One          
Debt Instrument [Line Items]          
Effective interest rate     9.40% 9.40%  
Borrowing base, minimum balance   $ 10,000      
Lockbox account, funds to be applied to borrowings   5 days      
Termination fees   3.00%      
Borrowing base, minimum balance   30.00%      
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period Two          
Debt Instrument [Line Items]          
Termination fees   2.00%      
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period Three          
Debt Instrument [Line Items]          
Termination fees   1.00%      
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility | Adjusted Term Secured Overnight Financing Rate (SOFR)          
Debt Instrument [Line Items]          
Variable rate   0.10%      
Line of Credit | Perceptive Credit Agreement | Subsequent Event          
Debt Instrument [Line Items]          
Credit facility $ 45,000        
Interest rate floor 5.00%        
Interest rate floor spread 7.00%        
Period of interest only 48 months        
Default, applicable interest rate 3.00%        
Commitment fee percentage 2.00%        
Principal payments, percentage 3.00%        
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period One | Subsequent Event          
Debt Instrument [Line Items]          
Prepayment fee 10.00%        
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period Two | Subsequent Event          
Debt Instrument [Line Items]          
Prepayment fee 9.00%        
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period Three | Subsequent Event          
Debt Instrument [Line Items]          
Prepayment fee 6.00%        
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period Four | Subsequent Event          
Debt Instrument [Line Items]          
Prepayment fee 4.00%        
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period, After Year Four | Subsequent Event          
Debt Instrument [Line Items]          
Prepayment fee 2.00%        
Line of Credit | Perceptive Credit Agreement, Initial Loan | Subsequent Event          
Debt Instrument [Line Items]          
Credit facility $ 37,500        
Proceeds from line of credit 37,500        
Line of Credit | Perceptive Credit Agreement, Delayed Draw Loan | Subsequent Event          
Debt Instrument [Line Items]          
Credit facility $ 7,500        
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.3
CHINA JOINT VENTURE - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 4 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2023
Dec. 31, 2019
Noncontrolling Interest [Line Items]                  
Contributions from non-controlling interest $ 147     $ 147          
Corporate Joint Venture                  
Noncontrolling Interest [Line Items]                  
Required capital contribution               $ 255 $ 357
Contributions from non-controlling interest $ 153 $ 0 $ 153 $ 153 $ 0 $ 203 $ 154    
Chinese Supplier                  
Noncontrolling Interest [Line Items]                  
Ownership interest                 51.00%
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.3
CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) - USD ($)
$ in Thousands
 3 Months Ended 4 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]              
Beginning interest in China JV       $ 211      
Contributions $ 147     147      
Net loss attributable to Apyx (46) $ (31)   (120) $ (78)    
Ending interest in China JV 238   $ 238 238      
Corporate Joint Venture              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]              
Beginning interest in China JV 142 269   219 317    
Contributions 153 0 153 153 0 $ 203 $ 154
Net loss attributable to Apyx (48) (33)   (125) (81)    
Ending interest in China JV $ 247 $ 236 $ 247 $ 247 $ 236 $ 317  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.3
EARNINGS (LOSS) PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share Reconciliation [Abstract]        
Net loss attributable to stockholders, basic $ (4,629) $ (5,764) $ (9,106) $ (17,135)
Net loss attributable to stockholders, diluted $ (4,629) $ (5,764) $ (9,106) $ (17,135)
Denominator:        
Weighted average shares outstanding - basic (in shares) 34,642 34,569 34,614 34,488
Weighted average shares outstanding - diluted (in shares) 34,642 34,569 34,614 34,488
Loss per share:        
Basic (in dollars per share) $ (0.13) $ (0.17) $ (0.26) $ (0.50)
Diluted (in dollars per share) $ (0.13) $ (0.17) $ (0.26) $ (0.50)
Options        
Anti-dilutive instruments excluded from diluted loss per common share:        
Anti-dilutive instruments (in shares) 7,713 6,635 7,713 6,635
Warrants        
Anti-dilutive instruments excluded from diluted loss per common share:        
Anti-dilutive instruments (in shares) 250 0 250 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.3
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]        
Stock based compensation $ 1,351 $ 1,692 $ 4,200 $ 5,056
Stock swaps equity instruments received (in shares) 6,662 55,853 10,967 92,520
Stock swaps (in shares) 5,338 33,313 11,033 72,313
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.3
STOCK-BASED COMPENSATION - Summary of Stock Options (Details)
 9 Months Ended
Sep. 30, 2023
$ / shares
shares
Number of options  
Outstanding, beginning of period (in shares) | shares 6,520,444
Granted (in shares) | shares 1,527,865
Exercised (in shares) | shares (57,000)
Canceled and forfeited (in shares) | shares (278,546)
Outstanding, end of period (in shares) | shares 7,712,763
Weighted average exercise price  
Outstanding, beginning of period (in dollars per share) | $ / shares $ 7.12
Granted (in dollars per share) | $ / shares 2.63
Exercised (in dollars per share) | $ / shares 2.65
Canceled and forfeited (in dollars per shares) | $ / shares 7.03
Outstanding, end of period (in dollars per share) | $ / shares $ 6.27
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.3
STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)
 9 Months Ended
Sep. 30, 2023
$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Strike price (in dollars per share) $ 2.63
Risk-free rate, minimum 3.60%
Risk-free rate, maximum 4.30%
Expected dividend yield 0.00%
Expected volatility, minimum 85.80%
Expected volatility, maximum 88.40%
Expected term (in years) 6 years
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Strike price (in dollars per share) $ 2.50
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Strike price (in dollars per share) $ 4.21
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.3
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ (318) $ 50 $ (2,519) $ 216
Effective income tax rate 6.40% (0.90%) 21.40% (1.30%)
Accrued interest and penalties $ 2,100   $ 2,100  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Loss Contingencies [Line Items]    
Costs accrued $ 0 $ 250
Reversal of loss accrual 250  
Purchase obligation 3,500  
Suit Against Goodwin and Simb    
Loss Contingencies [Line Items]    
Costs accrued 475  
Suits Filed In 2022    
Loss Contingencies [Line Items]    
Costs accrued 1,450  
Minimum | Suit Against Goodwin and Simb    
Loss Contingencies [Line Items]    
Estimate of possible loss 475  
Minimum | Suits Filed In 2022    
Loss Contingencies [Line Items]    
Estimate of possible loss 1,450  
Maximum | Suit Against Goodwin and Simb    
Loss Contingencies [Line Items]    
Estimate of possible loss 2,500  
Maximum | Suits Filed In 2022    
Loss Contingencies [Line Items]    
Estimate of possible loss $ 2,400  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.3
RELATED PARTY TRANSACTIONS (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]          
Accounts receivable $ (12,648)   $ (12,648)   $ (10,602)
Co-venturer          
Related Party Transaction [Line Items]          
Purchases from related party 50 $ 85 501 $ 455  
Accounts payable $ 12   $ 12    
Accounts receivable         $ (8)
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.3
GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting [Abstract]        
Number of reportable segments     2  
Number of operating segments     2  
International sales, percent of total revenue 27.80% 23.20% 26.60% 29.50%
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.3
GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Segment Reporting Information [Line Items]          
Sales $ 11,976 $ 9,114 $ 37,687 $ 31,899  
(Loss) income from operations (4,637) (5,782) (11,483) (17,629) $ (23,600)
Interest income 248 73 478 93  
Interest expense (585) (1) (1,362) (12)  
Other income (loss), net (19) (35) 622 551  
Income tax (benefit) expense (318) 50 (2,519) 216  
Operating Segments | Advanced Energy          
Segment Reporting Information [Line Items]          
Sales 9,836 7,080 31,248 26,258  
(Loss) income from operations 70 (1,174) (509) (3,765)  
Interest income 0 0 0 0  
Interest expense 0 0 0 0  
Other income (loss), net 0 0 0 0  
Income tax (benefit) expense 0 0 0 0  
Operating Segments | OEM          
Segment Reporting Information [Line Items]          
Sales 2,140 2,034 6,439 5,641  
(Loss) income from operations 591 356 1,795 1,142  
Interest income 0 0 0 0  
Interest expense 0 0 0 0  
Other income (loss), net 0 0 0 0  
Income tax (benefit) expense 0 0 0 0  
Corporate & Other          
Segment Reporting Information [Line Items]          
Sales 0 0 0 0  
(Loss) income from operations (5,298) (4,964) (12,769) (15,006)  
Interest income 248 73 478 93  
Interest expense (585) (1) (1,362) (12)  
Other income (loss), net (19) (35) 622 551  
Income tax (benefit) expense $ (318) $ 50 $ (2,519) $ 216  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.3
GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Sales $ 11,976 $ 9,114 $ 37,687 $ 31,899
Domestic        
Segment Reporting Information [Line Items]        
Sales 8,652 6,997 27,660 22,492
International        
Segment Reporting Information [Line Items]        
Sales $ 3,324 $ 2,117 $ 10,027 $ 9,407
XML 64 apyx-20230930_htm.xml IDEA: XBRL DOCUMENT 0000719135 2023-01-01 2023-09-30 0000719135 2023-11-08 0000719135 2023-09-30 0000719135 2022-12-31 0000719135 2023-07-01 2023-09-30 0000719135 2022-07-01 2022-09-30 0000719135 2022-01-01 2022-09-30 0000719135 us-gaap:CommonStockMember 2022-06-30 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000719135 us-gaap:RetainedEarningsMember 2022-06-30 0000719135 us-gaap:NoncontrollingInterestMember 2022-06-30 0000719135 2022-06-30 0000719135 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000719135 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000719135 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000719135 us-gaap:CommonStockMember 2022-09-30 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000719135 us-gaap:RetainedEarningsMember 2022-09-30 0000719135 us-gaap:NoncontrollingInterestMember 2022-09-30 0000719135 2022-09-30 0000719135 us-gaap:CommonStockMember 2023-06-30 0000719135 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000719135 us-gaap:RetainedEarningsMember 2023-06-30 0000719135 us-gaap:NoncontrollingInterestMember 2023-06-30 0000719135 2023-06-30 0000719135 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0000719135 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000719135 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000719135 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000719135 us-gaap:CommonStockMember 2023-09-30 0000719135 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000719135 us-gaap:RetainedEarningsMember 2023-09-30 0000719135 us-gaap:NoncontrollingInterestMember 2023-09-30 0000719135 us-gaap:CommonStockMember 2021-12-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000719135 us-gaap:RetainedEarningsMember 2021-12-31 0000719135 us-gaap:NoncontrollingInterestMember 2021-12-31 0000719135 2021-12-31 0000719135 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0000719135 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000719135 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0000719135 us-gaap:CommonStockMember 2022-12-31 0000719135 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000719135 us-gaap:RetainedEarningsMember 2022-12-31 0000719135 us-gaap:NoncontrollingInterestMember 2022-12-31 0000719135 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0000719135 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0000719135 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0000719135 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0000719135 2018-01-01 2018-12-31 0000719135 2022-01-01 2022-12-31 0000719135 apyx:ShelfRegistrationMember 2022-11-22 2022-11-22 0000719135 apyx:AtTheMarketMember 2022-11-22 2022-11-22 0000719135 apyx:MidCapCreditAgreementMember 2023-02-17 0000719135 us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:DebtInstrumentCovenantTrancheOneMember us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:DebtInstrumentCovenantTrancheTwoMember us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:DebtInstrumentCovenantTrancheThreeMember us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:PerceptiveCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 0000719135 apyx:PerceptiveCreditAgreementInitialLoanMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 0000719135 apyx:PerceptiveCreditAgreementDelayedDrawLoanMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 0000719135 2023-03-14 2023-03-14 0000719135 2023-05-08 2023-05-08 0000719135 2023-01-01 2023-01-31 0000719135 2023-08-10 2023-08-10 0000719135 2023-01-09 2023-01-09 0000719135 us-gaap:LandMember 2023-09-30 0000719135 us-gaap:LandMember 2022-12-31 0000719135 us-gaap:BuildingAndBuildingImprovementsMember 2023-09-30 0000719135 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000719135 us-gaap:MachineryAndEquipmentMember 2023-09-30 0000719135 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000719135 us-gaap:FurnitureAndFixturesMember 2023-09-30 0000719135 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000719135 apyx:ComputerEquipmentAndSoftwareMember 2023-09-30 0000719135 apyx:ComputerEquipmentAndSoftwareMember 2022-12-31 0000719135 us-gaap:LeaseholdImprovementsMember 2023-09-30 0000719135 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000719135 apyx:MoldsMember 2023-09-30 0000719135 apyx:MoldsMember 2022-12-31 0000719135 2023-05-08 0000719135 2023-05-01 2023-05-31 0000719135 us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-07-01 2023-09-30 0000719135 us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-01-01 2023-09-30 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-07-01 2023-09-30 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-01-01 2023-09-30 0000719135 apyx:TermLoanMember us-gaap:SecuredDebtMember 2023-09-30 0000719135 apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-01-01 2023-09-30 0000719135 apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember 2023-02-17 2023-02-17 0000719135 us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentCovenantTrancheOneMember us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-09-30 0000719135 apyx:DebtInstrumentPrepaymentPeriodOneMember us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentPrepaymentPeriodTwoMember us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentPrepaymentPeriodThreeMember us-gaap:SecuredDebtMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodOneMember us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodOneMember us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember apyx:AdjustedTermSecuredOvernightFinancingRateSOFRMember 2023-02-17 2023-02-17 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodOneMember us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-09-30 0000719135 apyx:DebtInstrumentTerminationPeriodTwoMember us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:DebtInstrumentTerminationPeriodThreeMember us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 us-gaap:RevolvingCreditFacilityMember apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-09-30 0000719135 2023-02-17 2023-02-17 0000719135 2023-02-17 0000719135 apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember 2023-02-17 2023-02-17 0000719135 apyx:PerceptiveCreditAgreementInitialLoanMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 apyx:MidCapCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 0000719135 apyx:PerceptiveCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 apyx:DebtInstrumentPrepaymentPeriodOneMember apyx:PerceptiveCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 apyx:DebtInstrumentPrepaymentPeriodTwoMember apyx:PerceptiveCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 apyx:DebtInstrumentPrepaymentPeriodThreeMember apyx:PerceptiveCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 apyx:DebtInstrumentPrepaymentPeriodFourMember apyx:PerceptiveCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 apyx:DebtInstrumentPrepaymentPeriodAfterYearFourMember apyx:PerceptiveCreditAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 us-gaap:SubsequentEventMember 2023-11-08 2023-11-08 0000719135 us-gaap:SubsequentEventMember 2023-11-08 0000719135 apyx:ChineseSupplierMember 2019-12-31 0000719135 us-gaap:CorporateJointVentureMember 2019-12-31 0000719135 us-gaap:CorporateJointVentureMember 2021-01-01 2021-12-31 0000719135 us-gaap:CorporateJointVentureMember 2020-01-01 2020-12-31 0000719135 us-gaap:CorporateJointVentureMember 2023-06-30 0000719135 us-gaap:CorporateJointVentureMember 2023-06-01 2023-09-30 0000719135 us-gaap:CorporateJointVentureMember 2022-06-30 0000719135 us-gaap:CorporateJointVentureMember 2022-12-31 0000719135 us-gaap:CorporateJointVentureMember 2021-12-31 0000719135 us-gaap:CorporateJointVentureMember 2023-07-01 2023-09-30 0000719135 us-gaap:CorporateJointVentureMember 2022-07-01 2022-09-30 0000719135 us-gaap:CorporateJointVentureMember 2023-01-01 2023-09-30 0000719135 us-gaap:CorporateJointVentureMember 2022-01-01 2022-09-30 0000719135 us-gaap:CorporateJointVentureMember 2023-09-30 0000719135 us-gaap:CorporateJointVentureMember 2022-09-30 0000719135 us-gaap:EmployeeStockOptionMember 2023-07-01 2023-09-30 0000719135 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000719135 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000719135 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000719135 us-gaap:WarrantMember 2023-07-01 2023-09-30 0000719135 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000719135 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000719135 us-gaap:WarrantMember 2022-01-01 2022-09-30 0000719135 srt:MinimumMember 2023-01-01 2023-09-30 0000719135 srt:MaximumMember 2023-01-01 2023-09-30 0000719135 apyx:SuitAgainstGoodwinAndSimbMember srt:MinimumMember 2023-09-30 0000719135 apyx:SuitAgainstGoodwinAndSimbMember srt:MaximumMember 2023-09-30 0000719135 apyx:SuitAgainstGoodwinAndSimbMember 2023-09-30 0000719135 apyx:SuitsFiledIn2022Member srt:MinimumMember 2023-09-30 0000719135 apyx:SuitsFiledIn2022Member srt:MaximumMember 2023-09-30 0000719135 apyx:SuitsFiledIn2022Member 2023-09-30 0000719135 us-gaap:CoVenturerMember 2023-07-01 2023-09-30 0000719135 us-gaap:CoVenturerMember 2022-07-01 2022-09-30 0000719135 us-gaap:CoVenturerMember 2023-01-01 2023-09-30 0000719135 us-gaap:CoVenturerMember 2022-01-01 2022-09-30 0000719135 us-gaap:CoVenturerMember 2023-09-30 0000719135 us-gaap:CoVenturerMember 2022-12-31 0000719135 us-gaap:OperatingSegmentsMember apyx:AdvancedEnergyMember 2023-07-01 2023-09-30 0000719135 us-gaap:OperatingSegmentsMember apyx:OEMMember 2023-07-01 2023-09-30 0000719135 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0000719135 us-gaap:OperatingSegmentsMember apyx:AdvancedEnergyMember 2022-07-01 2022-09-30 0000719135 us-gaap:OperatingSegmentsMember apyx:OEMMember 2022-07-01 2022-09-30 0000719135 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000719135 us-gaap:OperatingSegmentsMember apyx:AdvancedEnergyMember 2023-01-01 2023-09-30 0000719135 us-gaap:OperatingSegmentsMember apyx:OEMMember 2023-01-01 2023-09-30 0000719135 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-09-30 0000719135 us-gaap:OperatingSegmentsMember apyx:AdvancedEnergyMember 2022-01-01 2022-09-30 0000719135 us-gaap:OperatingSegmentsMember apyx:OEMMember 2022-01-01 2022-09-30 0000719135 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-09-30 0000719135 country:US 2023-07-01 2023-09-30 0000719135 country:US 2022-07-01 2022-09-30 0000719135 country:US 2023-01-01 2023-09-30 0000719135 country:US 2022-01-01 2022-09-30 0000719135 us-gaap:NonUsMember 2023-07-01 2023-09-30 0000719135 us-gaap:NonUsMember 2022-07-01 2022-09-30 0000719135 us-gaap:NonUsMember 2023-01-01 2023-09-30 0000719135 us-gaap:NonUsMember 2022-01-01 2022-09-30 shares iso4217:USD iso4217:USD shares pure apyx:monthlyPayment apyx:segment 0000719135 false --12-31 Q3 2023 10-Q true 2023-09-30 false 001-31885 APYX MEDICAL CORPORATION DE 11-2644611 5115 Ulmerton Road, Clearwater FL 33760 727 384-2323 Common Stock APYX NASDAQ Yes Yes Non-accelerated Filer true false false 34643855 22134000 10192000 652000 668000 12648000 10602000 0 7545000 596000 99000 611000 457000 11285000 11797000 3487000 2737000 50150000 42972000 2093000 6761000 5274000 710000 74000 115000 1855000 1217000 59446000 51775000 2050000 2669000 7914000 8928000 310000 216000 20000 37000 10294000 11850000 9009000 0 4992000 470000 58000 73000 1326000 1408000 181000 181000 25860000 13982000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 75000000 75000000 34643855 34643855 34597822 34597822 35000 35000 78154000 73282000 -44841000 -35735000 33348000 37582000 238000 211000 33586000 37793000 59446000 51775000 11976000 9114000 37687000 31899000 3998000 3357000 12857000 11009000 7978000 5757000 24830000 20890000 1276000 1061000 3596000 3289000 1831000 1936000 5165000 6611000 4667000 3871000 14770000 13944000 4841000 4671000 15474000 14675000 12615000 11539000 39005000 38519000 0 0 2692000 0 -4637000 -5782000 -11483000 -17629000 248000 73000 478000 93000 585000 1000 1362000 12000 -19000 -35000 622000 551000 -356000 37000 -262000 632000 -4993000 -5745000 -11745000 -16997000 -318000 50000 -2519000 216000 -4675000 -5795000 -9226000 -17213000 -46000 -31000 -120000 -78000 -4629000 -5764000 -9106000 -17135000 -0.13 -0.13 -0.17 -0.17 -0.26 -0.26 -0.50 -0.50 34493000 34000 69793000 -23922000 258000 46163000 62000 1000 156000 157000 1692000 1692000 33000 -5764000 -31000 -5795000 34588000 35000 71641000 -29686000 227000 42217000 34629000 35000 76773000 -40212000 137000 36733000 147000 147000 10000 30000 30000 1351000 1351000 5000 -4629000 -46000 -4675000 34644000 35000 78154000 -44841000 238000 33586000 34410000 34000 66221000 -12551000 305000 54009000 106000 1000 364000 365000 5056000 5056000 72000 -17135000 -78000 -17213000 34588000 35000 71641000 -29686000 227000 42217000 34598000 35000 73282000 -35735000 211000 37793000 147000 147000 35000 86000 86000 4200000 4200000 11000 586000 586000 -9106000 -120000 -9226000 34644000 35000 78154000 -44841000 238000 33586000 -9226000 -17213000 540000 688000 229000 158000 2656000 -76000 4200000 5056000 176000 283000 354000 0 56000 0 2192000 -3273000 698000 521000 -7545000 -97000 -401000 5672000 -613000 -439000 -1153000 -1536000 -3037000 -15750000 440000 868000 7267000 0 6827000 -868000 86000 365000 9289000 0 1754000 0 586000 0 32000 138000 147000 0 8322000 227000 -170000 354000 11942000 -16037000 10192000 30870000 22134000 14833000 834000 12000 261000 128000 4917000 0 0 769000 0 103000 0 28000 BASIS OF PRESENTATION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of its plan to accelerate and fully fund the development of its advanced energy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">business, with a focus in the cosmetic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures, but had not yet been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. Management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should assist in mitigating the financial effects of the Safety Communication in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the nine months ended September 30, 2023, the Company incurred an operating loss of $11.5 million and used $11.1 million of cash in operations exclusive of the receipt of the Company's tax refund, including interest, of approximately $8.1 million. As of September 30, 2023, the Company had cash and cash equivalents of $22.1 million, of which the Company must maintain $10.0 million under its Credit Agreement. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, the Company has not utilized this facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MidCap Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the MidCap Credit Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2023, the Company entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a more in depth description of the terms of the MidCap Credit Agreement and the Perceptive Credit Agreement, see Note 7.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company’s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For a more in depth description of the terms of the Purchase Agreement, see Notes 4 and 5.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company’s tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. On August 10, 2023, the Company received $8.1 million from the IRS, which included approximately $0.4 million of interest on the $7.7 million income tax refunds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also re-assessed its operating expenditures and cost structure and made adjustments in light of expected levels of revenue. This included reducing some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company’s U.S. headcount by 14%. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Management believes that the actions already taken, including replacing the MidCap Credit Agreement with the Perceptive Credit Agreement, alleviate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of its unaudited condensed consolidated financial statements.</span></div> 97000000 -23600000 -20300000 -11500000 -11100000 8100000 22100000 10000000 100000000 40000000 35000000 25000000 10000000 5000000 10000000 10000000 45000000 37500000 7500000 7650000 P10Y 200000 8100000 400000 7700000 0.14 RECENT ACCOUNTING PRONOUNCEMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div> INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,896 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,285 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,797 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,896 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,285 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,797 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 4578000 4979000 2522000 2160000 4796000 5115000 11896000 12254000 611000 457000 11285000 11797000 PROPERTY AND EQUIPMENT<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,125 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,295 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,761 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to improve liquidity and the balance sheet condition of the Company, management explored options to leverage the Company’s unencumbered real property. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser (see Note 5). The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit of approximately $0.6 million, equal to one year's rent, taxes, first months rent, expenses, and fees. The $2,700,000 gain on this transaction is presented in gain on sale-leaseback in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2023.</span></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023<br/>(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,426 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,125 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,295 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,041)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment in service</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,636 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,254 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,093 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,761 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 0 1600000 0 4426000 2635000 2613000 216000 211000 1079000 1420000 178000 178000 1017000 847000 5125000 11295000 3489000 5041000 1636000 6254000 457000 507000 2093000 6761000 7650000 P10Y 6600000 600000 P1Y 2700000 LEASES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Operating Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. These operating leases have terms expiring through December 2027. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the terms of the Purchase Agreement (see Note 4), during May 2023, the Company entered into a Single Tenant Industrial Building Lease (the “Lease”), pursuant to which the Property was leased back to the Company. The Lease has an initial term of ten (10) years commencing from the closing (the “Initial Term”), and a renewal term of five (5) years, exercisable at the Company’s option. The annual fixed rent is $619,500 for the first year of the Initial Term, and is subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company’s weighted average remaining operating lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.818%"><tr><td style="width:1.0%"></td><td style="width:60.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.878%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of September 30, 2023 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:86.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.628%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> P10Y P5Y 619500 0.04 0.03 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about the Company’s weighted average remaining operating lease terms and discount rate assumptions are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.818%"><tr><td style="width:1.0%"></td><td style="width:60.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.878%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td><td colspan="3" style="display:none"></td></tr></table></div> P9Y2M12D P4Y4M24D 0.0842 0.0254 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of September 30, 2023 are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:86.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.628%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,516 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 190000 773000 799000 826000 855000 4516000 7959000 2657000 5302000 310000 4992000 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations. This adjustment is included in other (expense) income, net for the nine months ended September 30, 2023.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees and legal related contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,079 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,914 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,928 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 879000 563000 1188000 0 1183000 847000 386000 391000 2060000 1825000 607000 901000 0 345000 712000 853000 0 2079000 245000 245000 654000 879000 7914000 8928000 DEBT<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Included in interest expense for the three and nine months ended September 30, 2023 are $36,000 and $87,000, respectively, of amortization of the debt issuance costs and $81,000 and $198,000, respectively, of amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three and nine months ended September 30, 2023 are $25,000 and $62,000, respectively, of amortization of the debt issuance costs and $3,000 and $7,000, respectively, of amortization of the debt discount on the revolving facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s term loan, net consists of the following at September 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:81.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.782%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount, including accretion of exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term loan, net was paid in full on November 8, 2023 in connection with the execution of the Perceptive Credit Agreement. The Company is still determining the appropriate accounting treatment for the MidCap Credit Agreement and Perceptive Credit Agreement. While the Perceptive Credit Agreement contains a subjective acceleration clause, management has determined that there is remote probability that Perceptive would accelerate of the obligations under the subjective acceleration clause. Accordingly, term loan, net has been presented as a long term liability in the accompanying condensed consolidated balance sheet as of September 30, 2023. The Company expects to record a loss on extinguishment of the MidCap Credit Agreement of approximately $2.5 million in connection with the write-off of unamortized debt issuance costs, debt discounts and unamortized debt premiums. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MIDCAP CREDIT AGREEMENT</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively “MidCap”).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The MidCap Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The MidCap Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the MidCap Credit Agreement. The MidCap Credit Agreement was to mature on February 1, 2028. The outstanding borrowings under the MidCap Credit Agreement were repaid in full using proceeds from the execution of the Perceptive Credit Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Term Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The initial tranche of $10 million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the MidCap Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company’s ability to access these additional tranches was conditioned upon, among other things, the achievement of certain minimum revenue targets. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each term loan bore interest at a floating rate reset monthly based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.8% at September 30, 2023). Interest was payable monthly in arrears on the first day of each month.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The first twenty-four (24) months of the term loans constituted an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans was to be repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, was to be due at maturity on February 1, 2028. The term loans could be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the MidCap Credit Agreement. Additionally, the term loans were subject to mandatory prepayment fees, pursuant to the terms of the MidCap Credit Agreement. Prepayments of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company was also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee was being accreted over the life of the MidCap Credit Agreement utilizing the effective interest method. In connection with the satisfaction of the MidCap Credit Agreement, the Company paid MidCap a prepayment fee of 3% and the full 4% exit fee with proceeds from the Perceptive Credit Agreement discussed below. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the MidCap Credit Agreement contained a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet as of September 30, 2023.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Revolving Facility</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company could borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility would terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must have been repaid. Borrowings were limited to the lesser of the Company’s borrowing base and the revolving commitment of $10,000,000. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the revolving facility, the Company was required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account were swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings were promptly returned to the Company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Loans made under the revolving facility bore interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (9.4% at September 30, 2023). The Company was obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility was terminated or reduced before maturity, the Company was subject to a deferred origination fee. Terminations and reductions of the commitments were subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company was also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10 million under the revolving facility. If the average outstanding balance for a month was less than the minimum balance, the Company paid a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees were payable monthly on the first day of each month. In connection with the satisfaction of the MidCap Credit Agreement, the Company paid MidCap a deferred origination fee of 3% of the revolving commitment with proceeds from the Perceptive Credit Agreement discussed below. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2023, the Company had drawn no amounts on the revolving facility. As of September 30, 2023, the Company had approximately $7,800,000 available to be drawn on the revolving facility. As the MidCap Credit Agreement contained a subjective acceleration clause and the Company was required to maintain a lockbox, any amounts drawn on the revolving facility would be presented as a current liability in the consolidated balance sheet. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Collateral</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The obligations of the Company under the MidCap Credit Agreement were secured by first priority liens on substantially all of its assets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Covenants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The MidCap Credit Agreement contained customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The MidCap Credit Agreement also required the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49 million, $60 million and $70 million for 2023, 2024, and 2025, respectively. Additionally, the Company had to maintain a balance of $10 million in cash and cash equivalents during the duration of the MidCap Credit Agreement’s term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2023, the Company was not in compliance with the minimum trailing twelve month net revenue financial covenant. As a result of the repayment of amounts outstanding under the MidCap Credit Agreement with proceeds from the Perceptive Credit Agreement discussed below, there were no implications to the Company from this event of noncompliance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Events of Default</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The MidCap Credit Agreement also contained customary Events of Default</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon the occurrence and during the continuance of an Event of Default under the MidCap Credit Agreement, the respective administrative agent, if requested by the respective lenders, could, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The MidCap Credit Agreement provided that, under certain circumstances, a default interest rate would apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the MidCap Credit Agreement. The bifurcated derivative is de minimis to the Company’s unaudited condensed consolidated financial statements. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Issuance of Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company’s obligations under the MidCap Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Debt Issuance Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with entering into the MidCap Credit Agreement, the Company incurred debt issuance costs of approximately $1.8 million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan were being amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and were being amortized over the life of the term loans starting at the issuance date. The Company recognized the deferred costs at the point that the Company’s rights to borrow on the term loans expired. The costs allocated to the revolving facility were to be recognized on a straight-line basis over the term of the MidCap Credit Agreement. The Company expects to recognize all unamortized costs in loss on extinguishment of the MidCap Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">PERCEPTIVE CREDIT AGREEMENT</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 8, 2023, the Company entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million. The Credit Agreement matures on November 8, 2028.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial loan of $37.5 million was fully funded on November 8, 2023, with approximately $11.0 million of the proceeds used to payoff the obligations under the MidCap Credit Agreement, including approximately $1.0 million of related prepayment penalties and exit fees, and $2.5 million for transaction fees and other expenses incurred in connection with the Perceptive Credit Agreement, which includes a 2% fee of the total facility payable to Perceptive at closing. The delayed draw loan is available until December 31, 2024, conditioned upon, among other things, the achievement of a minimum revenue target. After repayment of the MidCap Credit Agreement and payment of transaction fees and other expenses in connection with the Perceptive Credit Agreement, the net proceeds of these loans will be used for working capital and general corporate purposes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial loan and delayed draw loan bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The first forty-eight (48) months of the loans constitute an interest-only period, with interest payable monthly on the last day of each month. Subsequent to the interest-only period, the outstanding principal amount of the loans is repayable in monthly payments of 3% of the outstanding balance on the payment date. All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity. The loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Perceptive Credit Agreement. Additionally, the loans are subject to mandatory prepayment obligations, pursuant to the terms of the Perceptive Credit Agreement. Prepayments of the loans are subject to fees of 10%, 9%, 6%, 4% and 2% of the prepayment amounts made during the first year, second year, third year, fourth year, and thereafter, respectively. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Collateral</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of the Company under the Perceptive Credit Agreement are secured by first priority liens on substantially all of its assets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Covenants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Perceptive Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions set forth in the Perceptive Credit Agreement. The Perceptive Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $41.6 million, $57.0 million, $70.2 million, and $87.8 million for 2024, 2025, 2026, and 2027, respectively. Additionally, the Company must maintain a balance of $3 million in cash and cash equivalents during the duration of the Perceptive Credit Agreement’s term.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Events of Default</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Perceptive Credit Agreement also contains customary Events of Default (as defined in the Perceptive Credit Agreement) that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence and during the continuance of an Event of Default under the Perceptive Credit Agreement, the administrative agent, if requested by the respective lenders, may, among other things, (i) terminate commitments, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Perceptive Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations upon the occurrence and during the existence of an Event of Default, at a per annum rate equal to 3% in excess of the applicable interest rate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;text-decoration:underline">Issuance of Warrants</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company’s initial loan under the Perceptive Credit Agreement, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock, par value $0.001, with an exercise price of $2.43 per share. Upon the </span></div>issuance of the delayed draw loan, if applicable, the Company will issue Perceptive warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of equal to the 10-day volume weighted average sale price from the preceding business day. 36000 87000 81000 198000 25000 62000 3000 7000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s term loan, net consists of the following at September 30, 2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:81.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.782%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount, including accretion of exit fee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,009 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 10000000 414000 577000 9009000 -2500000 35000000 25000000 10000000 5000000 10000000 10000000 10000000 0.001 0.025 0.0735 0.128 P24M P12M 36 24 0.03 0.02 0.01 0.04 0.03 0.04 10000000 P5D 0.001 0.025 0.0400 0.094 0.005 0.03 0.02 0.01 0.30 10000000 0.03 7800000 49000000 60000000 70000000 10000000 0.02 250000 0.001 3.40 P10Y 1800000 45000000 37500000 7500000 37500000 11000000 1000000 2500000 0.02 0.050 0.070 P48M 0.03 0.10 0.09 0.06 0.04 0.02 41600000 57000000 70200000 87800000 3000000 0.03 1250000 0.001 2.43 250000 0.001 CHINA JOINT VENTURE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier (the “China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. In June 2023, the Company executed an amendment to the joint venture agreement to increase the amount of it’s registered capital. The amendment requires the Company to make additional capital contributions to the China JV of $255,000, of which $153,000 has been made as of September 30, 2023. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:47.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.51 357000 203000 154000 255000 153000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> investment in the China JV were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:47.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 142000 269000 219000 317000 153000 0 153000 0 -48000 -33000 -125000 -81000 247000 236000 247000 236000 EARNINGS (LOSS) PER SHARE <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:46.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,629)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> The following table provides the computation of basic and diluted loss per share.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:46.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,629)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,642 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> -4629000 -4629000 -5764000 -5764000 -9106000 -9106000 -17135000 -17135000 34642000 34642000 34569000 34569000 34614000 34614000 34488000 34488000 -0.13 -0.13 -0.17 -0.17 -0.26 -0.26 -0.50 -0.50 7713000 6635000 7713000 6635000 250000 0 250000 0 STOCK-BASED COMPENSATION <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $1,351,000 and $4,200,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2023, as compared with $1,692,000 and $5,056,000, respectively, for the three and nine months ended September 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278,546)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.03 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,712,763 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2023 and 2022, respectively, we received 6,662 and 55,853 options as payment in the exercise of 5,338 and 33,313 options. For the nine months ended September 30, 2023 and 2022, respectively, we received 10,967 and 92,520 options as payment in the exercise of 11,033 and 72,313 options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black-Scholes model.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.771%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.50</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.21</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.4%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span> 1351000 4200000 1692000 5056000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527,865 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278,546)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.03 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,712,763 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 6520444 7.12 1527865 2.63 57000 2.65 278546 7.03 7712763 6.27 6662 55853 5338 33313 10967 92520 11033 72313 The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black-Scholes model.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.771%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 Grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.50</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.21</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.4%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 2.50 4.21 0.036 0.043 0 0.858 0.884 P6Y INCOME TAXES <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense was approximately $(318,000) and $50,000 with effective tax rates of 6.4% and (0.9)% for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to interest income on the Company's income tax refund that it received during the quarter, partially offset by the full valuation allowance recorded on the net operating loss (“NOL”) generated during the period. For the three months ended September 30, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense was approximately $(2,519,000) and $216,000 with effective tax rates of 21.4% and (1.3)% for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company’s liability for uncertain tax positions, including accrued interest and penalties, of approximately $2.1 million, which were sustained upon the completion in January 2023 of the IRS examination of the Company's 2018 through 2020 income tax returns and interest income on the Company's </span></div>income tax refund, partially offset by the full valuation allowance on the NOL and net deferred tax assets generated during the period. For the nine months ended September, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions. -318000 50000 0.064 -0.009 -2519000 216000 0.214 -0.013 2100000 COMMITMENTS AND CONTINGENCIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. During 2022, the Company recorded an estimated loss of $250,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. The Company has not experienced any movement on the matter since our response to the distributor in the fourth quarter of 2022. Accordingly, we have revised our estimated loss on the matter to $0 as it is no longer probable that a loss has been incurred. The reduction in estimated loss of $250,000 is included in professional services in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Hattaway Complaint”) was filed in the United States District Court for the Middle District of Florida (the “U.S. District Court”) by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Hattaway Complaint sought an unspecified amount of damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the matter was in the early stages, management had determined that a loss was probable in the estimated range of $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. On June 15, 2023, the U.S. District Court issued an Order dismissing the Hattaway Complaint and granting plaintiff until July 3, 2023 to file a second amended complaint, failing which the U.S. District Court would close the case. On June 27, 2023, the Plaintiff formally notified the Court that a Second Amended Complaint will not be filed and on July 17, 2023, the case was marked closed based on the Court’s June 15 dismissal order. This closed the matter for the estimated loss recorded by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff’s allegations could be subject to separate deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the “Stein Suit”) against individual members of the Company’s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the “Pritchard Case”). The Stein Suit sought unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing. On April 3, 2023, the Company formally moved to dismiss the case as time-barred and on other legal grounds, which triggered the plaintiff’s right to file an amended complaint. On July 12, 2023, plaintiff’s counsel informed the Company’s counsel that plaintiff Stein did not intend to file an amended complaint, and on July 17, 2023 plaintiff’s counsel filed a notice of voluntary dismissal. An order of the Court dismissing the Stein Suit, with prejudice, was entered on July 20, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023, the Company had purchase commitments totaling approximately $3.5 million, substantially all of which is expected to be purchased within the next twelve months.</span></div> 250000 0 -250000 475000 2500000 475000 1450000 2400000 1450000 3500000 RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September 30, 2023 and 2022, the Company made purchases from this supplier of approximately $50,000 and $85,000, respectively. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, the Company made purchases from this supplier of approximately $501,000 and $455,000, respectively. At September 30, 2023 and December 31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $12,000 and $8,000, respectively.</span></div> 50000 85000 501000 455000 12000 8000 GEOGRAPHIC AND SEGMENT INFORMATION <div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate &amp; Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,836 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,976 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 27.8% and 26.6% of total revenues for the three and nine months ended September 30, 2023, respectively, as compared with approximately 23.2% and 29.5% of total revenues for the three and nine months ended September 30, 2022, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,660 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,492 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,687 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2 2 <div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,836 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,976 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,362)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,641 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 9836000 2140000 0 11976000 70000 591000 -5298000 -4637000 0 0 248000 248000 0 0 585000 585000 0 0 -19000 -19000 0 0 -318000 -318000 7080000 2034000 0 9114000 -1174000 356000 -4964000 -5782000 0 0 73000 73000 0 0 1000 1000 0 0 -35000 -35000 0 0 50000 50000 31248000 6439000 0 37687000 -509000 1795000 -12769000 -11483000 0 0 478000 478000 0 0 1362000 1362000 0 0 622000 622000 0 0 -2519000 -2519000 26258000 5641000 0 31899000 -3765000 1142000 -15006000 -17629000 0 0 93000 93000 0 0 12000 12000 0 0 551000 551000 0 0 216000 216000 0.278 0.266 0.232 0.295 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,660 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,492 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,976 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,687 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,899 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 8652000 6997000 27660000 22492000 3324000 2117000 10027000 9407000 11976000 9114000 37687000 31899000 EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( "Y^:5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " N?FE78 6?3^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R';&H";UI66G#08K;.QF;+4UC1-C:R1]^R59FS*V!]C1TN]/ MGT"UC MS %!_/3Z_SNH5O M,YG6XO@K>T7GB&MVG?Q6;;:[1Z8EEU4A1,%7.\G5_4H)^3&Y_O"["8?.^;W_ MQ\9705W#K[O07U!+ P04 " N?FE7F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M "Y^:5>TGU =P@4 *\> 8 >&PO=V]R:W-H965T&UL MM9EK<^(V&(7_BH;.=-J9$"R96[:$&>(D+=--:VJ"Q#\N_[ MRH"=3>47ZEF^)+Z=@Q[K=BP--E)]29=":/(21TEZV5AJO?K0:J7^4L0\/9'?6G@BBHP3E..?G6FC M^$TC?'N\=[_-X0%FQE/AR>CW,-#+RT:_00(QYUFDG^3F%[$#ZA@_7T9I_I=L MML^VVPWB9ZF6\4X,)8C#9/N?O^Q>Q!L!ZU0(V$[ W@EHU2^X.X&;@VY+EF-= M<\V' R4W1)FGPZT M_)W^:JMG%?H+ M+G^0ZW/B]&WRKXKC%N_'S?U<]/W\-9JE6D&3^]OVAK8.;;N#Z8.0/F9<::&B5_(D5E)I&QYNI55F>RD>JJJ)URWPNL?A380*96!Z M(8%QP%IYN%/1[RH['JJOR=DK.'M'MDS%80K)9X#J>L2]YCQ*K16)RFH"]@O M/EJHFT2'^I7X]/D\6GT/'Y\L/&B3C5YJ5/.JLXQQ./$ MEPI:*3<-]HQ,-71-(A7Q9)9H]0K_ ^MK..!^?6,CQD5UD=\$"7H,\C-_(>, MNFHX#_V<&VG/!RPI;;)NN]VEU,J+BNORLI*7'<,["@)P3\_V!^0.GB./B;U> M<U#$04CS3O68L>/%%R'2:^O99QS]L[*^@I4A(M8Q+%P\U[T(E, M-8_(G^&J>I#"'5VWUW6LI*<(3+1,3!0/.GES'<$G;S48;M!C/2O6*?(1+0,2 MQ5/-G?2AOB9+F6 !XH")VV\WF6N/?[BT+E^9CR@>;IY##=%(S@EE/\Q^)%/A M9PIJT@J).WDRCF%XG6KI?[&"GB(JT3(K43SD0,(-PF1!IJ_Q3$96OL,IR;(0E2'P@-'#:'H]LGYHXL*ZA&4"8D^.?D>W,J).U9Q MGB+HL#+HL*."CODF@\@.$_]"*NN <\#G029-[OL";, DV!I:>4\1=E@9=MA1 M86<:\R@B5UD*MU-[J\5]JA9*<%E=O#+BL*,BS@W$ZX7IE3^#@UY""HA7/+'7 M*VY8N9" Z^J"E@F'X0%E7X]+ ?6(X>$VU7BG2#JL3#H,#RG[8?;-- [!/%^_ M)H^9AMR:F G42OR-,LSN/6S=.KF;V2]9#]UVM^WV.YU!:VUC+-,..VHYR(/A M5$&L&R>!>"&_"GLU'EH5O:"N=5D(%]>MRS+LL -9)19)D"_LW4;<7F6X M074C/47:<L&LV*6NZUF407%D7M P]+AY1 MBI79'>EN(?H6+EOGC@-V'ZW?'KBH+F,9>%P\GKQGS&NSFA WJUI>QV7_E['U M9DO03'CY3FE*?+/PN-T=+*X6N[&C? ^R53Z^W"43)M.53E"01"/*E+4@_%I\]T='Y^RI2R+FMYQ()951?C+ M)UJRI[,!'+Q^\:UXG$O]Q6A\NB"/=$+E]\4=5ZU1ZV5:5+06!:L!I[.SP3D\ MOL"1[M!8_%70)[%U#70H#XS]T(WKZ=D@T(IH27.I71#UL:(7M"RU)Z7CY\;I MH+VG[KA]_>K]3JUT+UD^.+K[>75[>3JTN@KB9?;ZXO MS^]5X]/YS?GMQ168?+FZNI^ 0_!]<@E^._@='("B!O=SMA2DGHK3D50:M*=1 MOKG?I_7]D.-^$[HX C@8 A0@;.E^X>]^27/5'3;=T6[WD8J\#1^UX:/&'W:% MO^2N="E8C1&".#P=K;;#,:U@ M #/46NWH#%N=H5?G/2=3JN9WSI9*G*H5.55*'THZ!+6J:VP&2*FJ#ZESJAL' M<82:L [B.+6%LKY;M"T2Q6':"\5B%<2!(Y2H#27RAG)=YZRB0)+GK3"L^8Z, MVP<]@:9%$H6175_7[I,7&C:,L[HDS;;+,+BUII25[4K=28Y/Q M@HKVN2\X6Q4-0!2_ 'L03$G.:3L0(%P/A#!*;($DYB.&*(UZH=BLDBRQ1Y.V MT:3>:.XX79!B"NBSXJ^@HM')FNSG.R7(ICLU%.$P37JR32.48(?JK%6=^6U*KUC1T6JSB)(8.K5NPA?[YII026=2/H*1J[0&X7F09=B\ M:QKU:X#-"D'';((=V. >LC7SR2/.A%"4A6&_V-K,8)*X+-O4Z!F MO2JX3[Z%?]!(OH5_,':([_@'_0"TB)_MU,-]TDWF(4.Y:>/B-NJ@B/Q0W"7W M'I7(A!T,4-8?(#8S53L=A$$=%)$?BO>45Z!DI'8R&YEDRX(@Z^LSK5S:MK:' M?OK=L/KQ4&J![QRTR*1;F&WMC#:2+5:)2W3'0.1G8"?Z78,5F="+^KLDBTV" M'7H[+"(_%CN].:LE)_G^$6O9K6'4YZ3-*@P<%0UUF$3^3=UZB;%/H;E=@RGL M"_0;[>KKB(;\1%O/_7WZ++"*TKA?G"QF$&>I8]&..JBAQ+O4N/KS^_7]/U9A M7AJ^^[SE%WG;#;.#']J[[9M158.G0$B6_QB"@^ H"*!::W"P(N62G@ 8#(.@ M^0-B3KCF^U+.U;[W7SH] 0$HA-#T;Z"_E$*J"UV$B- PFM"%I-4#Y6O-K^=J MC?6EVM7KGQS'99MLF]@TAH#/9#$P#O%0+=O_ M5W:&C;ER$F7),$7([^1M:;0PO+^G\-OLGNAUG,=^SI]/IX5>F:@)K\\7#HL: MY&11J )@/=0S"9ZD,#).]2QF&+DF/>Y C_V@5RO99;4LB53)GM)9D1=6VF.3 MXX=AF(;]ZFFSPU'B3&H'?>R'_KJ -H-SSLHIY>+CAU1M_TZ:XP7Y8A5MDAQC M;)PRVLR2R)G:K:-=/_)O67W8P).5I1Z[1:UX2H4]OR;#$3:$6HR@ TVX(SU^ MRP;8DT63V!@K+/7%6V,$HHQM8@OZ:+23V M[%HE8@FDBHF42%B/K8E[.W4]DU!$_,Y@IQIM8JRLA'@RG?MH;#F&"#B$VDA0 M_-G"%#@W2LCQ=R5JU6.:Q&;[6?U]81[-K*B"J>!_L$C'8VM@D0C6-.?ZB]A] M@,J0;_1"P57QG^S*V/[0(F&NM$BJ9"1(6%K^TF_51#02W.XK"5Z5X)V;T*D2 M.H71DJRP-:.:!B,I=D2::%0SC6)NBFQTPU+S&9=:XEN&>3J8?GZ8S1^6\QG! MUO+SQ_O9Y!$[=Y./DX?IG"P_S.>/2W*UH!)2'8-F(>77Y!WYNIR1JS?7Y UA M*7F,1:YH&JF1K9')*-MA-?Y=.;[WROA+R&Y(QWE+/,?KM*1/CZ?/(,1TMTCW M]M-MG(EZ.KQZ.KQ"K_,:CJ8:<)5J(M;D/4MI&C+*R4(H5JRZ/R MH([9@^[6T-VCT/?I%C^X98&4$!&L\_ )J:DD6\IS(%=85I'@G$I%,L!]-\8*O&YC M+X?H-[B<&\A7UOH_Y0%IE1^&K__@NJ0^UC$'O"@!A[\%# >T4KC'LS2S2GJP4GJ M8Q%[U,.:>GB4>BJ2!&OQ/RSSX5G+_%34'KSK_#@DG0OP+U[EE7IS/OM^ZS(_ M)W+?0^.@=R_W<-XRKY2;5)UNK]L9^/XA?UND/^P//.\5_A\GLWOTQ&OGOV#5 M5_+GF&B+;#5A-RY>YM;[B!?4$L#!!0 ( "Y^:5?R;]E4AP8 @> 8 M >&PO=V]R:W-H965T&ULK5G;;N,V$/T5PET4";".1>J> M.@822[L-L)L$<;9]*/H@VW0L1!:]))VD?U_J$LDF1]ILZQ?KXC-#GAER>"B. M7QA_$FM*)7K=9+FX&*REW)Z/1F*QIIM$G+$MS=4_*\8WB52/_'$DMIPFR])H MDXV(97FC39+F@\FX?'?')V.VDUF:TSN.Q&ZS2?@_5S1C+Q<#/'A[<9\^KF7Q M8C09;Y-'.J/RV_:.JZ=1XV69;F@N4I8C3E<7@TM\'A.O,"@1?Z3T1>S=HX+* MG+&GXN%Z>3&PBA[1C"YDX2)1EV%+]^%X['31M%H;[]V_>/Y7D%9EY M(NB497^F2[F^& 0#M*2K9)?)>_;R.ZT)N86_!*JQO#]!B)R3;U,:J M!YLTKZ[):QV(/0/E!S8@M0'1#9P. [LVL-_;@E,;..]MP:T-2NJCBGL9N"B1 MR63,V0OB!5IY*V[*Z)?6*EYI7@R4F>3JWU39R<)QJ'OC4?/^T$U42'&SB$H,D&V M[P7^(2H&4#@(PP9U0,]MZ+F]]*9,2,162'31K,S=_5;#,-!8 B#;U?H?F2!, M AT5 RAL61TLO8:EU\OR,V="H"UGJU1")#VC43_T=9(FR/4-DB:(.(%M:20! ME!6$%DS2;TCZO;7C5JXI1PN54('4VH#HJY(U@HISB+%_S,IQ3&?1,9W%1W)V MD(^@R4?0.^CNE<>$+]9E,I;T6:G#;5'3H70$P-PP:@D LCRL#4 39+NAYBD& M0"3HF&-A0S?LI7NG9A<5A9)-,E3$,EW %24T:02V1F,*@$);HQ&9(!=[KL;5 M!'D>QC!7;+7ZS?K1LI#PE%8SC=-,K=?+:NZ!DLPR.N%XGE8[I@#*#GP]P0 * M.[ZOEQ@(9H>.TT%\3[CB?N)J68$3!1V'=_1(P# E#>W(P*DC0#IC< #DXHVZZBV('D"3&\/NSI[ M (9=.]3IFS [M"Q]W$.PP,4=LQRW"A7WRJW)9[4-1FJO62B&84;5;G&>+)Y MVK;1 TNG_$-(!$"(%Q*=;9^C0Z:M\L/]TN]+(1I6G&T0V])B:+,<3J]CM#UT M/-N8W@#,]0.B\P5@2C(&MLX8POD>Z4IPJPAQOR2\SB55JZ%4&\UB,P(R-E6: MDCDZ7Q/DVSI9$^/HPBL&0*'=P;)5A+A?$C8LZXD+TC1UVM -C&D+H(R2!6%L MSQC%$(QT4&UU(>Z5.;4P/*F)GM9Y_8AR"FJ1VMMA)T*=- "R79VU"?*(P=D$ MN6[7^MQJ+]POOO:+]/N9F[I(D=)E&(#2YWH$>2)FNDV49W>EN]5AN%^(E65K M3E>,TYHPDLEKQ\IDJJ.A$X:V3AF N;YCY!N 86S@8A#GA:$/4R>M*B/]JNRZ MH8M.YDJ?J.W>:=\$)Z9(&JI-M<8>0+GZ*@5Y(JX^;6( 1K#70;O59*1?D]U0 MB3*5=9"BJ8*&!RJHY@C 7#_4,PS!0D+T_04$PS[!'56;M-J+]&NO-Z8HD9*G M\YU,YIG*-T,YRX<+EDO.2GFJ!GY5WL&0F,I(A40/" #2=RD1!,)$E^(0:F^1 M.PQ%J\-(OP[K#(60;/&T9MF2@KF^IW^[@F"AVI?J,0!@ MV,=VAQHGK4@C3N]7C[+:*7F&Q#KA%/S607IEWL]^[#BJM^BHWN)C>3O,1:L< M2;]RO$I$ND G:G^P5-,PX7N).0434[D+]@>%=8;UU:<#IJ^Y,,RL32"L:QRV M>I+TZ\DHS7;%-X"?8.^]CST,,]B#,),]"-/9C_9.MC:4/Y9'BD+M=G>YK XS MFK?-L>5E>5BGO;_"YU,,O(_P>5P=2K;NJS/2KPE_3'.!,KI235EGODH7KXX= MJP?)MN6YVIQ)R3;E[9HFJM@5 /7_BC'Y]E TT!S^3OX%4$L#!!0 ( "Y^ M:5>*'H-OQ@@ &!* 8 >&PO=V]R:W-H965T&ULO5QK M<]LV%OTK&+6S;6:JB #XD+*V9Q()V'IGZW@CIYV=G?U 4[#%"46J)&6G_WY! M2A&%AR QN?$76Y0NSB7O 4"<0T@7ST7YJ5H*4://JRRO+@?+NEZ_&8VJ9"E6 MM(U6V8AX7CA:Q6D^N+IHW[LMKRZ*39VE MN;@M4;59K>+RKW.R;MX875VLXT1Y_[D '^YQ-P\/77]!Y>_'R8N[C2DR+[(]T42\O!^,!6HB' M>)/5'XKG7\7N@H(&+RFRJOV+GG>QW@ EFZHN5KO&\@Q6:;[]'W_>%>*@ :9' M&I!= W)N [IK0+4&)#K2P-\U\/4&QZXAV#4(] ;!D0;AKD'8UGY;K+;2L[B. MKR[*XAF53;1$:UZT=+6M98'3O.E9\[J4GZ:R77TU?7\S8S=S-D/RU?S]OZYG M;^_DP?Q._ON-W=S-T7N.IK^^O?D'FZ/K&\3^_?'Z[C]HB#[.9^CG'U^A:AF7 MHD)ICNZ6Q::*\T7U"_I1.;X8U?),FWRC9'=6[[9G18Z+X76.IO$ZM9\).X&5))O5)HMKL4 S M\9 F:6T!X6Z0FR(?)D5>ET4F/WI$UWDM9*TUI)%D?$\[V=-.6FC_"/0[\9CF M>0-Z'V=QG@CTLV1LR^4K%-?RI)/7B.)?$/$(MA'HQ&_FPS?5.D[$Y4!.>)4H MG\3@ZF\_X-#[NXW6+5C0@C5SX=,5]7WL78R>#NF#3,D@P3@0F$(EW5-)>U)Y M#GU;S/"@XH'O>1.UXE,SBOH:*69(&)(FYV$4,Z.&F 2!%L8M^;Q@'Z.4Q]^7 MQV\;T2/EN<>M9 >7-6E?O6HFIW:.6!;90I353XC]N4GKO]!_/\B1AN0= MZSDN%_^SEGJMK(F5C>&ZJ&=U2L MFXF^0N*S*).TDA%RC8:2N%H>SH.V#N!,U[<#!,:TA[U0&U^0"1DD& <"4W@- M][R&L+S:N S-NTX8:#-@:,Q(VIPULZ%HDR1S7DS?N@.!*76/]G6/W'5OR]PL MY12.C,($7:-U[ZDS7=PX\)R.#S,B!P!0NQGLNQOW&0"Z% M:"7J.A-2^M6H>-!&Q8FIS9FM[]0V-JB(B#9P(/,Q2# .!*:P.MFS.G&R>B-) MS(K**IHF1E&'."*8:F/*F:#OF(($8]8+P%2;=+DE+!K;EX'8ZX2NYRPLRQ<. MO3,7:[E@]MH%,[$*5B=ZW^&Q0U,53S >:T,$-"D#1>-0:"J=![X%[D/G611B MH^B^E"J1-GQV88H*"71B3*@(A[XN>RQA0S()Q]H]B5OB"(F.]/A.X^-O%/G_ MW.0G*@:J\K%5YD^H7EM0G0^*QJ'05$8[J8^_0NN?9I&:_3[$H7[;P&>H?0M4 M.(ET"IDE;$CHA!"]WYMQ)#@VTW>*'[^DY,>@FA\4;0:*QD#1.!2:V@DZX8]? M6/F[\_7N!Z;V#_4%,FA&!HK&H=!4=COYCU] _V-3NN/ 6 V<=@"L.+KL=%]0 M[_)_#Q, =RX AK,!L*G*<3@A>IE!C8"SU8]WRS-XW M[A204GL&BL9 T?B)J> *O[4V+&G:_W6+4\\CH^C][#\'1&!IJ10Z&I/'6. CGA*/0P>8BI[WWB>3HA MD)I\=E9.!IJ30Z&IE'0^ ''[ - FCSM=[WG1U.=8]TI!,S)0- Z%IF[C[8P( MZC8B;LLB$6)1H5(D(GV2!+>KDX;L=DDOR96+T3+.:ZL/1$WK(#"F1/[X#+BJ$743P@Q*'!FZ$T!)!JS7H*Q)Y7;PC#Q[,L^ MVOD2U.U+G._$46O]04T):C,E0M_8_@YJ2H"B<2@TEGT.)( M4,LL=H8C88&*QCC0=^9:PH:^/]8=.VZ)(_3(3@7:.1+4*7;[[="Q5PS4A=BA M:9V>3/3:@MH+H&@<"DUEM+,7J-M>.+E#Q\ZB*:-I&.E/R*:[,'>_-Z&B,(KT M'3J6L*'O$:SOT+'$87I$X--.X-/P!9TX"JKN0=%FH&@,%(U#H:F=H/,!J-L' M^$8GCEJ>\1M.G/L4>I,)B<9 T?B)^WF/5M ",;XV" M9F2@:!P*366WLQ-H3SOA:YPX:JI^JAL_[O/H/0Q/9V2@&3D4FOH-ULX9\-W. M0!\GSCWRPV!;J^ M3@1-R$#1.!2:RFWG0_AN'\)E\OBF+3#TPTC?;>7.T'M\@9H,]DO011ZWAQWY M,GYG"OB]3(&^'H\;O?-0:"J=!S^NX#8POL+CV2$J(M;B M\=C"C#G,C+%Y/)8PJ\=CB3,]GM'!;^TTO[WT6UQ*Q5^A3#S(5M[K2/:FS.U,62[(-I DS69)M,]/-9I;T]K.P1=!=8U%;Y*6_ MOI)L$%@OD#M\";9S=/R<%YWG'-N7+[SZ42\I%>!U593U56\IQ/IB,*BS)5V1 M^A-?TU+^9\&K%1'RM'H:U.N*DEPO6A4#%$7I8$58V9M22;T3!2OI0 M@7JS6I'J[3,M^,M5#_:V%[ZSIZ50%P:3RS5YHC,J_EP_5/)LL-.2LQ4M:\9+ M4-'%5>\:7DSC6"W0$O]E]*7>.P;*E#GG/]3)77[5BQ0B6M!,*!5$_CS3*2T* MI4GB^+M5VMO=4RW\M+)1#V2;6O!5NU@B6+&R^26OK2/V%D@][@6H78"Z"V+/ MPN MP-K0!IDVZX8(,KFL^ NHE+34I@ZT;_1J:0TK51AGHI+_97*=F$R_W=_S![ES]?;^\<9^/8%3*]GOX,O?WS[:P;ZX,_9#?CPTT?P M$V E>%SR34W*O+X<"(E&Z1QD[9T_-W=&GCN/P5=>BF4-;LN_ !0A[, S/7TY"L#!.\]BK0_[/$OJ)5C(;5*#1<570.Z\ MB@A6/C6IRP2C3J\U6F.W5K6K+^HUR>A53V[;FE;/M#?Y^3\PC7YUF7PF90<. MB'<.B$/:)_>R"!6\=AK9K$SU2E5IGB?],4+IY>!Y'[U#"@X1Q#NQ US)#E<2 M#,QU_C^YKV0I$C407-:BC)<9*R@H6\#JJCK.5 0W-?4&^+SF!:TS6F;4!7=H04%HW(%KR\#$ W>T M@SL*POWPFR37CTVB2\)@7@"["N5):)-^UM^O>&K566NK"/+%Q]E";= M_6-+#5,W^/$._#@(?B9X]D/S9@XROI+-1.U-A[%U]U@V%QV(ME 2)1Z0,#*D M%KTC)4@AJS"16:#/M2S-NT-DSCIPK2EQD,/ M2$..,,R.=RT?>KI-:#-<',$N,%NHGZ1#Y,%FF!"&J?"ZKRJ:R/(SSLX':)P628>(HU,J2'X+N&)=7%U:?@#G+I>XOTN;0= M.L%P*@ISZL.FRI9$E;YW]8+()L]^;#7>+JE1ZNEED6%9%"0NU6EEE.9MV&0? M2]\)'MN5$:56WME2OI0SE(B.CZ=ZKZQ5LYC+_3)_ Q_:C?/Q] RTV3 =(ZV6;!2]KDG@#[KD'HN;8=.,#2,PC3<24$]H?"UGEKI*ZTR M5GN<8-/MJ-N8.F1PFGC"9C@9'9U8]Q#++G\EQT'B'**03;UC-.J.J0XIW_XP MY(S"Y/Q WM2F5=LYIW,!6%UO]!"5\=K=C"$'"<.A-8XXQ'Q@#5&C,%$?>G0' M56)_(55%/%,>3*>\%!6;;]36:CU=JC%07>9%H%02"?:YVC I#D^?4Q_87\"CH2_)#0OB, L&#*!J>@E"MUD.(8B[A=LA!N,1]DS^V- A'A[O8O3LO^"5 M\UD,#O+INU^*G$G;H;F&6'&86.]"-=+FQI$=!UL(>F9Q;!@4AQG4/,SPU$&; M!E':?5#@$(+(PSNQ896I4"+.UUHTV\\ MAEV2=DAYZE=L2#H.D_2Y[6TD5CQG"Y9YWU'$H0?/K;&VR##U/%F*#;7'86H_ MQ5QO8_C_!C.]%<+@O K?;BD1'I)"L&"$2 #P-0 & 'AL+W=O:N,7;_>F^RE!Q_U9T&KU[O/=\3 MN5K(QM0?[?I[%?DYI?4R:SS_%>LX=KPGLL;7MHB304&AR_!??HER>,R$:9PP M9;K#1DSEI:SEFU?.KH6CT5B-/C"K/!O$Z9*4,JL=WFK,J]^\/9]=S\2'*W'S M\=WLW4^?SC]=?_CIU5&-I6G 41:7>1N6F=ZSS OQWI;URHMW9:[RX?PCD-32 M-4UTO9T^N.!,58?B>#P2T_'T^('UCEL^CWF]XWO6^^"6LM2_28+"2%S8TENC M;BQBFORCH\L MQI4M99EH:,<-#!1C67OSS?.YK!R#]WRX)!0).=A- MQO6=KV2F7N]5M)>[57MO_O:7R;/QRP?8.VG9.WEH]<>K\1N6$>?5YHMXKW*= M01P7UE76!3GM_^TOSZ?3\/)^.1 -88=A*"2/7GA1$GUDU].52X;%TBA==T2K0 M5N6PEJY L_JBLH:L'V,7.L.P6IQ.)J?B9U,H5X.3CU;F@(51TJVQIAN)JQ_% M\?'9L_&A^(2=(H=">VPA9'X+<( ^52JWW(#\;%5:8_$QBP/7NEX)*2KIV7W! M>PIXHEO(K5R*2MG**!+$Y.RE%P:4>3#D;+-<@>?2TCA06SF;-UGM1R05T^0T MESC[7AG=%.+&2%](\:G;/4V AW"?%4F0I6P-/GCQ497-+:@!ZLY.7I)P28B9 M]86J=0:_[);*;>)98"@&THJW2Q&T4SAL/<_9 2P3?PB* ?$7- M(WZ91,5(H;5AY:I=D):8CB?/&<5+9SW9ELV4REE<3UZ<(3(9 [VSX+WJ7J\5 MUFD\B 2'1C9EMA)S!V.+VQ.B&:+2D&I*76N&/F:N-,8&A09/X&2ETTA0L0:/ M2167*E/%')(_GG#$F/"BNB3(@+V%=KX6OS:0.L: 9 R9$JTZB+_$!G'%**V6 M=7))T S+1V/8'$*":O$)>5%P@P/S),ZAYZ0GFFA+PL>(8"4I.O;P0#,RB:@0 MH8]'M+_U!!K0BOCC QO$MIP;0N0MEK-N,P( C6P2T%C!/@78%XO M2XTH(;%V:94 ,3ZZ08\]G#?1[M# M *N#E03_A(33,/H=D-):R6? T\@OA):,8A79/[C\4(KW++[)"<-_&EC]^7!V M**ZL#5'@TC5+R ,YI*8D9A# KR[/8U@^$)7U'#C:B'\9O-A,+A3VA?P*N,1L MN,"NEVG%X(VQ!8S)D:G))0#A:Z81("([28'C*(4+]C7L1G(6,(Q L?&0A H* M$>S[A:RJ*(>4%+"0DF/8()D# 1KX%8J( MP?PN+XG;8CJ0(^;P@)09(V=J,_K0$2-RBF@X*YH8UCR&RBZ8 ]'RF% @5IV M\A12(+>H'21/A-@1R);+QL0DFBUR;MJ4V=M%G2)T'GP;U8X\SL#)(7!DMHH1 MB)'5Z7<$CUN33<+D:K%!^C%7F)HKR@QU&?0.H7K@C$081$*N@\CE**\\N.4 M1S+K06?_FV%T0.9C4+<2+YQP[H#YT*UTN0/,%3,5^;." [H-0)&YK9+('DKF MHEEOQ/19WZC;K 9I8L/;L+YU#9!G"A+)D=J.]S\?=!Y"+)PM>#+I.=$1==N' M2,S1+H/1? ^J*ZVR(.,L^/%=%M57HZ]4QMZ3'6[:B^TJQ<3"YB'-(<]-:9EJ M+8ZQXE:;&OD?%C,H#Z)7I!#5I5E7NOX-3YS./HL9J?O3IL+LZY&XOB9X7%]? ML_A^:&!QT[[X2 )-E0=G>X]&&1PE&2\9OF]0(P3*$'1,O*C\4L_YC3H(AR %:PTN6U7GEM!'3Y_]Q0?7X9-[Z]/88)?RDT-1/ M'C@>MA8WM_F&LQ?+ ;F-*9-QG\__'JOX,XPB+=*OA/Y\05/.VY=T3\@BEJ4[ MQ8P:!ZQY;@@1FID"CX0(^W7UJ75ZJ:D.VKD&8W!8$1SB>RF7H3"=P[Q4Z#G) MA.68XE#]U%5979'!J@Y]! ?Z4-2R' -#_D&.4$EG:HL<*C$;[DIY5"/$%2*] M7H;V6"C94_\U9K]MSV_7%IB_:*@2HZQ;VSQV@%+AOF%22PG=$\2AIISJ4/X4 M^\"4^+9;^J[ENT(I&W+1RJF*$V30W!2)SHNVWX MA<[(\!&=)FCFJ^HWGWGYI)O[MP#+;0="4&'!U:5?4Q_.,#Z1L!G]FPJ-)L"Q#@B@$G@EW3*\,#JT[73$!Z0--8;U4\BVG,V@ M5'?!!Z;.RJ&XP:-&A@J>AE(LT"Z2%[7=M>'/,R[W27XS6&DN7>[%6XM_;1]U MYY +FW,^.BA7SV<7;;W[B6N2Z?CTZ0E,]1(,&MBX8V)_+J/7"2RR4T-U]P[? MZTVW;]>[O!@@X.^L[HNH[A$U?I()%@U@KVZE:4A/B'!<(M8=R MYS:TD BOY&!#0XQ=W7*)C =KC*(Q2VIHPI=!U2"%6D.VF=<]A]QKUC/UO<[K M _AE=]?"K UR/91]FWUU,(S]N"@3TE9N(72J!VOY684V6!) #$F@H+*( &)E"/SS&!-(+JCM0)L";AL\T0 M6L0FB?P!\OC'2I4[5*F^P&7Z-D)"9@708W.N&@<@2_CR?8#MEE/J1%."1& 3?Y?:1F*%FOJ6#FC(=99F,[ )N!>+(+D_.: D37.? M>AY<6O*F@BXY_I M\>&S= #$A/)YSY/I^/"X?4Q-1&*PG[7X 3DE1"R*<(D@4#5351W)&N^JRKY" MUF1R>+J#+#R>/$S6781PAES56X#Y'XA>?J&;*7#%PV,6"!N5P8@FH!9Q]HNF MXQSXF"?/N]WY)! COL8G=469RA8FE"C!M:=$Z0G2^W95WC0*KS=*J9SO-Z'N=/33!DS-]9< "U(MN])^N@H.4I M@6RKO&]-0@[%-2&$@@&?(MDN[,5E._Z'JJDHA<6JMQ)4HVPD)!!/V*\)XB)D M.0[478EJ-/2']4*+]R<\8NU/I[N,;Z$-G\;XE3(+[FZUIS-*A[ZRHCD$8R+F>;. MDOA[0]4LOK0 %_NT1JP*WNO\0E9WC*"M%+CU' ==14U?_R(^.;*M?8+T$L,/ M0M!/XUJ\=CK(O0.\#\V&'93 MG!HQ>3P=26HX[AQB$FVL*3S[3NJ"J)+"*V.%U)!(#2%(MB^PIR6Z3 24'/Y/9Z(CN9S!0 MD4D,&S1D>$&J;&Y\I^T"2:T4WUN3ASK=58<\FU^^;?$*\ M M$=X-^JZ''V[TBH$\BV7[GC28:>)@#^ 5$GQ/L8L%M+Z%!],K#@1WF7W[GM MEBM@7TJ&>WRVE?-%9Y K(S=T%.ODNAO=&TP'O<0-WTOA0[BJIML#/G.Z/:U] MK!&T,G^ ']B[4K 4^(>S1YS5M)#CCA=?>=0P9T)4R#!O.4E(=\F\,N'LC3(H M-9?9YYV+49./!$OWX#:02Y8N70XO0MZ]8/*P2=\T&"KCO;H955/W&'0:=T^H M_>5_Q7F&5,G'U/.7:UC&CQ<[UW =XM,YP[".&W+>HC8Q_9@;H<8Z9)'L+1DG MH5\40#+O6G)WV1+[&=UCC(V&(+M$?Y1^RWE,@],:"!XAOWUR-GIV.AZ-Q^/V M$&>G>Z7N)<7+>VD)C=I0.W&/)]R.9?Q,QN&24GNMD:_M#3#$Q8+ACGJBO4O, M6VU\FSW=I;8S$R].F/33MFK\09;!8.[(8!VR2;W0ZW\L)-P'BM2T4+E[L+GJXJC$V.UD)9N<."<'PX M;3T62PO+QNP\9 LP2L-!>\8_Z !]=TK[<-C9+"D9G>RL M-]NSS7ZQVND88AS% K.K ;9Y.NF7V*D>3J"$XVUOC/)];PI&GS9AZ.Y4NNR;D>CHAK!A M-#AJJ34J-J1;)N'AFBQ4=R!X-PG]-H ,,PAK3W7Y%+K/^,)9PNV+3OA\"H>Q M*M^I8K[(U]UX1(XS.?GK R=ZC)XL=HX,_59GPSWTP1&H4X@666J_W!?*VNSO MP5@VJ)?[W8*N*YG_%_8,-+?1OZ5CL.LG&T>]7^$@B"SYMT;D,Z"S\(.<]FG[ M;GCX+12"[5)#?$8M,'5\>':Z)USX?5'X4MN*?],SMW5M"_Y(^%". M!N#]PL)EQB^T0?LCKS?_#U!+ P04 " N?FE7:FX\OXL$ #X"0 & M 'AL+W=O4O[]/;:7;4X"3KK[DOAEYIF99U[6IUMC MO[N*V=//6FEWEE7>-^]'(U=47 LW- UKW*R-K87'UFY&KK$LRJA4JU$^'A^- M:B%U-CN-9]=V=FI:KZ3F:TNNK6MA'\Y9F>U9-LD>#V[DIO+A8#0[;<2&E^SO MFFN+W:A'*67-VDFCR?+Z+)M/WI\?!/DH\+ODK=M94XAD9'F?4F@^+N^A']8XP=L:R$XX51?\C25V?9<48EKT6K M_(W9?N(NGL. 5QCEXB]MD^S;@XR*UGE3=\KPH)8Z_8N?'0\["L?C9Q3R3B&/ M?B=#T+;W=7 MMY=7O]'US;"5M:5$)OF*2F']=XTH^"Q# M"SFV]YS-7K^:'(U/7@CLH _LX"7T_Y3+_X=(EYH^MYJ1FLG1@'S%]%%J ::$ MHB=Y/C?XHS>O7QWG^?CDXWQY'I>3DSV2SK5=1;[Z\Z]6"Z?W)=+!C M^5(C0RU&AW=!;)*?+"R7TM,7XQP[>G-K&EG0-#_:&](MG&X3?!$S[V()!V92IQI*8 MY8+EO5@IAEB!K@EEU:$.J&)5[GNSC]'36ND?,&Q6GAP7824? MK415$7Q1HW] &LU2LL)H=A)DS> 4_Z M*CKY0*(T3?0/ZK7T"' 8JO3*W">EI! K%<77%]WR+M[L3\;/%!+MT[-%-(!/ M%HD,T:2T?.)R$SSNA(XGAWLI25]8["@?'^1[=-$3@0F..X13R:(*WQ:V,)DR MT N540CLXQC)=7V/!!J7-7A&E#?<&!M[:&%0R#I40V@JE+%T!2)[ %O_2FV> MI_9(&!VWG4.AI!YM$^C^+)! ^T"3-*=3)D%;Z",4=F>DC3=-_+:OC,=+(2XK M/,W8!@'H5S%\3P, /\& 8 M >&PO=V]R:W-H965T&ULA57;;MLX$/V5@;98)(!B6;(5 M7]8VD%MW [1ID'3;A\4^T-+((DJ1*DG93;^^0TI6W")Q7R1RR'/FS&AFM-@I M_<64B!:^54*:95!:6\^CR&0E5LP,5(V23@JE*V9IJS>1J36RW(,J$27#X7E4 M,2Z#U<+;[O5JH1HKN,1[#::I*J:?+E&HW3*(@[WA@6]*ZPS1:E&S#3ZB_;>^ MU[2+>I:<5R@-5Q(T%LO@(IY?CMU]?^$3QYTY6(.+9*W4%[>YS9?!T E"@9EU M#(Q>6[Q"(1P1R?C:<0:]2P<\7._9W_K8*98U,WBEQ&>>VW(93 /(L6"-L ]J M]P]V\:2.+U/"^"?LVKNC)("L,595'9@45%RV;_:MR\,!8#I\!9!T@,3K;AUY ME=?,LM5"JQUH=YO8W,*'ZM$DCDOW41ZMIE-..+NZO?MT<_?QP\/MS>,BLD3H MS%'6@2]; ;OE;2E@1N98_XS/B(AO9IDK^8R.4KXB/4 1L,0DF$R.L(W MZJ,;>;[1:]')+4JK]!-<()F! J\Z%:U7MZ(G[9%(2G MDLC)?%:JQJ#O\!R:FH+*N:;1T7FG4TT.#W.8*1I-QO%2UEP*"T6>=EQNYG!R M*\E$C*3:G +5M<5J30EVQ7V-6;>)0WA@NSY4 V]@'*:3J7_/)C/X3(DB<;!/ M5!*F24)/*KA?\SH.)[-S2,,X3N%OK7[):AR'4SJ.DS!)Q_".N.:.=,O]=*7A M#FIME$"3H63--V,9E-X*7:CPZ&4H5ZXT>O MRUHC;3N?>FL_W2_:H?9\O?TUO&=ZPZ4!@05!AX-)&H!NQVV[L:KV(VZM+ U, MOW3E@-I=H/-"*;O?. ?]/V_U U!+ P04 " N?FE7FPA#^W$% #&"P M&0 'AL+W=ON9P.$=S M8[^YF92>G@M=NN/.S/OJH-MUV4P6PNV:2I;8F1I;"(^E?>RZRDJ1!Z5"=],X M'G8+H2_]EVILL>JV5G)5R-(I4Y*5T^/.:7)PUF?Y(/!5R;E;>R?.9&+,-UY= MF .26F:>+0@\GN2YU)H-(8SO2YN=UB4KKK^OK%^%W)'+1#AY;O3O*O>SX\Y> MAW(Y%;7V=V;^BUSF,V![F=$N_-.\D>W#8U8[;XJE,M:%*ING>%[BL*:P%[^A MD"X5TA!WXRA$>2&\.#FR9DZ6I6&-7T*J01O!J9*+?GHXZGK89HENMK1SUMA)W["S3[>F]#-'EV4N\]?Z7<34 M!I:N CM+WS5X+ZM=ZL41I7':>\=>KTVT%^SUWDK4@LC6+R(::U%Z$F5.E]]K M58%AGOX\G3AO09&_-J7>6.YOMLS'YL!5(I/''9P+)^V3[)Q\^"D9QH?OQ-UO MX^Z_9_T_%.C_V*'MZY+\S-0.>+@= NI>%A-I6^CI0F;++TE$-PS;%GWX:2]- MTD.\)=$PCNFL5CI7Y6- 5165-4^2<76M9#_JIT.Z%=D,<=E%$)0M_&DT[ WX M/^G156U+Y6LK@\Q4/?.[HS09XI?0N2FJVB.<%VV6O6$NHA*]?0OHQOL] M/(?1:)C0-8='R!(A@&91PM[Q489<^ MEW0E)[;&E4'IJ"%EM-'*F1$VY[@N%(K@C74DJI 6ZA"JR8'@1M A.=8V8BN;D)DM\)F,TKZ&\(B(!'R426\"AK7$(7' MX/M>:$FG*%\#V#;K<1YI?-C*M=MA(SG_TZ)M7%[A=GZ2>M%@MXI_B7Z;.4>/$JYL5)8/ M![+8&D7#01S%<;PLQX+V-M4BT\8Q']^,A8L";F>UM5@B ?DLLSI@0$G\<8&$ M2;32@<_K[*EQZUF]X!;8GL*I-<4K=Y:VG93TR7A)@YU=>E@+$(25BHG*AS43 M;L8,S*1$@T*:@<;/"D,(D**M(3==3AJH3[D7,C&XS['_4&3$;KF0Z$<&1-E@ M(]X=8I[0&AR*N%F \\C*E)(XUW ,N'=X\2P=V*.L\ZAON.*;'1QRS&:\&?JT ME*[):"N-1DUT](BAL,%:A'QH-[K&1>X]'J U2_8P"B.9TK&A?XMI9Q2]Y1-EPU>UNNJZ[:[,5 M#L%CF" =N%*7OAFSVJ_MD'K:S&8OXLV$BV;QJ!"3EE.HQKNC08=L,S4V"V^J M,*E-C,?<%UYG&+2E90'L3PVHLURP@W9T/_D'4$L#!!0 ( "Y^:5=/75W* MB04 &H, 9 >&PO=V]R:W-H965T7T9VQASJX+=386J):$6DGU(Y4&>D3T*,])$TF#\]SDMS1@#A@= MTO3E=)_NECA=&WOO=W/OJ>#!P:2Y+X?JFDAI?EL:6PF-K5P-7 M62FRH%06@V0X/!R40NG.^6DXN['GIZ;VA=+RQI*KRU+8S:4LS/JL,^JT!S_4 M*O=\,#@_K<1*WDK_9W5CL1MLK62JE-HIH\G*Y5GG8G1\.6'Y(/"7DFNWLR:. M9&',/6^NLK/.D ')0J:>+0C\>9!?9%&P(<#XK['9V;IDQ=UU:_W7$#MB60@G MOYCBI\I\?M8YZE FEZ(N_ ^S_DTV\4S97FH*%W[3.LJ.()S6SINR40:"4NGX M5SPV>=A1.!J^H9 T"DG '1T%E%^%%^>GUJS)LC2L\2*$&K0!3FDFY=9;?%70 M\^??OUW41/^ M72[IBRDKH3=4Q"/E'2U%J@KE-Z0TW9JE$CVZK(N5L$J0T!FE4*F]M(YJT&M) M&_TY%3J5A5@4DLS63;!)8F6E1*=B/+!']TK"42X>),%BZ4@^5LKR)Y];4Z]R M^BI362[@!M3/^G2EX5_KIFW7RN>0;)7-,FQN:IOF[/JB=4U=)R7];KRDR4&/ MLCJXN!:;4%"]H-5F N+2R@S1>T.";B&)J.ZD%K!SI3.T'3)1(">JR+;9I"[; M^/3+49(,3\))6(].X*ZJK:M9&P;7N4HCY!O+>4":U\+%1&08(>D]2^W@"4EK M?" H, !DRC,"#CK$+#5U1\,#VD@!5L /8DX9VM*:,AA+"^/X8!?E56/F#F:> MP#+# A-5R_6.BR6F(W6GC8L>:)(V52X0+OPN7K8TFIV C(HIBO"%UC6L+=4C M@K1,B'+TX7 T[TV'0\+M$2PLE74^>&B9W(48H4'/U8M_P3\%>B8?2;I4%"+4 M@WR0=A,M0!WWT!(!;$OII<4^_6 H:U44M)#$_>+;[*>U#3AQ&=WC%/4JR>6F M+K+GQ1+S(,-AF[3=R"-QE34/*D.EI79=(E"!4:@6&-"((%;:O%@6B3XWS@55^YY9)D(1^4%Z##/7;'TNF((-TZ/*RG"/A+. 1[Y&XW(1R002M-/F>2=A>(@L M4QQ2[/F8*@P4#[RN<1TO5CQ"FJG"\00"74C%"@FW\+)I]8")YQ"F93/.0O$B M_WY3278:7T?AF;%H"7W9+>OP0H IC$*+RD"$G$-.^%BY8\(%ZN,8;6_1I\$Z'O7HY]ONGYQ2%S&& 7! \WY"D_[D MM>)S3$?]2?*1DOX4?7HM/.:N5S%#+Z,JE%AP>?!G$23V8'X95A>,>C2)0S8 M*LA\H-%\R,L)S69C7DQI-I_SXI".\,,7"1U-I]PL[8B8]*:C0[HS'@49\6P[ M<=:;3^>H%.>X!&L?KP9H8E9UD][A=': L3L0,P/HJ@E8W\=T[0W'B;13#M; M*F-#5>R5[XYYHG\W>O4YY/Y=X0\(8#Y/:-_+8[#S_BLE&H]?N7Q+@*3X%-R> M;A_2%_']^"0>7^'7Z%ONDT(NH3KLSZ8=LO%E&S?>5.$UN3 >+126.?X9D)8% M\'UI< 4W&W:P_??B_']02P,$% @ +GYI5_U4%:S/ P B@@ !D !X M;"]W;W)K&ULK59M;]LV$/XK![4H6L"+WOPBI[8! MQ_'0#&T:V,DV8-@'6CK;;"E2(ZDX^?<[4K*:=DZP#_U@FT?>\]P+CW>>')3^ M:O:(%AY*(AR?=8,G.F*I1TLE6Z9)9$O0M-I9$5'E2*,(FB85@R M+H/9Q._=Z-E$U59PB3<:3%V63#]>H%"':1 'QXT5W^VMVPAGDXKM<(WVKKK1 M)(4=2\%+E(8K"1JWTV >GU_TG;Y7^)WCP3Q9@XMDH]17)UP5TR!R#J' W#H& M1C_WN$ A'!&Y\4_+&70F'?#I^LC^JX^=8MDP@PLE_N"%W4^#+( "MZP6=J4. M'["-9^#X MRTMFV6RBU0&TTR8VM_"A>C0YQZ6[E+75=,H)9V?SQ6)UM[R$Y9\WR^OU<@WS MZTOX?/MAN8+%W6JUO+Z%CU?SBZN/5[=7R_4DM&33(<.\Y;]H^)-G^,?P24F[ M-["4!1;?XT/RM7,X.3I\D;Q(N,;J#-*H!TF4I"_PI5T"4L^7/L-WPQ[91J ! M)@N8Y[FNF3#PUWQCK*:2^?M4R UC_S2C>T;GIF(Y3@-Z)P;U/0:S-Z_B8?3^ M!7_[G;_]E]A_PH7]3/XF8U@ /E";,&T:E=VCINK5&J4%P=F&"VXYG>:*GK.Q M!%!;("W8*D%]@'@- MV6A,WX-AVIUME*R=/W$OSC)X\RI+XN1]=YJKLN3&=99&(X6L/_K&JU51YQ8. M3&LFO>-I-H1T'/]'Y1C<(^2"\1*X-#5AB1L&L=Y.LR]V/61Q&(QA',?RF.)TXF,%[U 0\9N2;6\?(T_X MUGNE[2\6=>F977U_QSN*$\@&*=R1_]HR=Q_L 2IEN/69.G)1.)3O-7.A>8WF M#4%"-MSGL[]_=JHT3A7%<-#W%WBK+(5P$O9\1;V&46\<]UT-],9)!I>UIHS! MO-)<^![1\W6V4&7%Y"-=J7'9Y92OK@8UNNE5D ':X-; E_^1UZ)&L,KC!:L, M'LF,9;:V7A2\Y"2YU)W![9Y3*,47:NFEBX$D+G-14YG0H@WP;1OT.W>F2NR! MI+E,H]=32WJJ4#;M%%T[_>&-N&C/3K68\,E\*%'O_!1TC[&6MAD5W6XW:.?- M?/FFWDSI3TSOJ,:I3K<$C^^C3IX!0 /). 9 >&PO=V]R M:W-H965T7QY-%X\ MI.9+ME0J%X^K.,E>'BSS?/W#Z6D6+=5*9L-TK1)\,T_-2N9X:Q:GV=HH.>.; M5O'I9#2Z/%U)G1R\>L&??3"O7J1%'NM$?3 B*U8K:3:O59P^O#P8'_@//NK% M,JJ623*>),&K^\N!F_,/K<[J>+_A5JX>L M\EH0)],T_4)OWLU>'HR((!6K**<5)/Z[5[%ZU'/#Q-TP8;KM1DSE&YG+5R],^B ,78W5Z 6S MRG>#.)W0H7S*#;[5N"]_]>;N]><7ISE6HO>GD;OKM;UKTG/7<_$^3?)E)NZ2 MF9K5[S\%!8&,B2?C]63K@I_4>BC.1@,Q&4W.MJQW%M@ZX_7.^MA2TUR\T5D4 MIUEAE/COFVF6&ZC _W0Q:]I\IU4T3+27>)5%@"KS-:*[2K> M#$0Z%W*5FES_6[+%X3UM-J.ST%E6R"12(DJS/'.KC,L5Q\^OG[KD#,>;%@E6 MT\RS3A8P\LBHZI7J4>=B#F;Q$7.NS$K$J4R&WT]2DXN2K\O)MY#46;G@DR7O MQ>0E8-1]&M^3L.8RTK'.-T/Q&9_?IJNU3#9__]OU9'SU8U9*:B 2!(9YQV2^$$\O9 MM3MB? =9)"ZJ/.A\Z11-1455^!^4B2 6G)"X-6H&DFX6T"4$M+PF<' MLEQC MMYDB>G1"#-$*T%%3(>TB*>E;LH+]=T&NL%[YJ) G9H1;"=L*&X@?P, MJ0J92^/8B=*I4HE@5PI/@&V)V3@E:?.UVE.IK1'1)H^_L MR260_CQJ0!Z!2%>Z M6&5#\?[=F]N;#^+VX]V;=Y_%S3\^WMV]O_OIL_@Y$6_5U!2 A&)\984R8&J" M4-@YDU5"+-*Q.H LH\+0F=#&_\#],L&;4@)'M :YL\GHQQXI\;?C'X\'8FJ7 M ?7.^/SF1Z0':L>LGP M15\4VXNB_DU([2VMDT KD;B"&R8#Q_='FM0 RJAS$CU091(MV3L=CD?E/4>: MKJ,]4I)^Y:K*PL03+N0K\Z4VLY[E+&_]O-?9LZS Q$&F7$ $"\F^%N%2KT$R ME+RP'L+Q6J7;.5+!IF85GW:BS$>H/PKB.!5KM3W#*J!@Z*C):!Y".E9IDSHZ'/12?RK.%8Z"8SKIO;8OT5-NPNCVT6#_74&P; MK:Y$3PEL5*S)CE13@69J%HN.YPPT5!PX%565B G DQ1Q?L*=D0$1H M);$W0",P K[C MRZZ&9Q?/1"3CJ(AE[I869YL,GZ.DE M\S> LB;SF=CA1K("SV7U@^AI6"+;>J]NRKGJ;+\S:H=?YK:IV,%11#38U(?9+I1W%T=GGL'+"7("XDW<(Q M4![0E$PE,RE9N('? B*3-LGH)!+TI]!'4F8K'MQ"Z57!@B2(Y[R@97U0H7T& M;88NL!Z,K(0 MQ$3PX9![;WBY"?;.*4+C?,C_5_9"G@.03P&-2=W8=$PI6/ZZ, 23@XY8LK:[ MU*'X$);I4F99WYTVHJO.8*N39Q9&C)_Y^RH467W+0.Z,3L?XS-(:TP;&-_". MW+YQ?AAF.!_*D*3+.4I_#$?9*Z6:RT+)2 M,Q?G@9D\S4N[<3&/">28;;4IW/G B5Q9#R"G=>\B>ZSG:E?.A*@=ZW][(:GY MW&64P0FO8!?IC!Q;9_J4P3EG] A0C+T@'Q*IFGW M-@K9EM!3SE9D%"ZF5)7'P69;Y>(* &JVLP(0R/2<46Y-2:W1"BB/L"LP+.LA MI;5D+SV8;"GO56=63O<34=\U)_\8(/9;#[&K:;IS6DSMP+ILYMPH^UD%47: M=:KCQ"W/R([M8:D) W R1H?M;[%(R$)G+@=1,D0%JHKPO+&7YE&KD.URXRM* M(4NI6P\\%*_+(V$G&.N5=H9K4TJN\X9,9[1>Q]H2LC/W*#F3P?(N" Y!Z\D;NXN0 M6*V#IYTSG=--(/PFV7@EYQ10/3*D=9>76TP;QPH'LEKGH!]NLS!)>IGQOZTPY/[&E#^CO"YH3VP$$"(._@ M:^V G9]IR;VL9;#+0G1"$@V!%B23-97.RM!19CU=!I.UHG,-P.CFSJ4O<64B M]B0S@E8PE2+B:#"GP_/XK6U8M;.8J;DRAE= ^I_8, YV9S6?9 YOX@-:KEE MA8\6N-H.;[I)KZ[W]4"GJ1 ,6GJ\BD_G*D=^-@K4UOUCPQ^"_FIRO\VLX _G M-97ITC:NMCDS(K)M'6 IK7XV".U (&UF2.V]FYQI ")#83QDX1W+MG2[CU"^ METFUC0&QU(LEN0QV$OZ*IN54SM8EAV^IDE<@:CK 6;H>$,*J9!U<(_W>A7C [2"V+6?OBV7[@.@21,<4Z0[7_1D^L#L7V MK6WZVC*@A#6)M=$I)_' +PD?.S4O8,A4GL2A,?J<"TV-'Z@6U:]ND6PEDF2Q MK51;'HD=;R$(+.?8%-K 9T.]=BI9TYO(+UF%LN%#"T9#N]2)KR$ KC_G6=E[ MT91U=-;L4MJD,-RY&H@%]68L^]38_$(>,,N-GG)Q%Y]Q7RJ4]Z#50$SV?2M)-UN5#3/7$AC+!E!&3-=VYQQ::CE MEA7?S-5N(->8^L?9P(%^*,.BO(/@HZ0=H$<1XL1"L:"M(XQD5B^PL+0K49VP MY9K?;B_.-Z)GY6RPJ'6HFY*DT-3J/'L?;< K.*.3;Y7LJ*7;J*WB?6P1*)TQ MWM_,[B7GHW<)!()C40O7,U0,1X'T#.0;;XX'5I*$&DX4N0BW(J4KY\_+OLGA M91G([:!&^9Z"F76$MBA-W^/5Q78$UW2:=1]4@1M5#$&-79DM;1F,7I#8[V7< M!$9X*?>(8;5ID'T]/'G.),UMDWF%!*C>X.D[PO;IM76!29 DMB+.RS!9J3^% M.%6!'7OXP*\.J@,WW,#>%/%2$^.1LY9Z+N771UY"C#+929J4LAJ*NWM?"7QC M)PQW&UB77VTOPU,6UIQ4MQ?TANAEZD8-0[1QL>)@'J0A'\P.>RJ3+Z98YY'SZ!0;L62T MJ:SX>S%;-&EFK\;M%Z(NC2O?!4[8.Y0I[QQZ26U$'L)86=^^@.OG(82@QF[\ M ,0Q07>/;JM;@FI9YOU K-FA,)XUDM71882?9#:3?XA/.="$>"_-%Y5;UT J M0M#(D.;+&7 THH-=?2A^6?MT,[+(P4'NBFT3ISHIO'L _+_S:N;58*=%#)QE M>?<$.LAN:8C213B^2,_9L5NG.=TT;W(#!P-;,.O6-^JG9P5N23BA*VMM*N+2GL,GA+NR\\40!].N%E"ZYXM*LLQ1V4@JC1U.#;W M5M:.X0I6$*[%NMPBP44N':F. *A'>!N=VFW3*!9B2W"B23 MZ%=.V^&IU%=XTU!\F3QKU[6XS!:YKEF%U'HF/]7SPD1LZ<2:05RT6AJ0=\,1 MK%/0R>WX6L( F+=8L#.@_B_W+CP+7F!'U@99_=8%OF*<=!R2C*P QW.;=6\JWY>1F1H26XA+G)E M/Q@&\GZS/COK2Z";6W:;W%XI-2!*/$A#TU W@@@*1CPX6@X&HT=,N36E;-<. 4' MRB@'YY1&59OVZP]LF=@F!O<<]/WQMV_.BX^%UUP@<_EO9+CV# M*@]VW.2TAU"!/> 7G:6V4YOYS1@DMX[&V;.-H=ZXZP. ?66@S\LP+]^S:CE7 MPYN[-G$85K7#7/FVMF]W+]D^2[!E_RY6RC9;* 0RWNVBK'/7REK0'Y.[.7S/ M+Y_KK!4 ::1XD?"JG /ZO1WEN0MZ.LF#1;;\M8,D5)ZSK<[F@Q7<[Z5,?ZM4 MN@IDROBR7X50ME("=+3O"3T'XUHZ02Z\\SZ!L6?(FC=B%%.=7K9TPZ+_U/CU MTS2RM]<=^B:M<^_T-3O#=Z.*^$2M[3? 3@YT$N9XW%,U=@F7++JRIRUY?1-V M/MQ]O+W[\/G=KW>=4^;-)SGV&#+?9[1\2XW@J>/E@][9\G+P_'41+R1%P[N? M?W[SE)%SRAV.9%:=00_SYYD;$F_SXJA &/IU(/[U@5?P,ZHVIW)!L9UW'1^U M)%0*I#F2WAY"KPVI6UW=5HYQB4WFFF!!,\LIY_/:1/=>0^=/W+8Q&LYVRF#P MJO+HA4OXCAE!TS)GR-W=4T^=N8\VU;. M\+L.)817615AF!YBA3BL,K1U!K&P;)O9V:+F@/7YX,^/+@>6AN.&IE%KU M=5N-U94]PJ5[2?_I0N=L2.6E1EJR,N5'.>E1.V ,5E12 WILG)&Z0_%$!_P7 M-]!,3LK9E[Z)EXOAJ!S-'CVK M3D73@.OFA!] %T?GU\VIZ.9 =-\\M+/V0'-/RQRI5V?'_%N/1[O'6++Z2'1K M^+G6,>^9.L>,.X>< M*\Y\QZSS5A(ZYIVWCCJ/2?F?X^\E_I[;<=C)-QEYMH^^:?;M&A/Y, M!WX;D)#?I0F_UV.]?_7A_Z_TX9_H!W9I2+5QGWVGQOU_O&<_'EY6NO875\/* MPX^'5Z/AI/YXYN'U55D'\YW\\X'KW^/?R]#/O]J_G\_#UCW=_+.O;N;O2$DK M#?WN/O-.G>AP'>V5CO@' .;^6<\=A!W_U9K^JS5=;TWOA/E?UY,&(.OO2/>T MH?^?=(_WJGA\30>9K"6*3U#M1H^S^KLH_5W, M\>";]S$GP_.S:A\SV'C73U^=5GZ';(48S;^VQH]X)KG]2;+P:?A!MQO[.V;E MY?;7X.!T%A1@8C7'K:/AU<6!U6?_)D_7_*MFTS1'!.*72P7,;^@"?#]/T]R_ MH0W"S]R]^E]02P,$% @ +GYI5_2!>>! ! O0D !D !X;"]W;W)K M&ULE59;3^,X%/XK5H8=@83:7%JN;:7"S&I FBX" MAGU8[8.;G#9>$CMC.Y3^^_WLI*&P!>V\^';.^<[5QQZME'XT.9%ESV4AS3C( MK:W.^GV3YE1RTU,525 62I?<8JN7?5-IXID7*HM^'(9'_9(+&4Q&_NQ&3T:J MMH60=*.9J[D:1M_(+MWPRTFK% MM.,&FEMX5[TTC!/2)>7.:E %Y.SD\MO5;,JN_[B:W;.'K[/['[=?1WT+8$?N MIRW(10,2OP-RRKXK:7/#OLJ,LM?R?1C4615OK+J(/P2\HZK'DO"0Q6&ROZ=Q8CY?3#>9@-Z:[+6>FXBF- M UP'0_J)@LGG3]%1>/Z!Q8/.XL%'Z/\W+[\, M\1U.CTD-F"GN&.9%D2)I1AE(N:U:QO&V:@\NZ15L6:N#T(>8,*NF5HP7E5:/0LT" )Y+QD>'X8A2A>D M52[2_"U#'":.@7&9L;UH.&BX$86*?(50LPIY+]'4MR5^A][*-KHBP9#XTK9?OY1]D(5/T?23 M\?%2U3B&E\*Z;$?'YP9>+(5Q*XI!=);7K7RNTPQW!<^JE MLA NP9-"LD(64U%!$J^JYMZI'MSAN7O5F=\X/\-%?DW?OW*@JC8H(W/@H^.&>&MU@11+ MZ8IQRP:Q!CCHU,W1FY,HF,XM9U'< T3C-[%^/P_^QE^(X4R:!.V MD>+S@ESVI]7Z&7S[@Y,#-R6)GZ)XZ.>3Z, Y\H%Q\>#8C+W/\KT@[!M 72MG-QBGH?FR3?P%02P,$% @ +GYI5RUZE$'0 M P M@@ !D !X;"]W;W)K&ULE59MC^(V$/XK MHUQU HDC;[PM"TBP2WLGW7$(VNZ'JA\,&8BUB9VSG67WWW?L! HM2]4O9&S/ M/'[FL6?,Z"#5LTX1#;SFF=!C+S6F&/J^WJ:8,]V6!0I:V4F5,T-#M?=UH9 E M+BC/_"@(>G[.N/ F(S>W5).1+$W&!2X5Z#+/F7J;828/8R_TCA,KOD^-G? G MHX+M<8WFMV*I:.2?4!*>H]!<"E"X&WO3<#CK6'_G\#O'@SZSP6:RD?+9#KXD M8R^PA###K;$(C#XO^(!99H&(QH\:TSMM:0//[2/ZSRYWRF7#-#[([(DG)AU[ M P\2W+$R,RMY^(QU/EV+MY69=K]PJ'SCP(-MJ8W,ZV!BD'-1?=EKK<-9P."] M@*@.B!SO:B/'\I$9-ADI>0!EO0G-&BY5%TWDN+"'LC:*5CG%F_%ZN3 DN]AJ6J&"=,H7PQW2CC:*K M\>>U?"NXSG4X6RY#7; MCCVJ!XWJ!;W)QP]A+[B_0;9S(MNYA?[_#N8FU'6B M[^+#C&F^!3R*UH@T3#I+:D0M66$AE[ P1Y#)IPR//'('_3B"I/<]3V%./T("['74-,!)8 MEH'SHWDHI$%A.,NN,&K#5#M&#Z0 $V]6#$Y=QR7NTBVDYJX36>X6MV),"_90 M!#%I5=,W=@'+G]'JIR.I-OQ*F^YD1NW5:W5%SD]7U(AIKTYD/]W>G1N%'?OI# ;P]4*I M85TKY]'$)FB'<;,V^K41]6JC&S1A>GZ =$NH!9$DPFBK8E9:=7=*YO\^G_-Z M&,+WPAZIAGZK'\;0:_7B[H7]Q)1B%C7J!F!O>!C=7]C7VI1_]I;0,>W=BVGK MNA2F>E9.LZ='>5J]17^[5R_Z-Z;VE!QDN*/0H-WO>J"J5[(:&%FXEVDC#;US MSDSICP4JZT#K.TFE4 _L!J>_*I._ %!+ P04 " N?FE7UT&.;\ % !W M#0 &0 'AL+W=ON["U*TY"A.TA>;P&+/ MGKT"NEA+=:\SS@T\%GFI+WN9,=59OZ_CC!=,N[+B)4I2J0IF<*E6?5TISA*K M5.3]P/.&_8*)LC>YL'NW:G(A:Y.+DM\JT'51,+69\5RN+WM^;[OQ4:PR0QO] MR47%5GS!S:?J5N&JWZ$DHN"E%K($Q=/+WM0_FPWHO#WPM^!KO?,-Y,E2RGM: MO$LN>QX1XCF/#2$P_/? YSS/"0AI?&DQ>YU)4MS]WJ*_M;ZC+TNF^5SFGT5B MLLO>N <)3UF=FX]R_2=O_8D(+Y:YMG]AW9P=A#V(:VUDT2HC@T*4S7_VV,9A M1V'L?4,<,F%TJN0=%I1*,/ZZK51G*BI*0LC$*I0#TS6=S= MS/\ZG4T7UU_UA,;U[=_/AHF\0G<[TXQ9IUB %WT%Z ^]E:3(-UV7" MDWW]/K+JJ 5;:K/@1< %KUP(/0<"+PA?P L[5T.+%WX/+V.*G\XPA0G0\PWVX# VM_S8._-&Y!BS!^!YD99NHREFI M'7MN)IE*0*9P)12VF%0:ZW(#*PRHP7;%4(K88*@;?58F+88&(Z&J59QA)B"6 M18&XFG)C)3L4?M? BRJ7&\[1IDQ3$7.%7TEGD%!CA,061*O:A;LG;6SX6-:X M"SBZ]KS0($HK50DK8XX=9S)X.UW,8+J8PYVL1 PC?^Q8))P_S+I^"@N+L;?I M-,H6_71I2RO>E?-'^N88CUBN2O$5Y?*A#?0#QDB4*ZBX$C*!1AMU2)8RH>"! MY37?[C1Q39CA4!N1BZ^D:O.0,[2]B#.98P0+F? <664BSM#-.*\3W&50UL42 M[6*ZR"I.,XIVQ@RP-,5@/C>Q8Y]B3%)64#0M0NL49JOS:S_T.^ZRJE+RT5K, M-W#D.V'D.Y[G6=RC@8.W!RT=*IF*VQF=;QS*T ^#FM1J&P23*=Y0+;'B,0IV M$G&:1(!SQ'#K_7:8.,"TA<2B2YH,(K'AF^")6.1XT? 0,2JF7[88N&WQM&UD M[R)A-B!T>QTVL:):S?&>U&?PH4O8MF@_VQN&CF$%X86)<> J%AB("EN-PTUM M-+9!0C'!Q%[QN.7@-QQ@Z$2!YPP& SB"D>L'\ 6"M(^#T=B)!L,3!/7"YS2^C3Z,G)$?.".T M= 1#-QCM=ZWU?W_J8&GC=++CH?-YMSK8&D>1AN4&@ZD4Y< 6QH$C-M>LQ/+" M\80OB[@M>,$OX\Q)@-.G#(-B>+V^,)54W*%947@F)>2WQ? M:6Y,;N^:9E*1%UN^V*.*;QLVZ2,H["SCIY5[57:\NHBAK&*G# <6[4P M=$*_4WNB^#/=^E,,?<]Y,QS9H]C&6.<_2=''810V)D;!/L?YWM6DL$1$F\\E M9DKK&A=U);_%W,_<6M9YLJ.2*ED JTTFVZ9'TW79"AMC^\,T9GE,]&,Z5/8'CH;=7?>0P77*WLDY_&/=Y> MS;NXV^U^54R;Q_33\>8GR7NF5C@E(. "0=(/&Z MVXV\RO?,LME$JQ5H9TUL;N!=]6@2QZ5+RMQJ^LH)9V?7GRX_WUS!E_._KN:3 MT!*C6P^S#GW1HI,GT"=PHZ0M#5S)'/.'^)"4]'*2K9R+9"_A'.LAI-$ DBA) M]_"EO7NIYTN?TA MX)I:W""LF %6UUJM.94[B@V\/DCC\2"*HD-@,H?71Y&;4(G:$K HT+>49],$ M,* *.!Z.WGCC@VAX:W):BX:4VY*1N:5IAK1Q3E2:RZ7'?6N8)L(! MU/3/F:"-5%$8.G87&V]0-$+ /1,-:X\K0>R<^)YXM\)$?V._#B0DX& M1_')3BDG\?&SM9S$?3''PW2GF"4UWO^NY?]"\O-"K_&>,$PXOW;JV)5+_.[, M@.!LP06W&^]D0TG1ENYT'Y!:&>X29@:NZ$63NVRP+-,-B>[[Q/E+\6?"!,9M15Q-W>6?DEL+]$5"&GYCDKIGTX:U MTW]]-Z=\,[H2VUIZZ!:U9Q+%8U??JEF6#AD];%C;:&F\YF<;_;%S/=RYQVXC;H7W2S[U!+ P04 " N?FE7&-V_ %X- M #P(@ &0 'AL+W=O3S-"R)-O-=V8<)VG272>>.-W.[,X^0"0DH0$)%0 E:W_]GGL!D)0LN[/M M/NQ#8I$B+N[GN0>7>KFQ[IM?*A7$;6T:_^IH&<+J^JEGYD5ZK!-W/K M:AEPZ18G?N64K'A1;4ZFX_$/)[74S='KEWSOVKU^:=M@=*.NG?!M74NW?:., MW;PZFASE&U_T8AGHQLGKERNY4#5[#DG>:4UGO\7F_CL M^?1(E*T/MDZ+H4&MF_A7WB8_#!8\'=^S8)H63%GON!%K^58&^?JELQOAZ&E( MHP]L*J^&N-N/CT5EQ^_O3UXZ%F(ZGIP_(.^WL/65YI_?9:^M:!V15\$(VE;B$NKI9J*;4RHNWVI?& M^M8I\<^+F0\.2?.O0UZ(FYP=WH0*Z;E?R5*].D*E>.76ZNCU]W^9_#!^\8 ) M9YT)9P])_^]#]B?$B;_IH!>2"^CK4HE:5;J4!GF_UJ42NJF0HFXKM!?E4I*[ ME-/_5I68;<7SV M?B1NVG*95:(M=5.:ME+Y%A0O6^=(;^L$H9YR0M4K8[=*8?]*PV ]:X-U40)+J I^1,PUW;)'/$ M_L^^TF3OVIHU7 W#I6C:>@9%(=&H!0(D&?0\<--(WAFN)%7:WB4?E-%M+:Z- M]+44097+QAJ[V,:= . 4"D]/8R&6[0J6J)'&!L!56";7)^6^_\O3Z>3)"_9" M<$ T,HL\38_/E/C6V$U#GB5;C47QP6JDC:WB9L#\D?A(CQJMUM @+&5 2O1A MH[UEA>R201F*]%JYF'.Z0?%*./^%6-H-5KLB)T8ID^F-2C;=55@ZIQ7%,>S[ M&BY&Y%=M4'#I0E*2Q=@&&^ 5@ZT,B65=T,V$7$MMY,S ED\VD)=\@"/R,IBO M%A97G7YVI9N4%+5L(() :E>3I43*PE/(-:X)=!^T1\I* Q^#[M*A<+LB>H@C($8(5N%LU%Q\-6TD!X!9O@/#6?4U%"1ZJ_ M.=*QYJ. CB.X U.IERA,I%^*>;@ ,CD#WNAP07*C<-RA. MA;VK8N]U% X>I(S$SZ"RA6+^A-N?=LZ M2J^WJE0,!FB9D]T$0L$A![ +C1E#"=]04B-IVC1T1[J6W# M1UUCD649!=(NH T5E1X3B#YX-P%_.'\@^7,?*0([DH&.@&X0&9(BAB3 ;T*, M5B(YTUV@IY+/A8R\10:3'6B62-JX49-:#/L638[""G1'RJRPMQ@C&> MT7XFNQJ2<2W9-U.*DHW;;A7-QX!&*0PP#2 M0-LJLLH!3HB?1S=@(@HF(^%5+.5WMZ!0\)1@CLI69-?N(]QE8BA?U,HZS@$Z MHHBGQW\%?AAL]%,+-9\4J1KP/=_X(=^0S%J 5)#QB#8@R=/QBP\(H=R@55_F MK_F+R8O'8B-]DIW<^7.C.X\QD1R&^XC1/9YZH$K+2J0 &7?0@BTPVJ1 0CAU?90?%I5 ( MRMZH1!(GXT>SQ_S5=/Q(/LY6#A*_2_J+F!V39Z=GO.!+B[R9C&?'Y[3$J1;% M!EU7#E#@M-E&9DL4P0I8$225?SM#YQ>^+V*25'6'NCO$W,[GQR!IH&ZM)UY! M_3#)NB<@%]5:,@B_:Y1;;'>Y.RU(K9W)6!2ZZ:G />6<#R?%?G>'=$\$+K'_ MN^4IO&T72\HST3;TJ)YKRNK:MK$)=>WQEZ5FZ.UPF@HZ\Z]8$X&>W&%!2PGW MJ=A[F8WUP$W+.T3/,U-06IL7YF'%[M\?]3H/.$OY_&O3G MA*>3\PCX18_I>S@(&&^C89]A(7,=AO:4?P<"2F%?P'W,@WK@0SBUP:Z(TVG< ME#Q*@(R >$5<$5&/*G?87H@Y#B$D:+/4Y?)>+6.&!97]1656@;74PI.]C9RA?++4=;1H"*N'Y1"COY>\G5YN8MY#U#-361KT1L# M,.$Y1<4(Q)@:88LA@51RS%:KGU.,C("*XQA'2P2_,)DQY-LQ(" MK(WM8+$#IL$@ 1[SPP,[C4@"CT1F/LUJH-86<$#)_X!I=-(^?*J*@:>6ZU!' M/F0<#4SQK=#S< BL(C6<48-N#IRLD?TUX0-9 MC,V5)""FYF$8&&P9W5>JNT3['JC3 Z2+,,_?=1BWFS:*%\@5EMSR;<3INTEQ MEAAKQ,&S/X"#O8Q!Z^NS&.KW:MVT!DH*GW;B!!/ M1H)S+'@U@T*K$ ZKR@3N6'0 M9NL15/D&VDK]45&"C\ 21Q\=9\PR!ZPR!^0L;&2=4SXG$'PB41-T4#9Q.%1)Z@(]:=KC/W/)U"7UJ3CW M.7APF2NXEGMNQ]Q*(Q'2. [,4]G^A# =3Y[%J10._=V]Z7CHVVM(HJEQ1?Z] M6&UOQ54:+U]:AX--FA-W_J8^0/Y^^GSR[+A<'X_'S[#)HZL1>/I[(T>/=WS? M2Z>%V?^QXOJX9 (U9$]Y!K4/U7$*0]Z@"<:J)1WI"7,!YYCQL90S]\%HZNY &" 7Z& J906Z/WG;#)9L. MC81COL19OS^KY2#L^J1(/24E1>J)B-S38PY?">K X?"AK3AW"'GO]$/RCUI+ M0P>J9,%V:G@QI)Y,ZK[M7%9JF:06^/ M[R,L#QOIV.XB>QKV>Y4[62EIM"#HP R.,8/&70-#RXV.Z+[LNQO78:EF5*B-V5WE/O=8/,D MFFDG<]U">+UH-$$0G("\6S "LZ6_M=I%W!@XLHLSAUUS@[6=A_ L6QI]5V22 MDX?S](JK0D$-1MR^-Q^Z7;=@,P1,PY?0%^' !''_M4]%W2:N+0=K^=T3OU;< M99NGHW-D@#'U2.'L#WT0? WNE4]<$D W'7L5W;@>7? MW]@)6;9B5[I[N!=BCV>^^6;LF6%T4.;!%H@.'DLA[3@JG-/7<6RS DMFNTJC MI).M,B5SM#6[V&J#+ ]&I8C3)/D0EXS+:#(*LH69C%3E!)>X,&"KLF3F.$.A M#N.H%YT$2[XKG!?$DY%F.URA^Z(7AG9QBY+S$J7E2H+![3B:]JYG Z\?%/[D M>+!G:_"1;)1Z\)O/^3A*/"$4F#F/P.BSQSD*X8&(QH\&,VI=>L/S]0G]UQ [ MQ;)A%N=*_,5S5XRCJPARW+)*N*4Z_(9-/$./EREAPR\<:MT^*6>5=:ILC(E! MR67]98]-'LX,KI(7#-+&( V\:T>!Y0US;#(RZ@#&:Q.:7X10@S61X])?RLH9 M.N5DYR;+V]^GZ]L;6$R7Z[]AO9S>KZ;S]><_[E>CV!&^UXJS!FM68Z4O8/T" M=TJZPL*MS#%_;A\3KY9<>B(W2U\%7*'N0C_I0)JD_5?P^FVP_8#7?RE8%,QA M#@MFW!'6ADG+PN.P\'6ZL<[0[MNEN&O8P6587S?75K,,QQ$5AD6SQVCR[DWO M0_+I%=*#EO3@-?1_>4/_%0M6N$?#!!4:Y8@*Q8+:PCU_4((=855P@?L.3/7Q M$6:5V#'#V;LW5VGOXR<+=TRR'9<[N.&&BDV9#C"#D%%>>8Z&$FZ:Q&M*/$?; MA36J7!G6 +,.W)ENLVEAK5:5Q0YP"TP"EEJH(Z*GY0J$N2HUD\=0]-XWET', MLDQ5TGE)CMX=-1!'T'MTR@JV;T.YY%#)VAO\J)C@]$1*'QF:$_A)S*RMZ/%D M^,S'FC3\3CX9-"3?6Y@77#+XKKATL"?UBA+D70FKR)^MM!:<[)PZM^L"=9X@ M<(6AT,NZO-"7%UV8=EANR.A4(92FW"_2SK,,E2PG8I7)"NI>%K9&E71.SENO ME%*FM5&/G-HV(V&%ZD M-G4O<;C!K)'V.@VA<]/G] J6@Z2QJ-F1;001I,OQ(/3&D>]KT07./Q'NI6>9 MO,#V4H>(S_IYB687II:%\++KUMY*V\$XK>?!DWH]5>^8H=*T('!+IDGWXS " M4T^J>N.4#M-AHQS-FK L:+BC\0ITOE7*G3;>0?MW8?(/4$L#!!0 ( "Y^ M:5>/BF'KW 8 %02 9 >&PO=V]R:W-H965TA"?15VC(H#QGU[G:%@2 M!3>OU]I_(]O!EAFWXK.N_Y2EJTY&TQ$KQ9PO:W>K5[^+WIX$]16ZMO3/5MW< M*!FQ8FF=;GIA0-!(U9WY8\_#AL#4?T4@[ 5"PMTM1"B_<,=/CXU>,8.S01M> MD*DD#>"D0J?<.0.C$N3+FZ^W9]]^O_S,SJZ_L+N+KU<7U_?L\OJWF]NK ML_O+F^OCB8-U=SK#5W3F[$HK5UEVH4I1;LM/ -\ ,ER#/ _?5'@G MVC&+?(^%?AB]H2\:C(Y(7_2JO@7$E6.WHM7&2;5@?YW-K#,0(O_>96ZG+=ZM M#=/FDVUY(4Y&D!=6F L\5O:_T\'O:ES-^+]"[&;5AA. M?-F.0_6A,6[,3NS%AK'IA)IF=(..'R @JJ M9D^D:H^9,*NGNENA4]+; V0]CWM$HBE!2?VT[>^*=V+/=G#6"&Y[GW'$:C=4 MC=G]AO3'7Z9AD!TQNS-^.;G1%K6VJ-?"(A(8;7D-;H6>R)7\+PX ^"X$:)); MZ0V;GX/IK'P ?\"<"R7,XHG$;BZNQ@0B](\ E $,D%+L(V_:(W8#=IIN-#@" MOHMZ60H('@$X(8*7"G#H@E*P&$1W1$NA+1BSJF11L94 FY OVX(SYK(@6[AS M1LZ6?10@,2_IZ(@#P(/3)!$";5V"BE(\0+-O!V\"(4M,MZ5!%B AJ=+24&MT M"4G"2@/H%/BVKF&]F@P1C[#SL*+C'N(/G-ZQBD:@0RVO^[2#3J[)F '0VJ8- M^K?T 85+8T0Y9G>T'2'O[4Z3E705K(\:'7NEO('] *RK+N#?^\H(L=4%&?0P M)YH9>''=R-@!5#=7Z:4%)NSABZ! ?G?'P;UV@/$.S69&-VM6H#:RS&=)'K"#Q OSZ2$[B+TTR@Y! M"(HBI#DRA=)KK>MS&$_I&.;U]+Z8>)!,D\/^OX./.#RFH'"\F!ODA]U?C]GQ M1S832LSECLE1@'CI_SV$AS^+\,SSISX1[D?Q%N&Y%P0Q._@G$=T3]R/?!X$7 M9/$ABY(4R<[3&-GQLFFXG_0LPM]^RH-#.O;2':%G\&^#[M>4)C[^KJ'M_5V! M'04>1M@'EGIQE&\1'65>.LWV,9WX$$F!E^4)T!%Z64K1%7CQ--K/=9Q-Z7@' MVUZ4AH?#N3.ET[J;]Q1B$8_W!'GH)904_?D=_/^T. ]3+TR0_\1+XV";_\"; MYOD^_B.@/$$/!#& "A(/WA21)W!>F._W0![A[QW\$_GO8CY) CK>$>]AD-)! MZRLR";BAGH,MX'F/T4(3>X3>YP3TOC ;3W^EUA:FX_17;%..2(4-D5!+86E' MA[L61R4+9RKT:=/Y5+R24]ZZ T&?Q'T/M4'8N$ +ZQK4#S"B<=C#R,?)3X,1 M;L,8PQL4J<--U4+HA>$M;"U@S@+8\NAU&?:/JML!TLNL,/^PZUV.K60+L-:[ M&MK 8,/M!6";J64!CJ1WC+>[Z\NT^"$'J"Y1&ULC5=;3QLY%/XK5E;J%BDA%RZE!2(E%%2J7A"!W8?5/C@S)QFK M'GMJ>T+37[_?L2=#VH6T+XG'/O?+=^RS!^N^^((HB&^E-OZ\4X10O>GW?590 M*?V^K&78V&[=J603>Z(_/*KFD&87[ZL;AJ]]*R55)QBMKA*/%>6B![^U%NS)W-HO_'&=GW<&;!!IR@)+D/A;T05IS8)@QM=&9J=5 MR8S;ZXWTJ^@[?)E+3Q=6_ZWR4)QW3CHBIX6L=;BU#^^H\>>(Y656^_@K'AK: M04=DM0^V;)AA0:E,^I??FCC\#L.H81A%NY.B:.5;&>3XS-D'X9@:TG@178W< M,$X93LHL.)PJ\(7Q=#*[GHG/5^+F]G)V^>EN6.URA3YO;-^@!:F M[6>-Q&F2.'I&XFOQT9I0>'%IA@ MA[R#UN6#*._@&7F?W5(:]5UR573%A34>SN8R%8G)Q8TC3R:D#;L05\I(DRFI MQ0R;A(H,7OPSF?O@4%/_/A6A9,#ATP9PG[WQEBSOC%'\/CP>D. M]PY;]PYW21_?4@8+Q23+;&V",DLX9 W663+]*7MW2[PVXGUM"/$?'G=%*&@K M)%MJ$!V32Y=[,;7X$R]?_'$R&@U.KR:S:5P.3_>$\KZF_&FV^PI9H)9O,KMO MV5AU;WC0W=)\;9" .KK$9,/1Z86C7 7QP7I/7KR\LY7*Q,'H>&]?W,'H.HG/ M"FF6.&<_5%E)Y5B&*&U.6@#EL/)!+%H]$M*0<*Z,C%P S@D+7B?4HP%=?&2Z MSMD?5$5.D3R1.>1#K>1<$\@RM 9732.U*PK2>2_8'O"E=BJL@2CS(#QE_(4& MC(*TE0:TO'3TM58H&@&UB2!847LH% 80"/L?$,N>!@RR,?2M OP1B_"^\3$4 M,@!EM(8P#_""[3$8))U6R6"[-&I3_E(#N!$+BL'1,;@<4.6;B,(P+ZQ32X1, MZW63XJYXP#8M%A1Q-S)+8VJ.*/Q0)I!3I:CP:Y'[.8'=L,ER@1/Q%E$KYU@, MC[CQAZ\A3X4B&KD6,K=5M _LI0IP5+MK@A.AD>[:4D?2"YQ7QR.-H3EVT@ -,X@SN% MR@H>(.2@,F6@)HT6V=\!RD9A724+,T%NIC#@>Y$0%$J&>.6Y=@&]+#4&'$ ';&2NJ9]Y,!S9%%P M@7O&4$RH1 <'V 2IA4N;GS-4>AQM(C"S2(72\LMRLGF*U9/F1X2EA$016V9 MEB"0VK!WA9;SV/50M2)7X,X8C631R(=%(?VX'[VK O2*>YR($\FFYQN-*TA MW]0+\-?<-K"EL(Q_?#7+@4AP*@= (MU).T[=SA0>MRD\WIF%6<'6)349"AH7 MTWA%>"J?NR7=XV+DMALCSJ]7IQZ9M=D7L<$V'5&?Z=) 18[?1MH2<%G$4Y?'&1)!/(+R9'8A$D"^&IYTHZ1- M2 '#LRCCA\UF D3IO?_G(2* @9O-_/I.J>RBEX#L!#1QW#19M&GN+7 %2%VR MV4EQC;>%&G"JOF^@9ZHE=,^RPF*:IW&Z ?*F^CT/XCK"*]+%6LL(Y7'HR@AG M/ZO8TL\QYE-9R_ CRY]+I)'\%6\44QMP'OD[CD)B;'!#A?6!LV'ZR@ M?6*._P-02P,$% @ +GYI5WB.K]._ @ P@4 !D !X;"]W;W)K&UL?51K;]HP%/TK5UDU@10U#PBO 5+I8T-:NPJZ]L.T M#R:Y$*N)G=D.M/]^UPED3*)\27SM>X[/M7WN>"?5JTX1#;SEF= 3)S6F&'F> MCE/,F;Z4!0I:64N5,T.AVGBZ4,B2"I1G7NC[/2]G7#C3<37WJ*9C69J,"WQ4 MH,L\9^I]AIG<39S .4PL^"8U=L*;C@NVP26:G\6CHLAK6!*>H]!<"E"XGCA7 MP6C6M?E5PC/'G3X:@ZUD)>6K#>;)Q/&M(,PP-I:!T6^+UYAEEHAD_-ES.LV6 M%G@\/K#?5;53+2NF\5IF+SPQZ<09.)#@FI696$%:ZZXTJE3?,L.E8R1THFTUL=E"5 M6J%)'!?V4I9&T2HGG)G.'YYO'YY^+.:W2V@]L56&NCWV##';=2_>L\QJEO # MEB'<2V%2#;1_O$>*&EGA0=8L/$NXQ.(2.KX+H1]VSO!UFC([%5_GHS+% M%H61ZAUNN(XSJ4N%\.MJI8VB=_'[5,4U8?OZ7,W*[C=SN.?;IDKR7E!F"7 ,_2#\E\BS-:9&'H^"H(9;D+FTPL1N9%&$M M,[(I%YL1M.:"IF2IF4AT&^A&#.8K5-6UW&"\#P(7%FQ'3]*@XBS3< %=-^H/ MJO^P/X07L QBABAU0N"-K2Z4;\-1S6[ M(*C575BVVJE,+7%FMFF05W5OOR77G>W>Z8V M7&C(<$U0_[(?.:#JCE$'1A:52U?2D.>K84I-%I5-H/6UE.80V V:MCW]"U!+ M P04 " N?FE7E?S"^S8# #$!@ &0 'AL+W=O572Y2%U\ M%_ 'QYUYU0:7R5JI[ZYS5\Z\T E"@85U#(RJ)[Q&(1P1R?BQY_2&)1WP=?O M_JG+G7)9,X/72OS)2UO-O+$')6Y8*^R]VGW&?3Z9XRN4,%T)NSXVI16+UEA5 M[\'4K[GL:_:\WX=7@''X!B#> ^).=[]0I_*&63:?:K4#[:*)S36Z5#LTB>/2 M'?OU$V5J@.9\&EA9QH4&Q M)USTA/$;A!-8*FDK [>RQ/+_^(#$#0KC@\)%?)+P 9L+2$(?XC!.3O E0\9) MQY>\E;&F&ZWM3Q]6@DD+3)9P^Z/E#5TU"W]?K8W5=%?^.99ZSYP>9W;OY](T MK,"91P_$H'Y";_[A792''T_H3@?=Z2GV^0.]Q[(5"&H#S3Z'3CP>Q!]3?)+S MN.*S.PFV4JTA2VU=C%;/BS M:QN(HYR^"*Y5W;26Y+R@79Q1&[MC!(K\<#2A,HU#^(+TA"LE?M$4C<;=MZ09 MXP#1",;I"!Z596+8;A^:X*GX\DYG&5^F$;GL#IZLL EN-/AA[?T^Z&DX3JW!_E$1R[H\$K9ZE1;SO_ M-%"H5MK>9(;1P:*O>F=Z">_]?Z]\R^8U73^=1:67*] MKEG1;P:U"Z#YC5+VT'$+##^N^7]02P,$% @ +GYI5]2E_#Q! P EP< M !D !X;"]W;W)K&UL?55;;]LZ#/XKA'=!"F2Q MX]A)W"4!VJ[#"K0XQ=)M#\-Y4&PF%B9+/I+^\EUIW4:X6M1LAVNT MW^I;3:NP0REXA=)P)4'C=AFV'(9S ,H<,L: M8;^J_1<\Q.,)YDH8_P_[5C>) \@;8U5U,"8&%9?ME_T^W,,S@WGTBD%\,(@] M[]:19_F)6;9::+4'[;0)S0D^5&]-Y+AT25E;3:><[.SJ^O)L?;F&P1W;"#0G MB] 2J#L*\P/ >0L0OP*0P8V2MC1P*0LL7MJ'1*9C%#\R.H][ ==8CV 2#2&. MXDD/WJ2+<.+Q)J]%B)0T S_/-L9J*H)_C\780B3'(5QCG)J:Y;@,J/(-ZGL, M5N_?C*?1QQZ"24]34:]1.KF&YW &UMR9SDH3G85%7!I@LH. F5XVT0.<(S%#? MULX/G6JWAJT2U-/F%"AE%JL-ZBYO\ GSP\YX"#]>=__D% 9Q),_=]>D<>26_TS$X$I2_E5C*']TC5[G+8RSR(D)S&83 M)Z0PRS(G3&%./Q)F,$]3N"N1YOJ6D@'),!U/X4Y9)@Y\:O9 L]@:F VS-*-+ M,09X53G;-V MV#ZIMT_6#=,[3OT@<$NFT6A&5:#;9Z!=6%7[T;M1E@:Y%TMZ.5$[!3K?*F4? M%\Y!]Q:O_@=02P,$% @ +GYI5];&HPAP P ?P< !D !X;"]W;W)K M&UL?55MC]HX$/XKH[2J6HENWG@)6T "EE,Y;;<( MV+N33O?!) -8=6+.=I;=?W]C)P3:8_<#P2\SSSS/>#P>'*7ZH?>(!IYS4>BA MMS?F<.O[.MUCSO2-/&!!.UNI($+!;K,)BCD<>B%WFEAR7=[8Q?\T># =KA"\WA8*)KY#4K&T^W'--@+UIX%O*+B%\-,ZT*0*%+T2J _?9&'V&F9% MAMG/_CZ1;IA')^:3Z$W %1YN( Y:$ 51_ 9>W&0B=GCQ*W@+]N*T 2LR&*>I M*IG0\/=XHXVBVOGGFN0*L7T=T=ZG6WU@*0X]NC :U1-ZHP_OPF[PY0V^[89O M^RWTT8KN9U8*!+FU=&59& VUB+,&S.">LPT7W'#4US2\&>6ZAA,R/E-OT'7* MI-FCHI)5"@L#XAP44DEW6!MR(*ID!5LIJ!GP8G<+'WE!2[+4!*$_ 1VJP7Q# M0/9D[S"M)V&KD7-@+XK\X3TDO3Y].]VXV=O(HK1\PE:8)/#A71*%T9=F-Y5Y MSK5M)Y5%#$F[=\95,BM3 T>F%"L<\3CI0MP/_V=R$O<"J6 \!U[HDGQ2I'Y@ M#;BKHZ@5= ,*E$2=2X0M.@I,P!;KU G](,0?I>< M=JR;QB=4Y'C*R)G627G<[L!J+Y7Y;%#E#MG6\D^XO3""I!/#(_%7AMGS8,]P MD)H;EZD3%LFA?*^8E>8LZE*+*(;]?7?GSZZ5QK6BZ';:[@#7TI"$JVZO5]1[ MZ+7Z8=O60*L?)7#M.OD733%'M7.MWQ8C792J/S:KS>LRKIKJV;QZFKXQM:,S MIG/:DFMPT^MXH*IV7TV,/+@6NY&&&K8;[NF%1&4-:'\KI3E-;(#FS1W]!U!+ M P04 " N?FE72XV3&Y " "'!0 &0 'AL+W=O3373C!%?X8, V4C+S/D.A M5].H'VTV'OFR#7U^2/C& M<66WUN [66C]XH.[8AHE7A *S)UG8/1ZQ6L4PA.1C%]KSJ@KZ8';ZPW[Y] [ M];)@%J^U^,X+5TVC\P@*+%DCW*->?<%U/Z>>+]?"AB>LVMQT%$'>6*?E&DP* M)%?MF[VMO\,6X#SY )"N 6G0W18**F^88]G$Z!48GTUL?A%:#6@2QY6_E"=G MZ)03SF4WM[,Y',W90J ]GL2.*/U!G*_ALQ:>?@"_@'NM7&7A5A58_(N/24JG M)]WHF:5["9^P/H%!TH,T20=[^ 9=?X/ -_BH/UPXN.$V%]HV!N''U<(Z0__" MSUW-MES#W5S>'V-;LQRG$1G HGG%*#O\U#]++OVYM MPU2.5,Q7.AKVA\?_9Q5T0[I1K@='H=#3:JMPV M<@ 75/T"=EU#O&4.B6891H"%4*[U2;?;39FKUEQ_T]L1=<_,DBL+ DN")B>C MTPA,:_LV<+H.5EMH1\8-RXHF)1J?0.>EUFX3^ +=[,W^ %!+ P04 " N M?FE713E1I=L" K!@ &0 'AL+W=OY0A:[H"SUPT:C[6>,"V_8=WN/:MB7A4FYP$<%NL@RIM['F,IRX 7>?N.) M;Q-C-_QA/V=;G*-YSA\567Z-$O,,A>92@,+-P!L%O7'3^CN')<=2'^A@,UE) M^6*-:3SP&I80IK@V%H'1\HH33%,+1#3^[#"]^DH;>*COT;^[W"F7%=,XD>E/ M'IMDX'4]B''#BM0\R?(.=_FT+-Y:IMI)*"O?J.7!NM!&9KM@8I!Q4:WL;?<. M!P'=QB#9B&#;VD+'4/%HE"_%!^H.(9 MS%:H7 5GQ./C^<74@LI",Q'K2U=B*\(#;8Q;+H0M%=^7BIC4++Y T Q)ANUK M*P,KHZ!#25&-^:JPC:^M5RLBZ5(,;_ZS9S3[4JDU,%-%V<\?C(11_OY&?A?- M[J5=HL@M0=AR:S>XM(F<(!#X# '!P &0 'AL+W=O M?%;LER[LPF]FPE9Q-1 MZR+GN)*@ZK)D\M\%%N(P=7SG>+#.]YDV!^YL4K$];E#_6:TD[=P32IJ7R%4N M.$C<39VY/UY$YKU]\%>.!W4F@_%D*\23V7Q-IXYG"&&!B38(C)9G_(1%88"( MQL\6TSF9-(KG\A']=^L[^;)E"C^)XC%/=39U1@ZDN&-UH=?B\ 5;?P8&+Q&% MLE\X-&^CR(&D5EJ4K3(Q*'/>K.REC<.9PLA[0R%H%0++NS%D67YFFLTF4AQ MFM>$9@3KJM4FG9_7R]_+K\8P.=;S\VFRZL[M>P^3)?WT/G M@6T+5-V)J\F.>>TF+>:BP0S>P+R#[X+K3,$]3S&]U'>)WXED<"2Y"&X";K#J M0^CU(/""\ 9>>'(ZM'CA6TXSR7.^5[!""9N,282_YUNE)=7(/]?\;>"BZW"F M;\:J8@E.'6H,A?(9G=G[=W[L?;Q!-CJ1C6ZASQ9,Y0DPGD*:%[7&%/!(OU,( MI;I0D1?*>'&-^DWPZ]0?,H2=**A?R0IH4P902?&,HEX416P)":7)YV<$[JH%2&I'N!+@I5^18&4ZKMK2\!\@C-I M69FN MYWNQE?QASP\'7?B,7%#7-=B/ML6)*7LF"F@6:[%X>!"?F12,H,:##QX M_VX4^,''"_E:N;MGPXG2M+W>K55]4>KKB5:J/7B ;>&MFH5Z%(ARYQ1+H(H#'M!SGCAC8=.]J3&0UD9P0M\4J"K/&=J-T4A MMR.OX^T%SWRU-E80C((Z%YK( AY?9/;/QQ!%,IM/O"MM9-8@_22AN9-\;$ M(.=%_6=O31R.# ;A!P918Q YWO5%CN4M,VP\5'(+RFH3FETX5YTUD>.%3XS0Z"SC'THTJYS.")[:C$#$R48L4*W?J?R4(;1?7R[RGG:^SD-+;MH6M=LA1' M'C6)1O6*WOC+ITXOO#G#/#DP3\ZAC^=UZX!< E5&N@%9VMK6P(JLD; M4YD^ M1?PL]&GB\Z-+Z@;B9@=<-SW,?U($F8:E%-3<^AH>JGR!RM+;$_ONVL*JO:*B M+@=\0Y5RC5 JGB(\5D8;8L^+%3 #MYBB@X@[+MT1]%K=*&PE20(7T/<[$?Q! MB;* '3KHMP:]+D1^+X:[!C>#RVZ_%8;AE95W8<:*E&9 YD)$0VR)W%I?1OU! MJYOTK@@TC/]/@RK.-#R:LH-^J]^)6GVZZ0)Z?M2',^GL'M+9/9].&K%9)? ] M8+!D7,$K$Q528"G*=1A/I?,\],L:82;SDA4[2)E(*\&LVX;$*QM R&A_?-M1 MSE9-A'E1NW[YY=,@BL(;MW'AUT[2N;F"RG#!?[JPP52P=-,FIR0-#LAEAL*' M(R,@@GRSS_Q%Y'=#:,-%XD<=>.9ZTUXJ1%"66.SW/M-9XL>?*;,EC7#BDU'Y M94AIW'$4&5@.G>CF_?Q5DI-$ATITT/4'%F P\),C!(,JATOR:X=,Z2OHG4IB M<#1-&ULO5=I;^,V M$/TK V^PM0$B%JD[AP$GF\T:: [$:?NAZ ?9HBUA)5$EZ3CIK^^0DK7)KF.[ MP** >$F M[6U>/.3+3)L7P]%9G2SYE.O?ZGN)K6'G) M\[5Z50<3R4R(KZ8Q2<][C@'$"S[7QD."Q1._Y$5A'"&,OUN?O6Y(8_BZOO'^ MV<:.L>ZNR\%_4@Y8MD5>@'L?["VW@LP+DHE,UAW?3U_![,5TJ+ MLC5&!&5>-67RW/+PRB!RWC%@K0&SN)N!+,I/B4Y&9U*L09K>Z,U4;*C6&L'E ME9F4J9;X-4<[/;J^NKM^&-]_F5S"^/833*^N;ZYN'V%R^_GNX6;\.+F[A?YC M,BNX&IP--0YHS(;SUOE%XYR]XSR&&U'I3,%5E?+TK?T0@79HV0;M!=OI<,KK M8W = LQA[@Y_;A>]:_VY[_I;HL T//!:2)U72_AS/%-:HE;^VA9NX\W;[LVL MGQ-5)W-^WL,%HKA\XKW1QP\T<$YW8/4ZK-XN[Z,IKL=T57 0"UP-&[QYU2Q, MH_#9"Z@FH&W8=WK?CGUJ5VK^#T]AD5=)-<^3XLV(ZUQG"$;5N,9 BQ:7D//N(>J'SOV_<@?M'D#W^ @4.%F_$-?&@^:K,6L MDV>8\8HO\BV=76KPVOP0PMG/(CPD3N18PAW7>T-X3"CUH/^K);HE[GN^^Y30 MT!N ZP>&[#CP##LDC-A^TD/7//LIIP.;]M+MFIDQV2NZWW/J.^:YQ27U?PG; MI<0H[ @"XKGQ&Z+=D 11N(]IWT$E41+&/M+!2!A8=5'B1>Y^KKTPLND MHD; ML$%7-J$T7K?S'J 633I$Y(SX=E&TY0'\_S2=LX PW_#OD\"C;_FG)(KC??R[ M2+EO9H!Z"(KZ!"]1AB>]ZE-!^B=T<"F':>:WYUJ M_G\XU9YXM>+F'%MRL91)G>5S2/"NN>T\V^EW^WGVL'4 R9[E(01A^\ MO7IQ^8NR43/G5&5YC6><;=%3W#KFS1G8&N35D\CGR"WBW7?@_:C4[V1IMPJK MUV^U1GH(_1/B4MHP4Z6-!"J+!.79?3J"B 0^LQM$'(=&L:BLP&[-C'@Q^\[0 M)2[SS#%)0Z .<5B(&[;GA*WLN_-RLX]WVTRG]VU:&+ZZER*72WO[5C 7JTHW M5]3N;7?!'S?WVF_=F[^#FT0NF WQ="Z$W##-#]]HS^!5!+ P04 " N?FE7]C]]MDT/ "X $ M&0 'AL+W=O MW$WOV]DB%?%H/6@V;6N=SDE[%D_FK8OS];+/Z<5YLLRGD[GXG"K9<%7R;WXWRUH'UQOHCOQ8W(?U]\3HM[[8TRFLS$/)LD-/K=.6,A)W\7*:?TD> M;5$^H?4*#I-IMOZO\E@^MM-2ALLL3V;EX&(-9I/YT[_QG^4+L35 [>T9H)4# MM)<#NGL&=,L!W4-GZ)4#>H<.Z)<#^H<.."D'G+P=[ MYNKS1G]ZP[>?WO'KW46/\_CB/$T>E73U^,);W5CO<^OQQ5XRF:_BX29/B[]. MBG'YQ=7EC7.C1*;R^8MQ8X1?+[\Z4:C\JHL\GDRSWY3WRN\WNO+K+[\IORB3 MN?)UG"RS>#[*SMMY,?O*: _+F:RGF;0],ZE*D,SS<:88\Y$8-8RWY>.[KXUW MY>//7AOOO[+^F@1H%R_[YK77GE_[*TTJ7B[O/RAJYYVB=;1NPPI=RX<'\7>E M<[IWM/[:Z+28O+=WN"$?[L;S#TKG;.]P4SX\3!X^*)JV'JXUO9<.F+VK[IW= ME@^_$8MB^/X7WCE\>-/*NW]O=N_OS>[+A^MBN'GIFH8'!P]73QN&AP=L=\F; M-I(/-\5M\:8=- VO[8'=3?IUUUYWC^?,A\E,*#=YG(OBF"=_IUS%TW@^+!:M MC\V*I%,N1Z/)ZD@FGBKZ)!M.DVR9BDRY_;ZZNTBR8KF5)LM%]DXIN.ER-)G? MKQ]9A,5DOA0C)5J(-%X1F?)?OU@#Q2EFR_[7\/2OGE:WU[RZJT/%C]DB'HI/ MK>)8,!/I@VA=_/,?ZDGG7TWQ06(ZB1DD9I*816(VB3DDYI*81V(^B04D%I)8 M!&&UU.MM4J\GTR\^I\E0B%&FW*7)3,G'0AFMDVP==W0?U!Z=:_4'N[H-4M7?:K3_*:WC4X$0[JS_*WWV4UCUYN>L% MY L1DE@$8;7]^&2S'Y](]^.PJ)"&<396EEE1Y4SF3W?D^[14/':?)C&=Q P2 M,TG,(C&;Q!P2V\3!MO]T%J?]!_L?/[Y'H%)!:26 1AM209;))D M($V2Z^T4D0>(%#HV0$A,)S&#Q$P2LTC,)C&'Q-S!;C:HZLL# X^I6'\?W)0+W\?";DHMTUA@W4N#HN)&OCMI1OHLX;2J:='1%#%0S46+\L*&YW2036WU+8KH_>#?J__HC)J>)[OSUY\A>.C:Q:@ M6HAJ$:754Z+JE%6E+6DOFL8FVYEQMYPWGA!P59+;6_!TYS/T:_G$1^< VJB* M:B:J6:AFHYJ#:NY![R,/G=-'M0#50E2+**T>+%4SJBKM-7LM6-X5BXK:2&3- M'\;T=OY7TML-&+)S3DU -5"5(LHK1Y$55>J M*F]+?36(%FFQ<+*(IXU)M-M).!CL1A':AHIJ!JJ9J&:AFHUJ#JJYJ.:AFH]J M :J%J!916CV*JL9:]97.VN7L5J2K4W&>3\O)%#&=S";S.&\\=_E*#A[]T0S: M68MJ1JF=;05MYX/ZHO?"1.>T4,U&-0?57%3S4,U'M0#50E2+**T>/U4WKBIO MQ[U9WF;BCZ68YXKQL.]K<+01%]5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42U MB-+JP50U^:I/;8)OYGH-*MI*C&HZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J): M1&GU%*RZF=6?T,XL-X].*K2A&=4,5#-1S4(U&]4<5'-1S4,U']4"5 O5W>;F M[D[7>$3-6;]N7=4IK*->I*(ZUE$M9N[1<.C9W4$U'-0/53%2S M4,U&-0?57%3S4,U'M0#50E2+**V>3U5;M::^K3I10[NX44U'-0/53%2S4,U& M-0?57%3S4,U'M0#50E2+**V>@EJ5@O+&[O+P["X>3J:3_'MC+J$=W:BFHYJ! M:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1=IN WZWO_<$6JWJ$=?D/>)[RD+E+V5] M>+2ZLNCZ3XU)A%[Z&-5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42UB-+J@57U MGAWS64CVO>.:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6 MHEI$:?7\JOKCM<$;*QO19GQ4TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)* MJZ=@U8ROR2^Y'21I?A_?"V6:Q/.MLZ.5>)8L]S2#H>WRJ*:CFH%J)JI9J&:C MFH-J+JIYJ.:C6H!J(:I%6L/ETB5E9-4'K\G[X'^PC"SNKO]QYEF>+I^.WZZ3 M!S&/5[>^IL6!W%@HT;RQC5Z^2DJJW;[;N=MU9M=M*D?U714,U#-1#4+U6Q4E,N'IU3:-L]JAFH9J*:A6HVJCFHYJ*:AVH^J@6H M%J):5&K[?WFG'D!:%4#R?OJ?6F]^?4P:$PQMT$M!5??S=[ANK-]&3 U!-1S4#U4Q4LU#-1C4'U5Q4\U#- M1[4 U4)4BRBMGH+5R0'%3;K>E(I'YQ2IZ:AFH)J):A:JV:CFH)J+:AZJ^:@6 MH%J(:E&I;=>;^[_>[%9M^5UY6_[/+3?'!=<886BG/ZKIJ&:@FHEJ%JK9J.:@ MFHMJ'JKYJ!:@6HAJ$:75HZXZ(:![\L8*3O2T E334>B8 JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1I=53L#H3 MH">_HO\AY2/:FX]J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:6VO:7AKW^[B]+ M4I/6 Z=JNB]N_F#YN#J(*@ZWBH,J/XGG/UQ,2N<_.JY(34U -5"5(LHK9YJ52M_K__&BDFTRQ_5=%0S4,U$-0O5;%1S4,U% M-0_5?%0+4"U$M8C2ZBE8=?GWY)?]/Z281/ON44U'-0/53%2S4,U&-0?57%3S M4,U'M0#5PE*K_3+(H+];3/Z,AOI>U5#?DS?42XM)74SC[ZMS)M/X\>]5E&@/ M/JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:75HZUJU>^=OK&*$NWQ1S4= MU0Q4,U'-0C4;U1Q4HIJ.: M@6HFJEFH9J.:@VHNJGFHYJ-:@&IAJ6WWHS85E#^CF[Y?==/WY=WTQ;'5]$[Y M(NXG6?YT8-04.7+DV,A!-1W5#%0S4;5)%M+B\BY*R)*_7BIM=H[RVWUHZ,V+'?5CU[3 M;.WFR^-126\IM MDN?);'US+.*12%S$YIQ<*-= M[(;8R?>^?E['CNEMN'B62P"%7G+*9-]9*E5T75=F2\BQO. %,/UDSD6.E>Z* MA2L+ 7A6BG+J^JU6Y.:8,"?ME??N1-KC*T4)@SN!Y"K/L7B] LHW?<=SWFZ, MR6*IS TW[15X 1-0#\6=T#VW=IF1')@DG"$!\[YSZ74'B:DO"QX);.1.&YDD M4\Z?36\(_"W O]?!>VMH%T&K)D-T>O()G2#"T/V2KR1F,]ES ME1[3*-ULZW]5^?OO^$^@N$#MUAGR6W[;(A\TRX>0:;E7ROU]N:N3UG'].JY? M^K7?B\O6P!07KVA(9$:Y7 E /R^G4@F]H'[9\E6&@=W0;+*N+' &?4?O(@EB M#4[Z\8,7M3[;TOXGL[WL[3I[N\D]'>.-7CD*!,'4^B8K>53*S>Y?IT$8)SUW MO9O 4M2).W71'EE0DP6-9$]ZIYMU5@B>@;2R50;ASK!^:%;$'INE2,^=G2VL MV<)&MAO"B-Y>,[3@W+X!PJ-1@[@3': =%X6>%]K1HAHM:D3[(KB4>MZJ)4W M2A<=#>QYR1&>IYZ?A =TMJJX/Y.8;B86M-XNW$6KM5 7[.DXPRMR3\1C-F?R MS*Y0%E%"4A[1%#"RG%B?X,4,#55"$?%'1#9\YQBH4IXH_:9.KA<3RU&,2$Q" MH2"P_'HF,Q+'"DGR^%Z"6M4]5>+N\1OZEZ)X6")F6R9)!$Z?8;OY2-V$F WIX$5":@ M'TUPRP2W*'3+K"CK$@L\'3.Z 4Q%2S1U4/2FR);51*D:QGO!Y*^1S!/3^=UO M\ZN[A[_ IZ^7X.KWQ^OY[=77!_ 1W$O!+/*8 +H$2H[F2')9_/6SYH#Y][ MDIT#USD#R$&N)GUF3K\DH4R'13IJIMNR,U5[4-4>5."Y^]I35GX&YC&6)3<; M\/>-# ?7@B3\'UVI6VQ/CZTFZ 7/<$@FEIR!G+!G8DU__@D&SB^ZPGL":[3! MK=K@FM"G#U3@&&15,[*J&>2M&;KZMZ!! :K6D^>I#Y$_MI]WZ^H&08A&=52# ML%<1]HR$;PCG%W*-"/,DC[$@"SFU95_""&\7#\D<)Y2)Z-_B@H[\]@;^#J^/ MKC<-[)OS+>JPVIFJ8&-0J+CZW>8P, -6G2[00'R/3W; MH&(;&-G.:,H%R[?+LN0H9;*2$M1._J!S?\\?M#AV8WQGH*##@/DC-P6S6Y0, CV#/RPXCDTRU;RTQ$R9AVZD/0$UBAP5!4X.N%Z.NJS M#3V!-=H G?IOUSG%BEJB[JK.:>E2$R)9.WIAPAV? (V$/^=1O(C25<$Q2B3S M9Z)8ZO_CC5B'CE1?:,W*:PL 3^D!8*\FH"^T9BMJ&P!/X@-*5*-JNR&>AX(] MJJUM #3[@%L"ZC%W6L7VF-0 *:D>#S(YF1I,L M%X3M/+ HNIPNQ08S[2.+&?'@!^2>T)KUUP8)P5-N%?3JF/I":[9B9]/$:$.. M%6^)VG"NSJ#]Q*V+\M >?XMJ:X/,UN:&8$[6-/Y_D)KEET;).2= M4K6]>J:^T)JMJ#T3,N^Z'*M:S<;+8-@6K3FHR;BV-LAL;6ZE7/42->8=/"X] MH36KK,T0&IQ2HKT:I+[0FJVH#1(R[P\=*]%A=X_5@>U]-TW4T&MOO-D[KQK4 M>YY;S%91RD%,EC++.1](B;/MJY/MB:!9\?;AB0I!D^)P3?"",!4@?U]2*MY. MU N-Z@76]#]02P,$% @ +GYI5VPE_W'B P )Q0 !D !X;"]W;W)K M&ULK9AKCYLX%(;_BL5652M-ATL2,DF32),$V$H[ MT^QD9E=5M1\<=K7=>8'$&-V35)(Q)45H3'FXI2N=992P,M<%$>Z91BV'N,PT4:# MO&U&1P.2\2A,8$81R^(8T^T8(K(9:J:V:W@(UP&7#?IHD.(US($_I3,JSO2* ML@QC2%A($D1A-=1NS;[7D_WS#G^%L&%[QTC>R8*09WGR93G4##D@B,#GDH#% MWRM,((HD2 SCI61J54@IW#_>T=W\WL6]+#"#"8G^#I<\&&HW&EK""F<1?R"; MWZ&\GX[D^21B^2_:%'V[AH;\C'$2EV(Q@CA,BG_\HYR'/8'9.B.P2H%U+&B? M$;1*0>M8T#DC:)>"]ELC=$I!YZT1[%)@OS5"MQ1T\V05LYNG9HHY'@THV2 J M>PN:/,CSFZM%1L)$.G'.J;@:"AT?S1Z^SIR'QV_H]GZ*G#^?OLSNG/M'] G= M8TJQM GZ, 6.PXA]%*U/\RGZ\.XC>H?"!#T&)&,X6;*!SL50)%#WR[#3(JQU M)FP+W9&$!PPYR1*6-7JW6=]KT.MB"JIYL';S,+8:@7=XBXR;*V095JMF.)-? MJ>DU,MMGY=-F^1S2:]0RSLJ=M\NMNKG\?]&]_QS](!.MRI&MG--S723+.'%!V'56NUJW>:;.4?M M4[/OF#7MKMGWBDVK?_'%%IKX(E^'"1/E?R5"&===L22AQ;94<<))FN^*+ CG M),X/ \!+H+*#N+XBA.].9(!J;W#T$U!+ P04 " N?FE7;/=5>XL" #N M!@ &0 'AL+W=O)"E;NQ>9JG8:$HXW$ND-HQAN5L %4LF,=7BZF-=P%?"33JJ(UL)2LAGFSG4S$+(@L$%')M M%;!Y;>$:*+5"!N/G7C-HE[2)Q^V#^@=7NZEEA15<"_J-%+J:!=, %5#B#=4/ MHOD(^WI&5B\75+DG:GSLX/92EEF:6F#R=?;Z=+V^7Z!WZ@J7$=H?0 MV0UH3*AZFX;:K&#CPGROMO!JR0FU&-T)KBN%;GD!Q9_YH2%K\9(#WB+I%;S# M.S2(SU$2)0/TN+Q!9Z_?]L@.VJH'3G9PJFHP!ZG0]_E*:6D^C!]=I7J)8;>$ M_5FN5(USF 7F;U @MQ!D;U[%X^A]#^"P!1SVJ6=+3 %12[G"^=,YTB 9$J4? MZH+MEXLCM ,L50_9J"4;O8A, H<&4T?8!=:O-OHGU[CE&K^("W.^,5@&3Z,: M[XR/Z"X\+SIVHM; MMDXOAQ%41IN.V F+T"N5BP[6WHW:T-?.Y M][#?X?XFN,-R3;@RT*5)C2XFYAN2WEU]1XO:.=I*:../KEF9"PFD#3#SI1#Z MT+$+M%=<]@M02P,$% @ +GYI5X38Y))> @ ^04 !D !X;"]W;W)K M&ULK91O:]LP$,:_RN'!V&"+'=GINBXQM$E'!QV4 M9EM?C+U0[$LL:DN>I"3-M]])=DP"3MA@;VS]N>>1?I+NQENEGTV!:.&E*J69 M!(6U]548FJS BIN!JE'2S%+IBEOJZE5H:HT\]Z*J#%D47805%S)(QW[L0:=C MM;:ED/B@P:RKBNO=#99J.PF&P7[@4:P*ZP;"=%SS%<[1?J\?-/7"SB47%4HC ME 2-RTEP/;R:)B[>!_P0N#4';7 D"Z6>7>=+/@DBMR$L,;/.@=-O@U,L2V=$ MV_C=>@;=DDYXV-Z[?_;LQ++@!J>J?!*Y+2;!90 Y+OFZM(]J>XVBRGX[A_=PCW08\ UU98#+'&;" M9&HM+3QRBP;>S-!R49JWX]#2LDX<9NT2-\T2[,02)3Q [4P,_KA;&:7M&O/J+&(NFW<)EU96J>X22@ MU#&H-QBDKU\-+Z)/?7S_R>R(-NYHXW/NZ9-_QY@#WZ"FM*3,<[DMY I*?^.6 M;KSO!,[;?H0=1\9_KPSSLEK5.R=V))C],1>]*Q)__&GN_? MM*8WW0?=^ TC;^@*X":-!M%E0N]N&PO=V]R:W-H965T^ A#H)8X2/C!60J17ILEG*X@QOZ0I M)/+.@K(8"WG*EB9/&>!Y+HHCT[$LWXPQ28RPGU\;L[!/,Q&1!,8,\2R.,7N] M@8AN!H9MO%UX(,N54!?,L)_B)4Q /*5C)L_,TF5.8D@XH0EBL!@8U_;5T':5 M(!_Q@\"&[QTC%65*Z;,Z^3X?&)8B@@AF0EE@^;6&(421Z^0;;0)[RF]&(YY]H4XP-? /- M,BYHO!5+@I@DQ3=^V19B3V!WC@B)5(GPM'=]>1N@B[0/189(X( 1W2!1B!+@T8$3TE4 M7#R_!8%)Q#_)L4^36W1^]@F=(9*@QQ7-.$[FO&\*":1LS=EV\IMB?@LS*;=SN7,H-V49REHX92VV!B/\^,'VK2]-^?Z3V4%:MTSKZMS#(S6_ M*51^KE(_ NO0[EE]<[W/K75NR=TIN3NGN#M-W(7*V^,. K?"K75NR>V5W-XI M;J^)VZMS]WH5;JUS2VZ_Y/9/ M5^'6.K?D[I;<72WWXPID/UX(8$WTW1I]Q[.K9==.T!*_5^+W]/A4X A%>?]( M\:OL^**Q,_0:'GNO^MQKIVH9Q+9VK='21AD!YXC$:29@+CN=7!'@HK'+6;4P M%X[O!94T^NG:QMGK]+8VSEB9)@*M<92!:O+%(D6[)M^8S:YE\US+J4;33MTV MVJYQV]I.6:S4+&-,Y4LIRW>([T[HU%?/M:LM;SO*/UCCO3?OD'S7A&U]%Q[1 M9'DAGZSXW['KC;K3Z]46IF%48%6HS;W]H]J\WV.V) F7' NILBX#61M6[(>+ M$T'3?$LYI4)N4//#E?P/ 4P-D/<7E(JW$[5++?^5A'\!4$L#!!0 ( "Y^ M:5=&PO=V]R:W-H965T$I+RH740(GNT;1X?4 +Y \U0*I_L M*$N@D$.VMWG&$-QJIX38GN,$=@)Q:D4#?6_.H@'-!<$IFC/ \R2![/4)$7H: M6J[U=F.!]P>A;MC1((-[M$1BG]4CO7KM^B_ M:?%2S 9R-*;D3[P5AZ$56F"+=C G8D%/GU IJ*OBQ91P_0M.I:UC@3CG@B:E MLR1(<%K\PY9I]GJYE\^GZ"!,2$?P ?P7HY >_??0#O $[!ZD!S#M,M']A"8JG@=EPB M/!4(W@V$)@._\ CS'\PWNXW;W"8JENZO=O4MW6R:CRHA79<33\?P;\>;P M%6X(XD"J :,X9CDD'/P]VG#!Y*+[QR2PB-@Q1U0[\9%G,$9#2VXUCM@16='/ M/[F!\ZM)[O\4[$*\7XGWVZ)'6B_:@@R^,DJ(26L1(- !5)$X1F&O/["/=0E- MFV[@5S879)V*K',7V8:F.4?&958$Z-;>ZKIA>(76-'+,8-T*K'L76$R3!'-5 MWHQP71.4.$%]\THH]L\%N $&8.IP.84!@T /PRN( TV?=<, MV:L@>_\)DF"XP02+5Q 3B!-98'@NJ6,D*[0RP&J#FOA[#3;/"9PK 4TC-_2Z M9@5AI2"\5\$.Z54 "=BALHP0M)=#A@@4>J7(_*=[E)Z%WIB.L$$:.+TK-4V; MOG-C.OJ5F'ZKF-\IEFP*G*,C8A*]K ?GB3'1]ENV5L':M/ [-Q+O.N<.YK32 M+@^4B8\"L41G5A7I'^6UC%@'Z;G>%:S!*.S>J&)NK=^ZK;1KN8J9[*$I$/ % M9)1C<:MDE)':$FHP\9Q:.;Z$/+= M[7)1$NH&J &++JA$<]KOKLVFR5@N]$E MW[E+N>UMZJLX(":/@,6>0R_R4,O+K1;GC-VQL\H77&RM;N<:OFD4WDSNN9&Y M[9UL187<449XJG7=*Z'3Z+*]OMO0T+0*^UYX)<*NG2#5\?T+9'M9=&7AVDDW MYZ$G<\"*$W$Q$#33A\H-%?*(JB\/\BL",64@G^\H%6\#=4ZMODNB?P%02P,$ M% @ +GYI5Q\]$/YV @ Q@4 !D !X;"]W;W)K&ULE51?3]LP$/\J5H8FD("D:1L&2R.M=-.0F(1HV1ZF/;C)I;5P[,R^ MM&R??F>G1&4$M/6A\=GW^W.VS^E6FWN[!D#V4$EE)\$:L;X(0YNOH>+V5->@ M:*74IN)(H5F%MC; "P^J9!A'41)67*@@2_W)RX%:LUNHDP2VN^@CG@77UC* H[ED)4H*S0BADH)\&'P<4T<02?I@/OC1_9/OG:J M9:*W8X ^1"VB.:G4/>&"C8#);X).F "<46:]U8K@J; MADA.'%^8[U2GK6K\@NH?L<.#HZ=_A2 M-<[HE;)H&KHXR+Y?4P*[0JCLCSZ7+=NHG\WUPX6M>0Z3@"Z\!;.!('O[9I!$ M[U_Q.NR\#E]CS_QN2MK-/F,M-/%0UU>;;!#1+PTW/8JC3G'TJN*=XI4V*'[3 MD19NIX2U#5-PF.Z5;EL"J%6 MU*VY =^WNF3P()"5 'T.Q\\=CL_.^ATFG&PO=V]R:W-H M965TD"669/E'EP9H+1(KT-X5 M;>^&8=@?BDTG6F7))\E).]R+GR3+IDC)7XOI<\/NCZN=6!\R>BA*^IBD;I[2 M[$O^(&7!OF[B)']U\5 4VY?7U_GR06["_"K=RJ3\S3K--F%1OLWNK_-M)L-5 MO=$FOG9'H\GU)HR2B]N;^F$' M'Z/[AZ+ZP?7MS3:\EY]D\>LVJO^4N3;]4;]ZN7EV,JBK)6"Z+BA&6_SS*A8SC"E56Y+>&>G$L MM-JP_?I %_5?7_XU=V$N%VG\]VA5/+RZF%VPE5R'N[CXF#[]339_D5_QEFF< MU_]G3\UG1Q=LNQ]VE2 M/.2,)RNYZMF>T]O/B>VOR[_]N /_&# M]K?O_^FIZ8(&"WEWQ9RI =Y4M8^_?0B_E<=G,:B<@"[GD]Q>,6]T\@_HV\=P MHJ")@5R61*L0%[-=H[B;XKV-LD+[)=O4?_^:[\ 'M;R$W^KYZ* MOMG3QOVTJB-_F6_#I7QU4?;4N

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

:_'(>NXAJWS'7-#Y%DPJ=)$Q \OT&NF8T+B<0V+!TXL],U %Q*/ M:U@\;6)QW78V6G-2#0]+R#FN8>>\$,(3QX-TXQG6S5 >I 'KF)!N/-.O3 8Q M$UXTS3T3'1,2CV=8/$#&UG2\C@F)QS,LGE!V"E..-N76&KG5,2#G>:)MG;4AU3,@[WJC/ M.KK 9Y!\9H;E V-Z.B8DGYEA^<"8,QT3DL^LE<_D\JG#GAY81?>1^HM:U>>D MR+<"-8?N'8XW:S9A#^>B"%1=7*D,9W_Y,ZF7V<^9H<>[B7R:VJ]5V&5_;Y>M!QI?)U>CM8U[U;Q]2A=)!"D%:/L@@R,H'.01Y M^: :@NKR05,(FI8/>H"@A_)!CQ#T6#[H"8*>R@?)!&6<$"0-L";06I!K(?!: M$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!;$&\AT%M1;R706U%O)=!; M!Q_;!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z M&^IM!'H;ZFT$>MM@LX1 ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U M;T>]G4!O1[V=0&]'O9U ;T>]G4!O'VQV$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3 MZ.VHMQ/H7:/>-8'>->I=$^A=H][U?^J=\GD?T[WGML;G_R?5^7)OO#_^NKR= M'+R7*\X!_I&_? -02P,$% @ +GYI5S+A@>'' 0 $A\ !, !;0V]N M=&5N=%]4>7!E&ULS=G);L(P% 707T'95L1X@ X"-FVW+8O^@)L\("*) M+=M0^/LZ89!:T:B(2KV;1(GM=U]LZ6PR?MM9\KUM5=9^DBQ#L ^,^6Q)E?:I ML53'D;EQE0[QT2V8U=E*+XB)P6#$,E,'JD,_-#62Z?B)YGI=AM[S-K[VA:DG MB:/2)[W'_<0F:Y)H:\LBTR&.LTV=?TOI'Q+2N+*=XY>%]3=Q0L+.)C0C/P<< MUKUNR+DBI]Y,N_"BJSB+;4OFPZXDGW:7.-.CF<^+C'*3K:NX)/76D<[]DBA4 M9;HO>M.='.(.T_[*K\YORW0%QIDS9ZR/)^;H\KCCD32K^S86(A>*[D\\)<;2 M5W\?-:>=4_[+[+B]'\:MVO/PK+U=O\=?S_A4_\(^!$@?$J0/!=+'$*2/$4@? MMR!]W('T<0_2!Q^@-((B*D97)PC$ 8 )PG 3 M " &UL4$L! A0#% @ +GYI M5[2?4!W"!0 KQX !@ ("!#0@ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ +GYI5_)OV52'!@ "!X !@ M ("!@1@ 'AL+W=O*'H-OQ@@ &!* 8 " @3X? !X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L! A0#% @ +GYI5S$WK!@A$@ \#4 !@ ("!*S M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +GYI M5YL(0_MQ!0 Q@L !D ("!R$H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +GYI5[[Z-.G@% \DX M !D ("!-EH 'AL+W=O&PO=V]R:W-H965TI1! MT , +8( 9 " @<1S !X;"]W;W)K&UL4$L! A0#% @ +GYI5]=!CF_ !0 =PT !D M ("!RW< 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ +GYI5SNF>L9V P .@@ !D ("!:(\ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ +GYI5WB. MK]._ @ P@4 !D ("!KZ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ +GYI5];&HPAP P ?P< !D M ("!BJH 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ +GYI5[L5A'@^ P !P< !D ("! M"K0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ +GYI5_8_?;9-#P N ! !D ("!-, 'AL+W=OXL" #N!@ &0 M@('0VP >&PO=V]R:W-H965T$V.227@( /D% 9 " @9+> !X;"]W;W)K&UL4$L! A0#% @ +GYI5V"\Y]M' P H0P !D M ("!)^$ 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ +GYI5UHOQ<"#$@ 7^L !D ("!9>L M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M+GYI5PD'B%>]! V1@ !D ("!U "0 &0 M @('(# $ >&PO=V]R:W-H965T&UL4$L! A0#% @ +GYI5\]3U6]@ P M*PP !D ("!K!,! 'AL+W=O&PO=V]R:W-H965TW MSU'!-@0 / 7 9 " @80: 0!X;"]W;W)K&UL4$L! A0#% @ +GYI5YH+3=][ P )1$ !D M ("!\1X! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ +GYI5V.:^8UW P X@\ !D ("!!RT! 'AL M+W=O&PO7BKL

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " N?FE7,N&!X< XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 177 285 1 false 50 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://apyxmedical.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Disclosure - BASIS OF PRESENTATION Sheet http://apyxmedical.com/role/BASISOFPRESENTATION BASIS OF PRESENTATION Notes 7 false false R8.htm 0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 8 false false R9.htm 0000009 - Disclosure - INVENTORIES Sheet http://apyxmedical.com/role/INVENTORIES INVENTORIES Notes 9 false false R10.htm 0000010 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://apyxmedical.com/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 10 false false R11.htm 0000011 - Disclosure - LEASES Sheet http://apyxmedical.com/role/LEASES LEASES Notes 11 false false R12.htm 0000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 12 false false R13.htm 0000013 - Disclosure - DEBT Sheet http://apyxmedical.com/role/DEBT DEBT Notes 13 false false R14.htm 0000014 - Disclosure - CHINA JOINT VENTURE Sheet http://apyxmedical.com/role/CHINAJOINTVENTURE CHINA JOINT VENTURE Notes 14 false false R15.htm 0000015 - Disclosure - EARNINGS (LOSS) PER SHARE Sheet http://apyxmedical.com/role/EARNINGSLOSSPERSHARE EARNINGS (LOSS) PER SHARE Notes 15 false false R16.htm 0000016 - Disclosure - STOCK-BASED COMPENSATION Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 16 false false R17.htm 0000017 - Disclosure - INCOME TAXES Sheet http://apyxmedical.com/role/INCOMETAXES INCOME TAXES Notes 17 false false R18.htm 0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 18 false false R19.htm 0000019 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 19 false false R20.htm 0000020 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION GEOGRAPHIC AND SEGMENT INFORMATION Notes 20 false false R21.htm 9954471 - Disclosure - BASIS OF PRESENTATION (Policies) Sheet http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies BASIS OF PRESENTATION (Policies) Policies 21 false false R22.htm 9954472 - Disclosure - INVENTORIES (Tables) Sheet http://apyxmedical.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://apyxmedical.com/role/INVENTORIES 22 false false R23.htm 9954473 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://apyxmedical.com/role/PROPERTYANDEQUIPMENT 23 false false R24.htm 9954474 - Disclosure - LEASES (Tables) Sheet http://apyxmedical.com/role/LEASESTables LEASES (Tables) Tables http://apyxmedical.com/role/LEASES 24 false false R25.htm 9954475 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES 25 false false R26.htm 9954476 - Disclosure - DEBT (Tables) Sheet http://apyxmedical.com/role/DEBTTables DEBT (Tables) Tables http://apyxmedical.com/role/DEBT 26 false false R27.htm 9954477 - Disclosure - CHINA JOINT VENTURE (Tables) Sheet http://apyxmedical.com/role/CHINAJOINTVENTURETables CHINA JOINT VENTURE (Tables) Tables http://apyxmedical.com/role/CHINAJOINTVENTURE 27 false false R28.htm 9954478 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables) Sheet http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables EARNINGS (LOSS) PER SHARE (Tables) Tables http://apyxmedical.com/role/EARNINGSLOSSPERSHARE 28 false false R29.htm 9954479 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://apyxmedical.com/role/STOCKBASEDCOMPENSATION 29 false false R30.htm 9954480 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables) Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables GEOGRAPHIC AND SEGMENT INFORMATION (Tables) Tables http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION 30 false false R31.htm 9954481 - Disclosure - BASIS OF PRESENTATION (Details) Sheet http://apyxmedical.com/role/BASISOFPRESENTATIONDetails BASIS OF PRESENTATION (Details) Details http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies 31 false false R32.htm 9954482 - Disclosure - INVENTORIES (Details) Sheet http://apyxmedical.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://apyxmedical.com/role/INVENTORIESTables 32 false false R33.htm 9954483 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) Sheet http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) Details 33 false false R34.htm 9954484 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details) Sheet http://apyxmedical.com/role/PROPERTYANDEQUIPMENTNarrativeDetails PROPERTY AND EQUIPMENT - Narrative (Details) Details 34 false false R35.htm 9954485 - Disclosure - LEASES - Narrative (Details) Sheet http://apyxmedical.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 35 false false R36.htm 9954486 - Disclosure - LEASES - Lease Terms and Discount Rates (Details) Sheet http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails LEASES - Lease Terms and Discount Rates (Details) Details 36 false false R37.htm 9954487 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) Sheet http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails LEASES - Maturities of Lease Liabilities (Details) Details 37 false false R38.htm 9954488 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables 38 false false R39.htm 9954489 - Disclosure - DEBT - Term Loan (Details) Sheet http://apyxmedical.com/role/DEBTTermLoanDetails DEBT - Term Loan (Details) Details 39 false false R40.htm 9954490 - Disclosure - DEBT - Narrative (Details) Sheet http://apyxmedical.com/role/DEBTNarrativeDetails DEBT - Narrative (Details) Details 40 false false R41.htm 9954491 - Disclosure - CHINA JOINT VENTURE - Narrative (Details) Sheet http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails CHINA JOINT VENTURE - Narrative (Details) Details 41 false false R42.htm 9954492 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) Sheet http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) Details 42 false false R43.htm 9954493 - Disclosure - EARNINGS (LOSS) PER SHARE (Details) Sheet http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails EARNINGS (LOSS) PER SHARE (Details) Details http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables 43 false false R44.htm 9954494 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 44 false false R45.htm 9954495 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details) Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails STOCK-BASED COMPENSATION - Summary of Stock Options (Details) Details 45 false false R46.htm 9954496 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details) Sheet http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails STOCK-BASED COMPENSATION - Fair Value Assumptions (Details) Details 46 false false R47.htm 9954497 - Disclosure - INCOME TAXES (Details) Sheet http://apyxmedical.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://apyxmedical.com/role/INCOMETAXES 47 false false R48.htm 9954498 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 48 false false R49.htm 9954499 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS 49 false false R50.htm 9954500 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) Details 50 false false R51.htm 9954501 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) Details 51 false false R52.htm 9954502 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) Sheet http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) Details 52 false false All Reports Book All Reports apyx-20230930.htm apyx-20230930.xsd apyx-20230930_cal.xml apyx-20230930_def.xml apyx-20230930_lab.xml apyx-20230930_pre.xml apyx-20230930_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "apyx-20230930.htm": { "nsprefix": "apyx", "nsuri": "http://apyxmedical.com/20230930", "dts": { "inline": { "local": [ "apyx-20230930.htm" ] }, "schema": { "local": [ "apyx-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "apyx-20230930_cal.xml" ] }, "definitionLink": { "local": [ "apyx-20230930_def.xml" ] }, "labelLink": { "local": [ "apyx-20230930_lab.xml" ] }, "presentationLink": { "local": [ "apyx-20230930_pre.xml" ] } }, "keyStandard": 229, "keyCustom": 56, "axisStandard": 17, "axisCustom": 3, "memberStandard": 23, "memberCustom": 26, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 177, "entityCount": 1, "segmentCount": 50, "elementCount": 434, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 666, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://apyxmedical.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:IncomeTaxesReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R3": { "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R5": { "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-35", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "us-gaap:SharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R6": { "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R7": { "role": "http://apyxmedical.com/role/BASISOFPRESENTATION", "longName": "0000007 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS", "longName": "0000008 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://apyxmedical.com/role/INVENTORIES", "longName": "0000009 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENT", "longName": "0000010 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://apyxmedical.com/role/LEASES", "longName": "0000011 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "longName": "0000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://apyxmedical.com/role/DEBT", "longName": "0000013 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://apyxmedical.com/role/CHINAJOINTVENTURE", "longName": "0000014 - Disclosure - CHINA JOINT VENTURE", "shortName": "CHINA JOINT VENTURE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE", "longName": "0000015 - Disclosure - EARNINGS (LOSS) PER SHARE", "shortName": "EARNINGS (LOSS) PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION", "longName": "0000016 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://apyxmedical.com/role/INCOMETAXES", "longName": "0000017 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS", "longName": "0000019 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION", "longName": "0000020 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies", "longName": "9954471 - Disclosure - BASIS OF PRESENTATION (Policies)", "shortName": "BASIS OF PRESENTATION (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://apyxmedical.com/role/INVENTORIESTables", "longName": "9954472 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables", "longName": "9954473 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://apyxmedical.com/role/LEASESTables", "longName": "9954474 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables", "longName": "9954475 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://apyxmedical.com/role/DEBTTables", "longName": "9954476 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://apyxmedical.com/role/CHINAJOINTVENTURETables", "longName": "9954477 - Disclosure - CHINA JOINT VENTURE (Tables)", "shortName": "CHINA JOINT VENTURE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "apyx:NoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "apyx:NoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables", "longName": "9954478 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)", "shortName": "EARNINGS (LOSS) PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954479 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables", "longName": "9954480 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "longName": "9954481 - Disclosure - BASIS OF PRESENTATION (Details)", "shortName": "BASIS OF PRESENTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-52", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://apyxmedical.com/role/INVENTORIESDetails", "longName": "9954482 - Disclosure - INVENTORIES (Details)", "shortName": "INVENTORIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails", "longName": "9954483 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)", "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTNarrativeDetails", "longName": "9954484 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)", "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-65", "name": "apyx:SaleLeasebackPurchaseAgreement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-66", "name": "apyx:SaleLeasebackNetCashProceeds", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R35": { "role": "http://apyxmedical.com/role/LEASESNarrativeDetails", "longName": "9954485 - Disclosure - LEASES - Narrative (Details)", "shortName": "LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-85", "name": "apyx:SaleLeasebackTermOfLease", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-85", "name": "apyx:SaleLeasebackTermOfLease", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails", "longName": "9954486 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)", "shortName": "LEASES - Lease Terms and Discount Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "longName": "9954487 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)", "shortName": "LEASES - Maturities of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "longName": "9954488 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://apyxmedical.com/role/DEBTTermLoanDetails", "longName": "9954489 - Disclosure - DEBT - Term Loan (Details)", "shortName": "DEBT - Term Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-90", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-90", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://apyxmedical.com/role/DEBTNarrativeDetails", "longName": "9954490 - Disclosure - DEBT - Narrative (Details)", "shortName": "DEBT - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-107", "name": "apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-107", "name": "apyx:DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails", "longName": "9954491 - Disclosure - CHINA JOINT VENTURE - Narrative (Details)", "shortName": "CHINA JOINT VENTURE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "apyx:NoncontrollingInterestRequiredCapitalContribution", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R42": { "role": "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails", "longName": "9954492 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)", "shortName": "CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:MinorityInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "us-gaap:MinorityInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "apyx:NoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R43": { "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails", "longName": "9954493 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)", "shortName": "EARNINGS (LOSS) PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954494 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails", "longName": "9954495 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)", "shortName": "STOCK-BASED COMPENSATION - Summary of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails", "longName": "9954496 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)", "shortName": "STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R47": { "role": "http://apyxmedical.com/role/INCOMETAXESDetails", "longName": "9954497 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R48": { "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "longName": "9954498 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R49": { "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails", "longName": "9954499 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-152", "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R50": { "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails", "longName": "9954500 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails", "longName": "9954501 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } }, "R52": { "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails", "longName": "9954502 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)", "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-170", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "apyx-20230930.htm", "unique": true } } }, "tag": { "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r108" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r61" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r444" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r96", "r170", "r215", "r229", "r235", "r238", "r248", "r281", "r282", "r284", "r285", "r286", "r288", "r290", "r292", "r293", "r420", "r618", "r681" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "verboseLabel": "Long-term portion of lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r439" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 }, "http://apyxmedical.com/role/INVENTORIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories, net of provision for obsolescence of $611 and $457", "totalLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r152", "r613", "r633" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r671" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r149" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r658" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://apyxmedical.com/role/INVENTORIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r16", "r88", "r89", "r90" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r100" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r648" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r172", "r217", "r228", "r229", "r230", "r231", "r232", "r234", "r238", "r281", "r282", "r283", "r284", "r286", "r287", "r289", "r291", "r292", "r681", "r682" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17", "r633" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r671" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r656" ] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases from related party", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesAndExciseTaxPayableCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales tax payable", "label": "Sales and Excise Tax Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r139", "r212", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r244", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r620", "r654", "r707" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r172", "r217", "r228", "r229", "r230", "r231", "r232", "r234", "r238", "r281", "r282", "r283", "r284", "r286", "r287", "r289", "r291", "r292", "r681", "r682" ] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedBonusesCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued bonuses", "label": "Accrued Bonuses, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/DEBTTermLoanDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Term loan, net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r14", "r121", "r307", "r322", "r622", "r623", "r705" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualClassifiedCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued product warranties", "label": "Product Warranty Accrual, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21", "r679", "r680" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r648" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r424" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r657" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r103" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross inventories", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r659" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r34", "r103", "r168" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase obligation", "label": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r82" ] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r686" ] }, "us-gaap_AccruedInsuranceCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedInsuranceCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued product liability claim insurance deductibles", "label": "Accrued Insurance, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r160", "r182", "r183", "r184", "r185", "r186", "r196", "r203", "r204", "r205", "r209", "r415", "r416", "r474", "r489", "r616" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r274", "r275", "r276", "r280", "r677", "r678" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r648" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r274", "r275", "r276", "r280", "r677", "r678" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r82" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r20", "r170", "r248", "r281", "r282", "r284", "r285", "r286", "r288", "r290", "r292", "r293", "r401", "r404", "r405", "r420", "r535", "r617", "r646", "r681", "r695", "r696" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,855 issued and outstanding as of September\u00a030, 2023, and 34,597,822 issued and outstanding as of December 31, 2022", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r82", "r479", "r633" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r81", "r324" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r82", "r536", "r554", "r713", "r714" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails", "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r333", "r451", "r452", "r530", "r531", "r532", "r533", "r534", "r553", "r555", "r585" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest", "periodStartLabel": "Beginning interest in China JV", "periodEndLabel": "Ending interest in China JV", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r27", "r122", "r170", "r248", "r281", "r284", "r285", "r286", "r292", "r293", "r420", "r481", "r538" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r81", "r536" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r451", "r452", "r694" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r81", "r536", "r554", "r713", "r714" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade receivables", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r87", "r123", "r482", "r633", "r665", "r673", "r690" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r61", "r126", "r159", "r219", "r432", "r565", "r644", "r710" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r81", "r324" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURE" ], "lang": { "en-us": { "role": { "terseLabel": "CHINA JOINT VENTURE", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r116" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MovementInMinorityInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInMinorityInterestRollForward", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "label": "Equity, Attributable to Noncontrolling Interest [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails", "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails", "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r27", "r55", "r56", "r97" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to stockholders", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r92", "r105", "r125", "r140", "r154", "r155", "r158", "r170", "r178", "r182", "r183", "r184", "r185", "r188", "r189", "r201", "r215", "r229", "r235", "r238", "r248", "r281", "r282", "r284", "r285", "r286", "r288", "r290", "r292", "r293", "r416", "r420", "r488", "r556", "r578", "r579", "r618", "r644", "r681" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r63", "r64", "r560", "r561", "r564" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to stockholders, basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r162", "r182", "r183", "r184", "r185", "r193", "r194", "r202", "r205", "r215", "r229", "r235", "r238", "r618" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r448", "r449", "r450", "r452", "r453", "r517", "r518", "r519", "r562", "r563", "r564", "r583", "r584" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of lines of credit", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r31", "r664" ] }, "apyx_ChineseSupplierMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ChineseSupplierMember", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chinese Supplier", "label": "Chinese Supplier [Member]", "documentation": "Chinese Supplier" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r171", "r382", "r385", "r387", "r388", "r394", "r396", "r397", "r398", "r516" ] }, "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearFour", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Twelve month net revenue target, year four", "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Four", "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Four" } } }, "auth_ref": [] }, "apyx_DebtInstrumentPrepaymentPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPrepaymentPeriodAxis", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Prepayment Period [Axis]", "label": "Debt Instrument, Prepayment Period [Axis]", "documentation": "Debt Instrument, Prepayment Period" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r560", "r561", "r564" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Canceled and forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r687" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to non-controlling interest", "verboseLabel": "Net loss attributable to Apyx", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r58", "r118", "r154", "r155", "r188", "r189", "r487", "r661" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r83", "r633", "r709" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled and forfeited (in dollars per shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r687" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r136", "r156", "r157", "r158", "r173", "r174", "r175", "r179", "r187", "r189", "r210", "r249", "r252", "r326", "r373", "r374", "r375", "r389", "r390", "r406", "r407", "r408", "r409", "r410", "r412", "r414", "r425", "r426", "r427", "r428", "r429", "r430", "r446", "r503", "r504", "r505", "r522", "r580" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r36" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r212", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r238", "r244", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r270", "r271", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r620", "r654", "r707" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails", "http://apyxmedical.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax (benefit) expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r127", "r134", "r188", "r189", "r223", "r383", "r395", "r490" ] }, "apyx_AtTheMarketMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "AtTheMarketMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "At-The-Market", "label": "At-The-Market [Member]", "documentation": "At-The-Market" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to stockholders, diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r162", "r195", "r197", "r198", "r199", "r200", "r202", "r205" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the disposition of Core business", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DilutiveSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecuritiesAbstract", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails", "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r431", "r454" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r242", "r243", "r524", "r525", "r526", "r587", "r589", "r592", "r596", "r598", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r611", "r627", "r637", "r685", "r707" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r364" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r66", "r704" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r238" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of property and equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r173", "r174", "r175", "r210", "r458", "r513", "r523", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r550", "r551", "r552", "r553", "r555", "r558", "r559", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r580", "r638" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of property and equipment", "label": "Proceeds from Sale of Property, Plant, and Equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r101" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r242", "r243", "r524", "r525", "r526", "r587", "r589", "r592", "r596", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r611", "r627", "r637", "r685", "r707" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r18" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": { "parentTag": "apyx_PropertyPlantAndEquipmentInService", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r43", "r146", "r483" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r108" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable, net of allowance of $652 and $668", "negatedTerseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r245", "r246" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails", "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r44" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "apyx_DebtInstrumentPrepaymentPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPrepaymentPeriodThreeMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Prepayment Period Three", "label": "Debt Instrument, Prepayment Period Three [Member]", "documentation": "Debt Instrument, Prepayment Period Three" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reversal of loss accrual", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in loss contingency liability." } } }, "auth_ref": [ "r676" ] }, "apyx_MidCapCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "MidCapCreditAgreementMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MidCap Credit Agreement", "label": "Mid Cap Credit Agreement [Member]", "documentation": "Mid Cap Credit Agreement" } } }, "auth_ref": [] }, "apyx_MoldsMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "MoldsMember", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Molds", "label": "Molds [Member]", "documentation": "Molds" } } }, "auth_ref": [] }, "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "OtherAccruedExpensesAndLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses and current liabilities", "label": "Other Accrued Expenses And Liabilities, Current", "documentation": "Other Accrued Expenses And Liabilities, Current" } } }, "auth_ref": [] }, "apyx_SaleLeasebackSecurityDepositWithheld": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackSecurityDepositWithheld", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback, security deposit withheld", "label": "Sale Leaseback, Security Deposit Withheld", "documentation": "Sale Leaseback, Security Deposit Withheld" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r119", "r148", "r170", "r215", "r230", "r236", "r248", "r281", "r282", "r284", "r285", "r286", "r288", "r290", "r292", "r293", "r400", "r404", "r420", "r477", "r548", "r633", "r646", "r681", "r682", "r695" ] }, "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearThree", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Twelve month net revenue target, year three", "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three", "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Three" } } }, "auth_ref": [] }, "apyx_DebtInstrumentTerminationFees": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentTerminationFees", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fees", "label": "Debt Instrument, Termination Fees", "documentation": "Debt Instrument, Termination Fees" } } }, "auth_ref": [] }, "apyx_DebtInstrumentPrepaymentPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPrepaymentPeriodTwoMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Prepayment Period Two", "label": "Debt Instrument, Prepayment Period Two [Member]", "documentation": "Debt Instrument, Prepayment Period Two" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/INVENTORIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r257" ] }, "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "label": "Accrued Liabilities and Other Liabilities, Current", "documentation": "Accrued Liabilities and Other Liabilities, Current" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r348" ] }, "apyx_DebtInstrumentCovenantsAxis": { "xbrltype": "stringItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantsAxis", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Covenants [Axis]", "label": "Debt Instrument, Covenants [Axis]", "documentation": "Debt Instrument, Covenants" } } }, "auth_ref": [] }, "apyx_DebtInstrumentNumberOfMonthlyPayments": { "xbrltype": "integerItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentNumberOfMonthlyPayments", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of monthly payments", "label": "Debt Instrument, Number Of Monthly Payments", "documentation": "Debt Instrument, Number Of Monthly Payments" } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs accrued", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r274", "r653" ] }, "apyx_ProceedsFromIncomeTaxRefundsPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ProceedsFromIncomeTaxRefundsPrincipal", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from income tax refund, principal", "label": "Proceeds From Income Tax Refunds, Principal", "documentation": "Proceeds From Income Tax Refunds, Principal" } } }, "auth_ref": [] }, "apyx_DebtInstrumentNumberOfMonthlyPaymentsExtension": { "xbrltype": "integerItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentNumberOfMonthlyPaymentsExtension", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of monthly payments, extension", "label": "Debt Instrument, Number Of Monthly Payments, Extension", "documentation": "Debt Instrument, Number Of Monthly Payments, Extension" } } }, "auth_ref": [] }, "apyx_CapitalizationOfLeaseNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "CapitalizationOfLeaseNonCash", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets capitalized and operating lease liabilities recognized upon execution of lease", "label": "Capitalization Of Lease, Non Cash", "documentation": "Capitalization Of Lease, Non Cash" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax receivables", "terseLabel": "Income tax receivables", "label": "Increase (Decrease) in Income Taxes Receivable", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": [ "r4" ] }, "apyx_DebtInstrumentTerminationPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentTerminationPeriodAxis", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Termination Period [Axis]", "label": "Debt Instrument, Termination Period [Axis]", "documentation": "Debt Instrument, Termination Period" } } }, "auth_ref": [] }, "apyx_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment and software", "label": "Computer Equipment And Software [Member]", "documentation": "Computer Equipment And Software" } } }, "auth_ref": [] }, "apyx_DebtInstrumentPeriodOfInterestOnly": { "xbrltype": "durationItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPeriodOfInterestOnly", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Period of interest only", "label": "Debt Instrument, Period Of Interest Only", "documentation": "Debt Instrument, Period Of Interest Only" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "apyx_SaleLeasebackRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackRenewalTerm", "presentation": [ "http://apyxmedical.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback, renewal term", "label": "Sale Leaseback, Renewal Term", "documentation": "Sale Leaseback, Renewal Term" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Increase (Decrease) in Interest Payable, Net", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r4" ] }, "apyx_CapitalizationOfLeaseExecution": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "CapitalizationOfLeaseExecution", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification", "label": "Capitalization Of Lease, Execution", "documentation": "Capitalization Of Lease, Execution" } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "verboseLabel": "Other income (loss), net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "apyx_DebtInstrumentTransactionCostAndOtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentTransactionCostAndOtherExpenses", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction cost and other expenses", "label": "Debt Instrument, Transaction Cost and Other Expenses", "documentation": "Debt Instrument, Transaction Cost and Other Expenses" } } }, "auth_ref": [] }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non cash activities:", "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "apyx_CapitalizationOfLeaseDerecognizedExecution": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "CapitalizationOfLeaseDerecognizedExecution", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification", "label": "Capitalization Of Lease Derecognized Execution", "documentation": "Capitalization Of Lease Derecognized Execution" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r52", "r53", "r337" ] }, "apyx_DebtInstrumentDefaultApplicableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentDefaultApplicableInterestRate", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Default, applicable interest rate", "label": "Debt Instrument, Default, Applicable Interest Rate", "documentation": "Debt Instrument, Default, Applicable Interest Rate" } } }, "auth_ref": [] }, "apyx_UncertainTaxPositionsLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "UncertainTaxPositionsLiability", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax positions", "label": "Uncertain Tax Positions Liability", "documentation": "Uncertain Tax Positions Liability" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r98", "r458" ] }, "apyx_StockSwapToAcquireOptionsShares": { "xbrltype": "sharesItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "StockSwapToAcquireOptionsShares", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued on net settlement of stock options (in shares)", "label": "Stock swap to acquire options, Shares", "documentation": "Stock swap to acquire options shares." } } }, "auth_ref": [] }, "apyx_DebtInstrumentTerminationPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentTerminationPeriodThreeMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Termination Period Three", "label": "Debt Instrument, Termination Period Three [Member]", "documentation": "Debt Instrument, Termination Period Three" } } }, "auth_ref": [] }, "apyx_AdjustedTermSecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "AdjustedTermSecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjusted Term Secured Overnight Financing Rate (SOFR)", "label": "Adjusted Term Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Adjusted Term Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://apyxmedical.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r24", "r48", "r49", "r59", "r60", "r62", "r67", "r112", "r113", "r622", "r624", "r666" ] }, "apyx_PerceptiveCreditAgreementDelayedDrawLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "PerceptiveCreditAgreementDelayedDrawLoanMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Perceptive Credit Agreement, Delayed Draw Loan", "label": "Perceptive Credit Agreement, Delayed Draw Loan [Member]", "documentation": "Perceptive Credit Agreement, Delayed Draw Loan" } } }, "auth_ref": [] }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyEstimateOfPossibleLoss", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimate of possible loss", "label": "Loss Contingency, Estimate of Possible Loss", "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date." } } }, "auth_ref": [ "r275", "r276", "r279", "r280" ] }, "apyx_DebtInstrumentPrepaymentPeriodFourMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPrepaymentPeriodFourMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Prepayment Period Four", "label": "Debt Instrument, Prepayment Period Four [Member]", "documentation": "Debt Instrument, Prepayment Period Four" } } }, "auth_ref": [] }, "apyx_AdvancedEnergyMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "AdvancedEnergyMember", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advanced Energy", "label": "Advanced Energy [Member]", "documentation": "Advanced Energy [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from income tax refunds", "label": "Proceeds from Income Tax Refunds", "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r35", "r104" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for doubtful accounts receivable", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r150", "r247", "r253", "r254", "r256", "r706" ] }, "apyx_PerceptiveCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "PerceptiveCreditAgreementMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Perceptive Credit Agreement", "label": "Perceptive Credit Agreement [Member]", "documentation": "Perceptive Credit Agreement" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax receivables", "label": "Income Taxes Receivable, Current", "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes." } } }, "auth_ref": [ "r65", "r655" ] }, "apyx_PerceptiveCreditAgreementInitialLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "PerceptiveCreditAgreementInitialLoanMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Perceptive Credit Agreement, Initial Loan", "label": "Perceptive Credit Agreement, Initial Loan [Member]", "documentation": "Perceptive Credit Agreement, Initial Loan" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_CoVenturerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CoVenturerMember", "presentation": [ "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Co-venturer", "label": "Co-venturer [Member]", "documentation": "Other venturer from the perspective of the entity in the corporate joint venture." } } }, "auth_ref": [] }, "apyx_DebtInstrumentInterestRateFloorSpreadAdjustmentPercent": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentInterestRateFloorSpreadAdjustmentPercent", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate floor spread", "label": "Debt Instrument, Interest Rate Floor Spread Adjustment, Percent", "documentation": "Debt Instrument, Interest Rate Floor Spread Adjustment, Percent" } } }, "auth_ref": [] }, "apyx_DebtInstrumentPrepaymentFeePercent": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPrepaymentFeePercent", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment fee", "label": "Debt Instrument, Prepayment Fee, Percent", "documentation": "Debt Instrument, Prepayment Fee, Percent" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "apyx_NetCashProvidedByUsedInOperatingActivitiesExcludingOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "NetCashProvidedByUsedInOperatingActivitiesExcludingOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash used in operations", "label": "Net Cash Provided by (Used In) Operating Activities, Excluding Operating Income (Loss)", "documentation": "Net Cash Provided by (Used In) Operating Activities, Excluding Operating Income (Loss)" } } }, "auth_ref": [] }, "apyx_SaleLeasebackNetCashProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackNetCashProceeds", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback, net cash proceeds", "label": "Sale Leaseback, Net Cash Proceeds", "documentation": "Sale Leaseback, Net Cash Proceeds" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "apyx_SaleLeasebackManagementFeeOnRentPayment": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackManagementFeeOnRentPayment", "presentation": [ "http://apyxmedical.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback, management fee on rent payment", "label": "Sale Leaseback, Management Fee On Rent Payment", "documentation": "Sale Leaseback, Management Fee On Rent Payment" } } }, "auth_ref": [] }, "apyx_ProvisionForObsolescenceInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ProvisionForObsolescenceInventory", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories, provision for obsolescence", "label": "Provision For Obsolescence, Inventory", "documentation": "Provision For Obsolescence, Inventory" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearTwo", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Twelve month net revenue target, year two", "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two", "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year Two" } } }, "auth_ref": [] }, "apyx_ShortTermContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ShortTermContractLiabilities", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term contract liabilities", "label": "Short-Term Contract Liabilities", "documentation": "Short-Term Contract Liabilities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "apyx_DebtInstrumentTerminationPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentTerminationPeriodDomain", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Termination Period [Domain]", "label": "Debt Instrument, Termination Period [Domain]", "documentation": "Debt Instrument, Termination Period [Domain]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://apyxmedical.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r437" ] }, "apyx_DebtInstrumentCovenantTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantTrancheTwoMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Covenant, Tranche Two", "label": "Debt Instrument, Covenant, Tranche Two [Member]", "documentation": "Debt Instrument, Covenant, Tranche Two" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "apyx_DebtInstrumentPrepaymentPeriodAfterYearFourMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPrepaymentPeriodAfterYearFourMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Prepayment Period, After Year Four", "label": "Debt Instrument, Prepayment Period, After Year Four [Member]", "documentation": "Debt Instrument, Prepayment Period, After Year Four" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee percentage", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term contract liabilities", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r327", "r328", "r331" ] }, "apyx_SaleLeasebackAnnualRentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackAnnualRentPayment", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback, annual rent payment", "label": "Sale Leaseback. Annual Rent Payment", "documentation": "Sale Leaseback. Annual Rent Payment" } } }, "auth_ref": [] }, "apyx_SaleLeasebackTermOfLease": { "xbrltype": "durationItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackTermOfLease", "presentation": [ "http://apyxmedical.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback, term of lease", "label": "Sale Leaseback, Term Of Lease", "documentation": "Sale Leaseback, Term Of Lease" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of revenue by geographic area", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r40", "r95" ] }, "us-gaap_CorporateJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateJointVentureMember", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails", "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Joint Venture", "label": "Corporate Joint Venture [Member]", "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September\u00a030, 2023 and December 31, 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r81", "r478", "r633" ] }, "apyx_SaleLeasebackAnnualRentIncrease": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackAnnualRentIncrease", "presentation": [ "http://apyxmedical.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale leaseback, annual rent increase", "label": "Sale Leaseback, Annual Rent Increase", "documentation": "Sale Leaseback, Annual Rent Increase" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails", "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r333", "r451", "r452", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r530", "r531", "r532", "r533", "r534", "r553", "r555", "r585", "r694" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "apyx_DebtInstrumentPrepaymentPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPrepaymentPeriodOneMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Prepayment Period One", "label": "Debt Instrument, Prepayment Period One [Member]", "documentation": "Debt Instrument, Prepayment Period One" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r132", "r133", "r135", "r138", "r176", "r177", "r180", "r181", "r190", "r191", "r250", "r251", "r391", "r392", "r393", "r411", "r413", "r417", "r418", "r419", "r421", "r422", "r423", "r435", "r436", "r447", "r459", "r460", "r461", "r506", "r507", "r508", "r509", "r510" ] }, "apyx_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "NonCashLeaseExpense", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Non-Cash Lease Expense", "documentation": "Non-Cash Lease Expense" } } }, "auth_ref": [] }, "apyx_DebtInstrumentCovenantsDomain": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantsDomain", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Covenants [Domain]", "label": "Debt Instrument, Covenants [Domain]", "documentation": "Debt Instrument, Covenants [Domain]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted earnings (loss) per share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r670" ] }, "apyx_ProceedsFromIncomeTaxRefundsInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ProceedsFromIncomeTaxRefundsInterest", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from income tax refund, interest", "label": "Proceeds From Income Tax Refunds, Interest", "documentation": "Proceeds From Income Tax Refunds, Interest" } } }, "auth_ref": [] }, "apyx_NoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "NoncontrollingInterestTableTextBlock", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of China Joint Venture", "label": "Noncontrolling Interest [Table Text Block]", "documentation": "Noncontrolling Interest" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "apyx_DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantTwelveMonthNetRevenueTargetYearOne", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Twelve month net revenue target, year one", "label": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One", "documentation": "Debt Instrument, Covenant, Twelve Month Net Revenue Target, Year One" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r165" ] }, "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from stock option exercises", "label": "Proceeds From Stock Options Exercised And Warrants Exercised", "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised" } } }, "auth_ref": [] }, "apyx_DebtInstrumentCovenantTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantTrancheOneMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Covenant, Tranche One", "label": "Debt Instrument, Covenant, Tranche One [Member]", "documentation": "Debt Instrument, Covenant, Tranche One" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of finance lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r439" ] }, "apyx_DebtInstrumentAnnualFeePercent": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentAnnualFeePercent", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual fee", "label": "Debt Instrument, Annual Fee, Percent", "documentation": "Debt Instrument, Annual Fee, Percent" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r165" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate & Other", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r13", "r229", "r230", "r231", "r232", "r238", "r672" ] }, "apyx_SuitsFiledIn2022Member": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SuitsFiledIn2022Member", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Suits Filed In 2022", "label": "Suits Filed In 2022 [Member]", "documentation": "Suits Filed In 2022" } } }, "auth_ref": [] }, "apyx_PropertyPlantAndEquipmentInService": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "PropertyPlantAndEquipmentInService", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment in service", "label": "Property, Plant And Equipment, In Service", "documentation": "Property, Plant And Equipment, In Service" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net cash used in cash operations", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r103", "r104", "r105" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "apyx_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "TermLoanMember", "presentation": [ "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/DEBT" ], "lang": { "en-us": { "role": { "verboseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r111", "r169", "r294", "r300", "r301", "r302", "r303", "r304", "r305", "r310", "r317", "r318", "r320" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r332", "r334", "r365", "r366", "r367", "r455", "r456", "r502", "r527", "r528", "r586", "r588", "r590", "r591", "r593", "r609", "r610", "r619", "r626", "r628", "r634", "r637", "r674", "r683", "r698", "r699", "r700", "r701", "r702" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r689" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r110", "r272", "r273", "r599", "r675" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r334", "r456", "r502", "r527", "r528", "r586", "r588", "r590", "r591", "r593", "r609", "r610", "r619", "r626", "r628", "r634", "r683", "r697", "r698", "r699", "r700", "r701", "r702" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued professional fees and legal related contingent liabilities", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r373", "r374", "r375", "r522", "r667", "r668", "r669", "r688", "r713" ] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r332", "r334", "r365", "r366", "r367", "r455", "r456", "r502", "r527", "r528", "r586", "r588", "r590", "r591", "r593", "r609", "r610", "r619", "r626", "r628", "r634", "r637", "r674", "r683", "r698", "r699", "r700", "r701", "r702" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r336", "r338", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of reporting information by segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r37", "r38", "r39", "r42" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r336", "r338", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r364", "r365", "r366", "r367", "r368" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r37", "r38", "r39", "r42" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails", "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r275", "r276", "r277", "r278", "r334", "r456", "r502", "r527", "r528", "r586", "r588", "r590", "r591", "r593", "r609", "r610", "r619", "r626", "r628", "r634", "r683", "r697", "r698", "r699", "r700", "r701", "r702" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued payroll", "label": "Accrued Salaries, Current", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21", "r614" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds received from issuance of warrants", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r9", "r45", "r114" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r163", "r166", "r167" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r68", "r381", "r703" ] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued commissions", "label": "Accrued Sales Commission, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21", "r614" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of stock options and stock awards", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r51" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of option fair value assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r115" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r220" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r325" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r19" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r99" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r443", "r632" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r335", "r343", "r362", "r363", "r364", "r365", "r368", "r376", "r377", "r378", "r379" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails", "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r24" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://apyxmedical.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Costs", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r691" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails", "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Strike price (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r348" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r349" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r444" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r26", "r136", "r156", "r157", "r158", "r173", "r174", "r175", "r179", "r187", "r189", "r210", "r249", "r252", "r326", "r373", "r374", "r375", "r389", "r390", "r406", "r407", "r408", "r409", "r410", "r412", "r414", "r425", "r426", "r427", "r428", "r429", "r430", "r446", "r503", "r504", "r505", "r522", "r580" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS (LOSS) PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r192", "r206", "r207", "r208" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r136", "r173", "r174", "r175", "r179", "r187", "r189", "r249", "r252", "r373", "r374", "r375", "r389", "r390", "r406", "r408", "r409", "r412", "r414", "r503", "r505", "r522", "r713" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/DEBTTermLoanDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loan", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r14", "r121", "r321" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r140", "r154", "r155", "r164", "r170", "r178", "r188", "r189", "r215", "r229", "r235", "r238", "r248", "r281", "r282", "r284", "r285", "r286", "r288", "r290", "r292", "r293", "r399", "r402", "r403", "r416", "r420", "r475", "r486", "r521", "r556", "r578", "r579", "r618", "r630", "r631", "r645", "r661", "r681" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r82", "r536" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://apyxmedical.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r692" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r692" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r444" ] }, "apyx_LineOfCreditFacilityPeriodicPaymentPrincipalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "LineOfCreditFacilityPeriodicPaymentPrincipalPercentage", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal payments, percentage", "label": "Line of Credit Facility, Periodic Payment, Principal, Percentage", "documentation": "Line of Credit Facility, Periodic Payment, Principal, Percentage" } } }, "auth_ref": [] }, "apyx_SaleLeasebackPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackPurchaseAgreement", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase agreement", "label": "Sale Leaseback, Purchase Agreement", "documentation": "Sale Leaseback, Purchase Agreement" } } }, "auth_ref": [] }, "apyx_DebtInstrumentInterestRateFloorPercent": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentInterestRateFloorPercent", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate floor", "label": "Debt Instrument, Interest Rate Floor, Percent", "documentation": "Debt Instrument, Interest Rate Floor, Percent" } } }, "auth_ref": [] }, "apyx_ClassOfWarrantOrRightNumberOfSecuritiesToBeCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesToBeCalledByWarrantsOrRights", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to be issued", "label": "Class of Warrant or Right, Number of Securities to be Called by Warrants or Rights", "documentation": "Class of Warrant or Right, Number of Securities to be Called by Warrants or Rights" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r386" ] }, "apyx_NoncontrollingInterestRequiredCapitalContribution": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "NoncontrollingInterestRequiredCapitalContribution", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Required capital contribution", "label": "Noncontrolling Interest, Required Capital Contribution", "documentation": "Noncontrolling Interest, Required Capital Contribution" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest income", "terseLabel": "Interest income", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r94", "r557", "r594", "r595", "r643", "r644", "r719" ] }, "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": { "xbrltype": "sharesItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock swaps equity instruments received (in shares)", "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received", "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received" } } }, "auth_ref": [] }, "apyx_SuitAgainstGoodwinAndSimbMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SuitAgainstGoodwinAndSimbMember", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Suit Against Goodwin and Simb", "label": "Suit against Goodwin and Simb [Member]", "documentation": "Suit against Goodwin and Simb" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r25" ] }, "apyx_DebtInstrumentTerminationPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentTerminationPeriodTwoMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Termination Period Two", "label": "Debt Instrument, Termination Period Two [Member]", "documentation": "Debt Instrument, Termination Period Two" } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r715", "r716", "r717", "r718" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "apyx_SaleLeasebackSecurityDepositEqualToAnnualRent": { "xbrltype": "durationItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SaleLeasebackSecurityDepositEqualToAnnualRent", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposit equal to annual rent", "label": "Sale Leaseback, Security Deposit Equal To Annual Rent", "documentation": "Sale Leaseback, Security Deposit Equal To Annual Rent" } } }, "auth_ref": [] }, "apyx_DebtInstrumentExitFee": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentExitFee", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exit fee", "label": "Debt Instrument, Exit Fee", "documentation": "Debt Instrument, Exit Fee" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r431", "r454" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "apyx_DebtInstrumentCovenantTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantTrancheThreeMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Covenant, Tranche Three", "label": "Debt Instrument, Covenant, Tranche Three [Member]", "documentation": "Debt Instrument, Covenant, Tranche Three" } } }, "auth_ref": [] }, "apyx_DebtInstrumentExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentExtensionPeriod", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extension period", "label": "Debt Instrument, Extension Period", "documentation": "Debt Instrument, Extension Period" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r667", "r668", "r688", "r708", "r713" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": { "parentTag": "apyx_PropertyPlantAndEquipmentInService", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total property, plant and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r108", "r145", "r484" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r102" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": [ "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r476", "r484", "r633" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r431", "r454" ] }, "apyx_SecuritiesRegisteredNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "SecuritiesRegisteredNewIssues", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities registered, new issues", "label": "Securities Registered, New Issues", "documentation": "Securities Registered, New Issues" } } }, "auth_ref": [] }, "apyx_StockIssuedDuringPeriodSharesStockSwaps": { "xbrltype": "sharesItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "StockIssuedDuringPeriodSharesStockSwaps", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock swaps (in shares)", "label": "Stock Issued During Period, Shares, Stock Swaps", "documentation": "Stock Issued During Period, Shares, Stock Swaps" } } }, "auth_ref": [] }, "apyx_DebtInstrumentPrepaymentPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentPrepaymentPeriodDomain", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Prepayment Period [Domain]", "label": "Debt Instrument, Prepayment Period [Domain]", "documentation": "Debt Instrument, Prepayment Period [Domain]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r33", "r35" ] }, "apyx_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r173", "r174", "r175", "r210", "r458", "r513", "r523", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r549", "r550", "r551", "r552", "r553", "r555", "r558", "r559", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r580", "r638" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for allowance for doubtful accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r161", "r255" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r335", "r339", "r370", "r371", "r372", "r629" ] }, "apyx_ShelfRegistrationMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ShelfRegistrationMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shelf Registration", "label": "Shelf Registration [Member]", "documentation": "Shelf Registration" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r93", "r316", "r433", "r663" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENT" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r107", "r129", "r130", "r131" ] }, "apyx_OEMMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "OEMMember", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OEM", "label": "OEM [Member]" } } }, "auth_ref": [] }, "apyx_TotalRevenuePercent": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "TotalRevenuePercent", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International sales, percent of total revenue", "label": "Total Revenue, Percent", "documentation": "Total Revenue, Percent" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantBorrowingBaseMinimumBalanceAmount", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing base, minimum balance", "label": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount", "documentation": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Amount" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails", "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from non-controlling interest", "verboseLabel": "Contributions", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r8", "r50", "r117" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r441", "r632" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "(Gain) loss on disposal of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r5" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r141", "r153", "r170", "r248", "r281", "r282", "r284", "r285", "r286", "r288", "r290", "r292", "r293", "r400", "r404", "r420", "r633", "r681", "r682", "r695" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r160", "r182", "r183", "r184", "r185", "r186", "r193", "r196", "r203", "r204", "r205", "r209", "r415", "r416", "r474", "r489", "r616" ] }, "apyx_ProvisionForInventoryObsolescence": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "ProvisionForInventoryObsolescence", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for inventory obsolescence", "label": "Provision For Inventory Obsolescence", "documentation": "Provision For Inventory Obsolescence" } } }, "auth_ref": [] }, "apyx_JointAndSeveralPayrollLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "JointAndSeveralPayrollLiability", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint and several payroll liability", "label": "Joint And Several Payroll Liability", "documentation": "Joint And Several Payroll Liability" } } }, "auth_ref": [] }, "apyx_DebtInstrumentTerminationPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentTerminationPeriodOneMember", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Termination Period One", "label": "Debt Instrument, Termination Period One [Member]", "documentation": "Debt Instrument, Termination Period One" } } }, "auth_ref": [] }, "apyx_DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings": { "xbrltype": "durationItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentLockboxAccountFundsToBeAppliedToBorrowings", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lockbox account, funds to be applied to borrowings", "label": "Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings", "documentation": "Debt Instrument, Lockbox Account, Funds To Be Applied To Borrowings" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "apyx_DebtInstrumentCovenantCashAndCashEquivalentsBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantCashAndCashEquivalentsBalance", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents balance", "label": "Debt Instrument, Covenant, Cash And Cash Equivalents Balance", "documentation": "Debt Instrument, Covenant, Cash And Cash Equivalents Balance" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r108" ] }, "apyx_DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent": { "xbrltype": "percentItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "DebtInstrumentCovenantBorrowingBaseMinimumBalancePercent", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing base, minimum balance", "label": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent", "documentation": "Debt Instrument, Covenant, Borrowing Base, Minimum Balance, Percent" } } }, "auth_ref": [] }, "apyx_RepaymentofFinanceLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://apyxmedical.com/20230930", "localname": "RepaymentofFinanceLeaseLiabilities", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of finance lease liabilities", "label": "Repayment of Finance Lease Liabilities", "documentation": "Repayment of Finance Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r46", "r47" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r22", "r142", "r170", "r248", "r281", "r282", "r284", "r285", "r286", "r288", "r290", "r292", "r293", "r401", "r404", "r405", "r420", "r633", "r681", "r695", "r696" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r91", "r124", "r215", "r229", "r235", "r238", "r475", "r485", "r618" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/DEBTTermLoanDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r61", "r684" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r650" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "negatedTerseLabel": "Loss from operations", "verboseLabel": "(Loss) income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r215", "r229", "r235", "r238", "r618" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r7", "r12", "r15", "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r77", "r78", "r109" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of warrants", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r325" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r651" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term finance lease liabilities", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r439" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of positions eliminated", "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r36" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage loan, principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r60", "r62", "r295", "r434", "r622", "r623" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMinorityShareholders", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from non-controlling interest", "label": "Proceeds from Noncontrolling Interests", "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership." } } }, "auth_ref": [ "r29" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r652" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r9" ] }, "us-gaap_SaleAndLeasebackTransactionGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleAndLeasebackTransactionGainLossNet", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale-leaseback", "label": "Sale and Leaseback Transaction, Gain (Loss), Net", "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale." } } }, "auth_ref": [ "r440", "r445", "r632" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r34", "r144", "r612" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r647" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r69", "r116", "r511", "r512" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r128", "r143", "r151", "r257", "r258", "r259", "r457", "r615" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from term loan", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r30", "r514" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from line of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r30", "r664" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: provision for obsolescence", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r41", "r659" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r649" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://apyxmedical.com/role/LEASESLeaseTermsandDiscountRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r442", "r632" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r23", "r60", "r323", "r434" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r439" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r635", "r636", "r639", "r640", "r641", "r642" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "negatedLabel": "Less current portion of lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r439" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r82", "r85", "r86", "r106", "r538", "r554", "r581", "r582", "r633", "r646", "r665", "r673", "r690", "r713" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r147" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r369", "r380" ] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesAndWages", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Salaries and related costs", "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r662" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r660" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discounts", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r316", "r433", "r624", "r625", "r663" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails", "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r24", "r172", "r295", "r296", "r297", "r298", "r299", "r301", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r434", "r621", "r622", "r623", "r624", "r625", "r664" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r438" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other costs and expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_SaleLeasebackTransactionLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleLeasebackTransactionLeaseTerm", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leaseback term", "label": "Sale Leaseback Transaction, Lease Term", "documentation": "Lease term for sale and leaseback transaction, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r693" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r438" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareReconciliationAbstract", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share Reconciliation [Abstract]", "label": "Earnings Per Share Reconciliation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued on stock options exercises for cash", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r26", "r114" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r648" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/DEBTTermLoanDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt discount, including accretion of exit fee", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r59", "r62", "r684" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share:", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://apyxmedical.com/role/INCOMETAXESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r384" ] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment penalties and exit fees", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Professional services", "label": "Professional Fees", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r644", "r711", "r712" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://apyxmedical.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r84", "r114", "r480", "r506", "r510", "r515", "r537", "r633" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r648" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r195", "r205" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued on stock options exercises for cash (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r9", "r81", "r82", "r114" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails", "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r172", "r295", "r296", "r297", "r298", "r299", "r301", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r434", "r621", "r622", "r623", "r624", "r625", "r664" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails", "http://apyxmedical.com/role/DEBTNarrativeDetails", "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r14", "r79", "r80", "r120", "r121", "r172", "r295", "r296", "r297", "r298", "r299", "r301", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r434", "r621", "r622", "r623", "r624", "r625", "r664" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Domestic", "label": "UNITED STATES" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r648" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r36" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://apyxmedical.com/role/DEBTNarrativeDetails", "http://apyxmedical.com/role/DEBTTermLoanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r24", "r48", "r49", "r59", "r60", "r62", "r67", "r112", "r113", "r172", "r295", "r296", "r297", "r298", "r299", "r301", "r306", "r307", "r308", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r319", "r434", "r621", "r622", "r623", "r624", "r625", "r664" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding - basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r193", "r205" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in shares)", "periodEndLabel": "Outstanding, end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r344", "r345" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails", "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r216", "r217", "r228", "r233", "r234", "r240", "r242", "r244", "r329", "r330", "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in dollars per share)", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r344", "r345" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://apyxmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r648" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of debt issuance costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r32" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive instruments (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r206" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r366" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://apyxmedical.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r227", "r232", "r236", "r237", "r238", "r239", "r240", "r241", "r244" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r54", "r326", "r667", "r668", "r669", "r713" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r54", "r55", "r57", "r136", "r137", "r157", "r173", "r174", "r175", "r179", "r187", "r249", "r252", "r326", "r373", "r374", "r375", "r389", "r390", "r406", "r407", "r408", "r409", "r410", "r412", "r414", "r425", "r426", "r430", "r446", "r504", "r505", "r520", "r538", "r554", "r581", "r582", "r597", "r645", "r665", "r673", "r690", "r713" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r81", "r82", "r114", "r349" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r653": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 71 0000719135-23-000056-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000719135-23-000056-xbrl.zip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

79!25'#U[R_YF9H:#CGN*,8FP !$GY1RC@FX5\? M/Z/<9B>7\_)VHT36 ZN93]IR\$P'$)XO4N<.F#4IDFB]-36NN)^C83.0-)R= MK"SF-D"#DINZT=$XIN__.Z&+%"4RH#UXRR4(9Q,X*S@8XDGV'+TG)VO@Y.&R MFT&CX>'W?4EX'R.^'L^!&_TQNNGQ00*U/)"0'^+=!23!$KF$$ MDI1$9TU]W*FV&AX31F%9$V\D;CFHGKIR;O\7NS@4N"4DLT".W+A0S2 M;WQ&]\@2X=!'IC[4><7U9.G-@-%P$K..4)M"1H'W-0O>]X_W#CW\[/#S_^)"!#5]JO_RI59YQOY+X'=]X7\[@ MDW-?!HMRN(*'D_Q^.';C,$13,;E^U76+M< 4H^6*0\B(]B)'=# B^I:(0$T] M#9F0Y_* V @]I/[&V;IE M@E.EC$(F2+8H%.$P_*:L%(]QQB@3A.O<"68>$=(O=';1[$J0["+F!K"R[V:? M]\:Q_'7X?R^'7]T(F9GMS??=='HU''_Z+S>Z3 /!-+.!2% Z6PS6,P-',@7N M57#2,#SQ43M82!(C%B$$D3&!$E1*VX%O@/0JC*N%E/33]M-KH#3R6Y M-X"@H_%7I'HRO4(6!H)$Y67VX+GB()31)7M-H.L=DM&!+=Q'!J0#' M P$BHJ9)!,[Y&I.Y&U6R.Y,O:3J_.ATY%,@&TY M04Y<>23P(;E9.BL]?$_R;V@XB[@&0ND8G G@\8N2.T5FT*\'HIC61JK(PG/% M4%OYQ<\1U$)<505"]<3> (:NT^YI)2LN4<4SS\ I*\W5D@>C1 "&1ZR/@2CS M;#G=-@AZAIP60JLJ^*DE\@;0<\\_.YZ,P\TYG#WUULD(5$913O2,L8 W$+-1 MW">:(GONGGSKB/PQ(2V$674LSLYB;@ KU_0/F S)&W32C/>(\) X6(%.FM=4 M:BN5B*FV4;E>N85@J>)UU:L$V8"W^V'H_' TG _3#-VN167QY\D(A3XK+MC\ MZJ[() ?C"$8!T2Z\^*#!9!T6KV$3%]Y[]5Q5WC8 V92V?KW@SB_+.U%1 Y;G M'E^/@\^4)+$)'35&90+!?<;@DVL(5% ;R_T)JYW764]-OY>@W6A_/<1V444# MH%I>R)VZJY(9OTU/1>UXBJ7GFRLA),K%2R$A>:Z2IUHQ63W#LY*29L"TDY[7 MW(+N(/0>H5-J\ H+TTM<\L%N6SAX3V4V4-9XS5TJG)C"6'E601RPTC+&:9^4 M>U2)_+26\-6K]GO*549.MS)OP X]S$8L^;FZY490[ADR@DR94F(BP3$5P2 O MZ()&%:IGG)^GJ-\T4$=VJ:(2&H#4_03%$UZL(5F4OD4AEE[(HI1_"]PCG&GB MG XYQ><>1^R:%-H*3IUEA3J"4S4%- "F%1969R:H,AD\*9U*7.F:3!,%RJUB M@J!7&9^;[%7'Z>XW.=01<'84=@MI@LGXTWF:7APD/[^7Z])2$Z8X!Q(EQK9, M>O!LD?N0@:A@\'^U4XJK*6G&.>HP1MM=!0W8G35'\CV&*-$V*8)1 U7EX3*> MSTYZ <0(QD4FS#S[_+.B:_1*>+V%=]0=O.HJI@&DK3RM[^?IA4$#3CQPSC@: M= Q1K:9HU6-4AKCDLZO]7N,%DIIQFKI#64VE-("Q_?]R]G\\G% M7>QZGZV0\3AG-I36'*1TDHY@I94@I8^,Q:1DKHVU#4EKQM_J#G-=**D![#U. ME-SCA 06C\PQ*B05EM*17$)U?[2OC>\OW61+[UKB5(C+5?R&^T]5P]<8=;XJB2JIHP/B<+M==L'3] M%C.;G @2#;Y<) E1>EL0I8%1%:W)V0I1.RFU@HR^G^/7T?#3LOZ=Q-T 8N[U MP[NF'ZE,XGI*@RI==H,!2X,'P@+UW+NH?.V$U&,:^JY&Z00K.PFZ :#LQ;@H MR'&C4S>,1^-]]V6(9^& 6D>\CADBMIX64-*ORFF MCF!30^P-H.=0D4"V]E:%S)[K?W%!'\-E1V W$7K\.QY/IOJ8D MYD5T8"078"/1T@AC4_7.0X]IZ#?)TQ%4=A)TDW;E:!Q&EZ59]&D98X/*F<^G M0W\Y+U5[YY.2MBJYTLD(/_'3+=>"6V63MV7Z703A! ?'#0/O/"5),>U\[:.M M#N7]II#>S'YUKM0&;-Y+F90!Y9IK'SA(6GI@2I?*R#8%/ 6>@S8F/3OWK(OG M"?W,5^\K@[F[6JK![*U;B9XN%/(YS%& Q\+)="'!N$@%GZ;I8A;-P)- #&<)E/44!29+ M[4ZID#4Z,,:9M/RYV4^[7]6LHZSOU&K'IJH#]30'NNMI1WN7\\\8D?]WBH/$ M/,FRO"TCH4PK0%G9J PH'AA%$QQX]X#6M@II %_W[M_7'O#"QAA9 MM,#*'X)E!EXG IX(3Q1E@O'J3>1?)JOO)&S'.*NMF+:P]N2]H>.4S)[P=2V^KB1YHA]_$<__SU\/C\X\G[D]/#L[WS(_S7:I<^ M:SZ^LPN?3=BI=-ES/?#B%I5WC::9\9FR!$2K,K)VT=U7,,C.2Z:LMN.K-V>'WFWOZTBD0_R^>N^\#S56,E@J@@='2EI^6?6* M&H\'?#3%1ZQ>-_AJ,ON][*F!G*=5A-WJJHFS3/"R=)E*T1EM(JM1RQ"#!$"XAEO83Q"*!HO95]+WE^[W$Z0(EV\JV@7*L M O "[9N1(/<:Z"8I578*N'821)(H#Q(]FDCC?4@I"U;[\=\Z6OJ]D.G*K.PL M]0:,RAFJ @DHDQ@/\!@>31:3'FZX&M#@,.Q( H0S)2+5#!SE'!*5R@F?O92U M*_F>):A?WZ>.SI\X/[44T ":B@5%%VWQRNA]2K-!$M:X\M!>RW+139P!+XP& MASM.9Q4SU_6?C#ZDH5^7IA/,["3F!F#RT8W<]+I.]>_N$]+O=#39*PN9E0YL MD0N$.0I#42FSLSY032O#Y#$-_?HTG6PN:2:YR="[3VF'[9I3UZ_5T ZGZ*FD M:+?]UI:R&N!!*Y0OA?A<&C2HI1VM< PDXU80XDD2M=_\/2&BWX*33N"SFZ ; M"+;0I):ABXN>:=Z%?YU/W7B&4D&E_.*&XP\8198I:41SE[FQ8)"MDIV28#/* MB'CJI+2B!)7US[,-*.L74UT$8AUHI"6+="VRPL4@6$.EUA&HLPI9X!;P%_GB M<1 *#AD+M1.%*\CHMU:I"P3M*NL&S-+R*>$U![<,#92BBG 3D'BND0V!<4% MZXHV-P9B0N:Y=@IH#2G]EAYU 9L:,F]BN/.2D:7SQIE,1E,/TI%O^(A'YKB;H$RS8R?CU([#5(QNE3*8 [K]OF\I&YO.&HG+%* MG6$DIVMZ=* 08)W) IP MI=NZL"AO(] OU%%DKWE6WM=&8X?L; ;E'ZJ,I!7E-[,/D,6;??PNC5.YV@XI M$59:G#!7$L A9C#$HJL:*//2.F6J#PY=0\IF^/NA*DUJ"+V!0_FZ"F(1!4<4 M!N,)I4$#>JF9!C!<>- V":D]1L6BMLF[6WTSA/Q0529;BK8!@X+.Y9UYW:BI MD8LN<$(U2D=F9-!Q0 O*()&8E*":^^HOH%Y-Y&80^Z'J4KI55 /FZ0&# ZNC MMIID-+5?1:PDI-_JMSHZ?@$XKQ=X@Z@Y M&(XNY^4]7U!$9D/0\3<:;2?!\+%T+,V"1V$\H5+7OK!;0TJ_-7!O@IQMA/ZC M/G;;_]O>\2^''X^.#__SMZ/S?SYDI]*+M\=KO,FSMV<9J]_H\)E.G%$Y3F1Y M!,!R:2_,BU>,0;OQGA(>&.&D]M[=B+#=^Q#?+'*^Z)DGDI,A$@?:: :"*P_. MQ@":L22\23)UT-O\/@7-M"ZLA(6G+8*WEG<#)]LM]=<2V9]]^' MLX%$;Y$2@=(@F8)@>$);RST$29 I(8C0M>_[GB6H$2QMH>EUH-E9[ U@Z!$/ M!Y,+-QP/3"8LE7QHY!3W%!.ZS*PI8T:UR8J+0$EM[*PDI!',[*[HQ^[1SE)O M #KWNAK\FBY\F@Z4]()(M+TIE@[#=E?L M^MX16TBY 9BLF6QTPXQ1TD1>>NH+94K')PN.: V:"TN8(M3JVC5PSQ+49+085)+2+I@H#M91F;EQU)#ZG2%64=+O*Z7Z MX*D@[P90L_IFY887*SQEAC.@L@@EI0A>:PE>!9@*UGZJ_QP]_3Y*JH^@ M:K)O $>W[N 'W!.+Z%]Y/I-S>- VXCXIQ&<(O>7YE2 M<-)Q8)FF[ .S--5.\+R2Q$8BL"T1\;0&J#/U-("^!^T*J8W.:AZ0=B1;1,K MAXRLR& 445D24WVX^&N;1'99P-B=HA];K6VEOC5BOJ3I'(NC9UF:D6*)W-)XME#VP#K' M70@!F,# 2K#2*(U)"1BAAT!L3*FZ;[D%F;WW'GM;V]NA#MN%Z:+'_^+?3KXL M7GHQ\LB8UOMB*_O%6/$LHZ=EPGFYZE%Y+YBR%R:?QXE,6 M0AHDR0/%$P144(L-6]K%DS(B5D>,!O!K4]L'[IJGWEM*O!G\FT)'K\T'%M,9 MK_O5?W-?4!@!^9NFF^U_?60-G')6:25 ^43+8" -QG(%-K@<@PF"V4?)SS4S M,%]8J/?F%)T#L+JX?Q!3^W)8D9# &!T9QKJQ) MG(3:W2A?363OO2^:,H;;ZZ\!@-Y[[J=D$((2"R@A 4(EAH$@S9!C)(0DW%ZV M]JG]RI>47;;!>#-(;2GQ!K#R(,=KI3 (=0V:.<0YVETP,C((.M- A(PDU[93 MK\^L=]GFHI_4^FO$OF/2\7 <6TJL"XW<,>HA,(I!EBB/)LK;+Z>MQW]*R:CZ MU>YOEECOM(W%CY99?XVJJX+\K=_(['W\V_L/)W_O9A[4W:>_S;N8U]6EVRNA0 (C@-A)Y>8Q@$[64O2Z%*G?RO09>BH\'R^?B8[" MUR%*[MW5;QAH'XUO6VKMA?GP*WJB]QK>4LXIX8("-R*H!6/T;M45P..WSV7->/)D#SW:) Q"!?22PR]F0%&)6,L M,>5RST%"9P#J6L_KXX37"+V)=IT/PN:2 !R'X2@]Z-IP/GFU,*.F(<4 V96B M.FTB6$X=)&&X=BQFSFN7&7;!1[]U%F\,XMZ!T(#U/$BXCJU^+VCYY)QZKL M$9Z+=/M"<&5(#T9_1^.O*.G)].K$SW")64BE1L3QJ)7,!%TA@6>/"!B&\5Q. M(4:,"<%+'5X*539;JE_#V S6.M!+ T9P.>?@9%R&(9QD9!#E-K\Z';GKEZ6+ MD6*#0'GPR3.0(3@0BLA24T= 6MQ00C":>.URG>K!EP=JC.75N(UTMQ MKZA LI;$I!-0[3 \S,2!4S8#X<9GQY76L7J"H<%"L>9@6$%=#=C&^\;^8'+I MY_ERM!?"Y!+E//"*R<"( N\B!6%, A^(!2)-J:7GGE4?O?PS_3TFL9T;E--**P) $3%8.8A$O).B:K']";T-5O M>59SL*RNRK[CE./)N,AO,4%KV?=?T.0(B0:4,1($CPP\);I,P_;6<&5E4!M% M)BL^O-]JJV;P5$7V39JV6TG=%/'9V0FDBII*A^ ME[0Y=?T67C4#RX[5VB1@EUX%RCT-ORY>F9N4&,_: GH3Z.:644T^\P2Q-"9E M1B2K:G?\V(2NUAZ]UL'$B]#;44%-A+]/N3J=IB]N& ]N*+JQ_WOCN!C*LS>; M)71TA264.F,@Y/(:O33(L,(J2$Y2B2>%R+3^"+]M*&WMC>L;0;.Z$ML9][;* MT[T=G7-O*U(C%1'> [:U #54"F9"9YI(!R.!4&4O-%)>6B)2J-P-XEJ#6WIF^&=:V4TG+ M9F[I;MP$] /C@Q D<& J8C1/@P1GB (MM-<^"^=4]P;N$5&MO1E]8T]P&]6T M&GM,+Y&.H?/#T2)\&V3)'2EMAUR.$D2P'"PQ ICVA*0RR%QV[_(]I:NU9YIO MA[A=%-0 Z#:O2QIXR= E\ PR*?5(7@HPD2H0A"!O-%K\7V^UKOUZ6 MX0ZL?6.\,75-EG!7P\GCV^%NE-9$X(NLA)3B8H[QBAJ@!\Q9S:.5MLQK+&^B MHPH8T!,-5*+_*XWA3-C:B-R?OEF_05JP%B\J;::>!\OL_DL@7I M2?XP&7\Z3].+@^1+25K*"!X"6C(\26B.X*G!@P4]#B6((<;4CJ%?IJI)_[ V M##M24@NPNPG"3G*A?LG3_F0VGPU0'EH+12%SC1ZNCA)W.DNS/; ^,E-J)(TJD_)2TN"99J!9H,1%1B2O?6/R M/$7]7@8W8=>V4D[?KMQ9^G*]=R;Y6EII49I[__*'2Q*]4!94= &$4!'P0SPP MYWBVC(KLW49^V\MK]7O'^Y9.6F6YMVFX?AV.)]/A_&KQLNJFD]- .,^\"!:( M=65>.4;>AC-T-#W/@IKHLNC2=*VBJ=^+WAZ-U\X*:L EVUQ\ R$]5[3<8$>* M,8Y(' RZG."-#BXX9*QZ!=7FU/7[2N2-0=B1TAK(U!WFG,+\)!]^#Y_=^%,Z M0_-ZLGCS4OZ_Y,._NE%:E':C'(K DEFZZYTK5K\SM@HU\7L;-<7]\*;\ $[\3L=6/WIV5(-ZT>[XOU6M2# MZ"63GA T-P8=(\4S6"():&]3]%YSPFOWIWM;#OMU@SO;*0W#I(S>+P34) M?-'5+3I3YL@RL,DP$"%JF:R+TM2N8^O^,.C,Y6X3XJ]28C-#X'9C67(M(Y$* MHN 4!(T:?$BE3Z^5@LF0W.-WUS\ ;COSTAO%[6N4V$H?\-,U;4?V[]@(2>&RAWH>8G M3QNVEWD3D+E]U%@X&)#,1:(R@2%E6H,+ DR@":PU20:92*(=O/^[3T+/!=]O M IGM9=X 9.Z&"BT%='@ML1F>WQO+CY,83+88+5F4GXN%>SS7;L>B]K7K M&6O0W>_0G\[.PS=7:=\WDC>/VVX:X)[DQ;W83=N@019>$>\R>%\>W#(KP663 M@%A-G"")$?^HQF+-7>1SJ_3=I_BM%3[I0OI-PNCP>PJ7BZZ.*DDTY [W("EU M1\:5EVI"0BG\)9Y*8H+9'DBWZ_3=AK@Y*&VG@0:.UK/AI\]HW'^;I46+DQ,_ M=\-QN;-:9A[?3Z:K;O*O!A2EQ 4)H# >!I'MHC#$@XW.H&09'@JU4QQ;$]MW M9^*>\/JV2F[2-!Y@J+28K?O?I:?/Q^//IZ\/ST[_'AX?+YW?G1R_)#B MS6:7K?J8&D/*7B2OTC2RD^DG-[Y1^?YD/)N,AM'=S((XO4?\R4VEV-"-;J.- M>T_O%1')$P%428:@< 2LQZC7!&*X2=&87'N@317"=SV7=R+B8#@+H\GLWX_.CXE].SDV/\%3ZQA@E]#="5K?)R^ MW;1<*G-&IY,Q?AEN/8#]A124\E4WLZ2 MNCLR[T(@C'0P("Z);CRTA64>/!,>B-'9):NBM[5K])XA9_>KN"GAV M_L^]XX/#__SMZ+0X.-O8D)6?4\.8O$Q@):NRMH7,+8X4'DY44W$]C$D$Y\!' M)<%J([-A+ M3.Z'Z(E$5GDVM7F!E.(+;ACDN(3)?WD7XC'@7#O\S6&V5)%S5 M+O9\#7W]6J"Z^%GQ>JH;/35JESX<[GWN<%1T53 M]L8"'AIXDMBLP <10*H8X^=]*T=GCU/$7]VHH=M/_8,%04?*.F8&]__^RWPX/# M?YP>'N-V1$?@Y/QOAV?[OYV=H2_PX6COW=&'H_,M8Y_-/[R&0=F2E5H>SG4K M[Q(;+WHMN]&]4B'CDM I@D)<@# 2PW!M#"3*#2."<5I]+OTSY.Q?ER MA0?-I5<=G(:CS^YC!AG0JQ?9U*2'I2=/8& M>FO4RAT8@N*%@4V# 34+_/RAK8VUCLH:4 M?HU%!?T_MA,U1+ZU'?B:IG[2H278_]O1\=[_.CDZ/B]IU-_.#K(&T6E=ADW&8C.>X(O[$I^5KBKMTGI*YC/,"[G1")4N*!PP&U-)(295T(E1_ M6-MXZ6G5O$//K< M.RBK$#1/1 %QCH HN0?'M "60Z1<&R4(ZYC)1FQ*%1P\:=521?"-VI"/YR?[ M__O=WL?#@_V37TM>8^N"RC6?5,..;$)DK7#G]J@XR?N3BS*E=$'O61J5CG>+ MYJ +%'@W2W'90?069TX8IUQY])<8GBJ.XH&2K(08,@^,F9RJST/>C>*=PZ=- M5W]W?_5[L;]4R3$7097H07A5AH[$\KJ6>R]T3BS7]HQV)+GG<.SM\/DD;'M# M53=J+8^.T0 =GN_]8]M2G;M?KU.JLX:<:J4Z-^^:5R0 F&,V"2%!T5+<*FT MDU3$$U7@=[PS7G0P[',=.=5>S:\*%937/LF403.A2TM5"0[C _ 8)DA/K!:F M=G;].7KZ+M6I@XFU;^AWU4"CI@-WZJ]'YXL*Y+UC]&,6E@0:#<;LJPWA\ MZ2T:M*]>[_LJ G?NCK7)8G?;PTGF@_<4F,'H0_C(P,O2>Y=&':BBGKC:3M3K M*.S79'6'K2<-L;K36Z-F[>SPP][YX<'IWMGY/\_/]C TVR^QV99/0]9\5IU' M(9L06LF:W;C$IVXZOSJ?.G24PV*8SAW(9+)1<@;.XODHK*1@M-2@'95,IYA- MKOZZ^P6:=G[JON;S5Y;>1B4C0 K9A4A',O1#/&,$1E4#P8GM ;H+ZV:=J K)[;[M7 QI.6C965 MT:@)6M$/X'0R&A:75":U?7?]X[TS4EN#DQQ""Y1!R4@*%E-H:*E!'AM?"U MKPI?2^/OH0W!:_#XBF>QN^NT@998MV_R'O,A#!?HO K0DJ!?2T,$XY,"9P2A MA)DH6.V3=QTM_39@ZQ^#5734 -;NKJ/N7UA=3[9%81[AQL)M]C65=UDWNVL0 MM*5.E7:%0I?PBB?P+)-RQ\^3SCPE4SN9M@69_;9.V 170$B@XZRNL': MD+:^KRKK8.6)[>E",XT:G%4/^+>W/,]\6E?=!CJT12^_&6?H'%%MRX@30T&H M7$X<$L"I%!(+R4;]9D_N.^\Y<(=[PK,@-D4\: 7!S44IN%RZ I6\==0FFT#? MBNU&;%%=K&S<7V [G31JBZX?]&]O?1[\?KT. QU:F$$6BF=*-T%*^^KVGT&\--*H>"C@S)QFF,T9>)Y\HC]A-C/,4"BA@4\ M*7/@M0W&&E*:ZBSP>_[2RPNZ@;B.!7-4BX[9_]JYM?EG<^C]VNC+))W$/R M@H.@+(-A$>V=E]D8ZHRC]='T:C+[S3%515JW*FKT--JX&\3V!]9KEWC3)A== M.M;/-"A(-"?I%;I)I+3,IUR"#U9#T(X6"$E=?1I[AZTN[D+)39HG/#;E$2GU MI5%"5!A>6B_ BFB )F.-2SQF7OLR9Q=ZVVUZ\1I,K4\&=*S!1LU@:3RQO86[ M]]NUNF!T:)?6]$+P+#/NM 0B?'G8(CD&68: C7AN6IZM][5-4C>],.ZP7#[_ M:(R?>OGH$0\5S#)A91E_B&$D1>PZB@Q;*K),F24B:VJ-2 M11&-FHXG_2BVMR/K/JJ3MAD=6I@7FB+XZ(/R3H&5&<\+&0+"27I0AEDC6!+, MUZYSZ:9YQF)NS>J/?G1$ZFPP(B )-*(2!*<,K(H.3.D#P8/U\O'CJS6SA#99 MK>F.&*]1_H/Y0-7EW*@]6=5N8GN3\LRG==4;HT/#LK8S E&66VLYI(QGE1"1 M@4O4 :/9(@ 8LZGV@=Y5AXR[4_/Q"N_<;!C0(3\8CB[G*3Z"?C *.58$"%,4 MH4\4&(TGM>.<<4&$0 8Z\VE>16JCW35>@Z'UKDYW2FO47JUN:[&]Q7KV\[KK MP]%EP+5;MP-F-)?&).#")A Q$?"9VM*N+@F77#"D]C/1?KMQW&VFU?51'^>X M=:Z+I&9[83[\^C0SRX/C2CL)Z&D($(18<,P$D-9&SSGAC-5N[+@[U3]T3X[7 MH'2]]7P3A3=P(;2*XQN1[GUSTWB?X_]RH\MK%,QFEQ?7WWO$O8N2!L8I<*]U M>4R'$71, 4\RF973C.CJ$55=#OJ]1FH,^F\$A$;]B1>>#6[O6&SVP6_P\K%# M5V/M&S<:K=,V(B:88""T-N!9H)!8<%F5R;RFZP>!';@'CU:X-X_XW=7-/][; M&S3(S)@&ERD'D7+)8D8'.F:#IX;T4G;H$[R&U$;?2;X&0\_8NH_B/<2]/2U3M2]G\\D%KK4WGT^'?A$.3MY/IFGX:;Q?+MVFPS1[=_5+ MFGR:NB^?,6R<)G["L>Y1ZDN1N.:CTA7GY:1R^(5Q+;U /B)'/V5C*P/$D0@0:PBD1@ M@6>3LW VU2X9:^(!\777M=O/?>=&N%+Z^#FE4D:\%^.PD.!&=WX^[C3\CR^3 MF1O],IU)FJGB.Z.NI_ M#*JZNN@178OZ MRQ(W3&Z#X%R"YA[WG2<:3(H>>!2. M&VFB4>8E9_6Y!7J&1F4E3BI+M&]4[,W//Z=?W?1?:;ZD'IE7*G"(J;R_#]2! MD5: -I&%$CVZQV-2U^#AR4?W'!)WB(3=I-C N?.P@'%A.ITT-@G&(1":0:24 MP3/T/I4.B5KAJ9==C%9[2$6_D/D17)\=-=<<]LK>O-F..M+HF!+@XA$HC)B@CAJH?[ZVCIOW9Y%QT_"YDM!=[WP?7K,.Z[+_NXZG"^]VF:%COT MQOA:&BPU*@'7!H7#RBOJ4-Y1>NL8]S&P)#8ZPIY9I"5$;*O"20?R[!L7IVD: MTI?25&@-+\RH8(('C187.0CEK3U:74/P:";.!?3=-L+&"POU?.-?'1\UY=HL M1H[&>**[T8>)6_KRD5GI%*.E:-*41V<,C @9+(W>*6XT)7$WN#Q9L]^F86^( MG-VDW2R(#M+(7:5X,'7?[K&6LK",1@X\>XI-^ *?YB,/^&G712YG>/O+%R]:!S5T65(0F)TX(P#;]#SBXX* MY9)S1--PCFI8Z^,X["4QP93EN(,^K-]5X3$1+,-E&KT^FR^PBY 90H^ M%,T-,\X+@QX@QK:6&HP^,P5/!4'19.XPR&6Y>LN99PGJ-R=9'3WUA-]W+NEA MGF1_\C6-72G]6]STL#(Z-Q+@UEA G@Q*B#C(R1+<'YRCF[=1XNB9138"AOPC M>C]5U=,HS&ZV8E9))>H-8 R!&T9( :8T6T_2,R>T1_N[$]#Z='3JJG$#;&PA MTS;14:IDPN=T,D[+BYX8+&Z@""*6#MC2H,7.V@'5E+% +'-TLQN1S=9K#R_; MJ/9EQ.PDYZ:A<_YM;Q>/^Y. M;]#93LYM0P=1L-P/)&E-"E,JEN:"^PK@N5NQGPN/_N"S MI:P;B,)*_7?ZOY?(TV&9]'*;F9?,ZYR4@J!I*<2E&$P6.\JR$<&9B%QV\8AC M!2D;84G]$1WLFCIL$XK+*V]N?0I&@?$Z@="*@%$Z@L_,9";PRUB[S=%:8OI_ MKK&SJE^&SQ9R;P] -P:9,B==$+0$)0I/=*'!D1R 9LY%,N7.J/8=R4I"F@/. M-DI^'CI;2+P!V'1OXLO=XQ%^^FP00Z*"EA<-H302$!'%+CD%2:@,&+5PKVIW M8WI#]C:"N/XC']6M8JV!;7@ZG824XJQTQC@8?DVS^7"^:+OU[G*&/,UF:3;0 MD<40*(-$2RLW+B1@?)* >F^U5(;$QP_N:LQ=>XFLW_LCXRTA]72$6U7]-@#9 MVY% USKX,)FA)Z8=X\Q[T*649-%MT"1E2N\W+8E,W-1OM/&4C-_[XZ\ZD-Q5 M?Z^'H+V&X#A]*MT#SZLA\3C-]]WL,^ZQK\.8XKNKWV8I'HUO&;QIC3G$/29Y M,,&X!,SJ ,(DAGZ:)>"-5$IF29.M#=#-J?N]5\K6P6U'VMX5SKMG-#=G[/#[ MC9Q7[>%(B)>4E"Z7Y1* *@G>XD;67'+

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end